AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 1 of 139 
 
TITLE PAGE  
A Phase 2  Drug -Vaccine Interaction Study to Examine Whether 
Co-administering AV7909 with Ciprofloxacin or Doxycycline Affects 
Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults  
Clinical Protocol EBS.AVA.210   
   
Sponsor:    
 
 
 
Sponsor Representatives:  
   
VP, Clinical Development:     
  
 
 
 
Clinical Project Manager:    
 
 
 
 
 
Medical Monitor  (IQVIA) :   
  
 
 
 
Medical Monitor (Emergent) :   
 
 
 
 
Immediately Reportable Serious 
Event(s):     
  
 
 
Protocol Version / Issue Date:  
  Version 3.0 / 28 October  2019 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 2 of 139 
  
SPONSOR’S SIGNATURE PAGE  
 
Protocol Title : A Phase 2 Drug -Vaccine Interaction Study to Examine Whether Co -
administering AV7909 with Ciprofloxacin or Doxycycline Affects 
Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy 
Adults  
 
Protocol Number:  
 EBS.AVA.210  
Protocol Version 
(Issue Date):  3.0 
(28 October  2019 ) 
 
 
 
  
  
 
  Date  
 
 
 
 
 
 
  Date  
  
 
 
 
 
 
  Date  
 
 
  Date  
 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 3 of 139 
  
INVESTIGATOR’S AGREE MENT  
 
The signature below constitutes the approval of this protocol and the attachments and provides 
the necessary assurances that the study will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and acco rding to local legal and 
regulatory requirements and applicable U.S. State and federal regulations and International 
Council  for Harmonisation (ICH) guidelines.  
I will provide copies of the protocol and all pertinent information to all individuals responsi ble to 
me who assist in the conduct of this study. I will discuss this material with them to ensure that 
they are fully informed regarding the product and the conduct of the study.  
I agree that all information pertaining to the study, including protocols, electronic case report 
forms (eCRFs), and verbal and written consent information will be kept strictly confidential. 
Distribution of such information or information on the conduct, progress, or results of the study 
will be restricted to the clinical person nel involved with the conduct of the study, members of the 
Institutional Review Board/ Independent  Ethics Committee (IRB/IEC), and/or regulatory 
authorities.  
I understand that Emergent Product Development Gaithersburg Inc. (Emergent), its 
representatives, r epresentatives from the Biomedical Advanced Research and Development 
Authority (BARDA) and regulatory agencies shall have access to any documents relevant to the 
study, including documents that demonstrate protocol and regulatory compliance.  
 
 
Printed Name  of Principal Investigator  
 
 
 
 
Signature of Principal Investigator  
 
 
 
Date  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 4 of 139 
  
TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
SPONSOR’S SIGNATURE PAGE  ................................ ................................ ................................ .2 
INVESTIGAT OR’S AGREEMENT  ................................ ................................ ............................... 3 
TABLE OF CONTENTS  ................................ ................................ ................................ ................. 4 
LIST OF TABLES  ................................ ................................ ................................ ......................... 12 
LIST OF FIGURES  ................................ ................................ ................................ ....................... 13 
LIST OF ABBREVIATION S/SPECIALIST TERMS  ................................ ................................ ..14 
1. SYNOPSIS  ................................ ................................ ................................ ................. 19 
2. INTRODUCTION  ................................ ................................ ................................ ......29 
2.1. Study Rationa le ................................ ................................ ................................ ........... 29 
2.2. Background  ................................ ................................ ................................ ................. 29 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 31 
2.3.1. Benefits  ................................ ................................ ................................ ....................... 31 
2.3.2.  Risks  ................................ ................................ ................................ ........................... 31 
2.3.2.1.  BioThrax  ................................ ................................ ................................ ..................... 31 
2.3.2.2.  CPG 7909 ................................ ................................ ................................ .................... 31 
2.3.2.3.  AV7909  ................................ ................................ ................................ ....................... 32 
2.3.2.4.  Study Procedures (IM injections and Venipun cture)  ................................ .................. 33 
2.3.2.5.  Ciprofloxacin  ................................ ................................ ................................ .............. 33 
2.3.2.6.  Doxycycline  ................................ ................................ ................................ ................ 33 
3. STUDY OBJECTIVES & E NDPOINTS  ................................ ................................ ...34 
3.1. Study Objectives  ................................ ................................ ................................ ......... 34 
3.1.1.  Prima ry Objective  ................................ ................................ ................................ .......34 
3.1.2.  Secondary Objectives  ................................ ................................ ................................ .34 
3.2. Study Endpoints  ................................ ................................ ................................ .......... 34 
3.2.1.  Primary Endpoints  ................................ ................................ ................................ ......34 
3.2.2.  Secondary Endpoints  ................................ ................................ ................................ ..34 
4. STUDY DESIGN  ................................ ................................ ................................ .......35 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 5 of 139 
  
4.1. Overall Study Design  ................................ ................................ ................................ ..35 
4.1.1.  Group 1A Schedule  ................................ ................................ ................................ .....39 
4.1.2.  Group 1B Schedule  ................................ ................................ ................................ .....39 
4.1.3.  Group 2A Schedule  ................................ ................................ ................................ .....39 
4.1.4.  Group 2B Schedule  ................................ ................................ ................................ .....40 
4.1.5.  Group 3 Schedule  ................................ ................................ ................................ .......40 
4.2. Scientific Rationale for Study Design  ................................ ................................ ........ 40 
4.3. Justification of the Dose and Schedule  ................................ ................................ .......41 
4.3.1.  AV7909  ................................ ................................ ................................ ....................... 41 
4.3.2.  Ciprofloxacin  ................................ ................................ ................................ .............. 41 
4.3.3.  Doxycycline  ................................ ................................ ................................ ................ 42 
4.4. End of St udy Definition  ................................ ................................ .............................. 42 
5. STUDY POPULATION  ................................ ................................ ............................. 43 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 43 
5.2. Exclu sion Criteria  ................................ ................................ ................................ .......44 
5.3. Lifestyle Restrictions  ................................ ................................ ................................ ..46 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ................... 46 
5.3.1.1.  Precautions for Participants Taking Ciprofloxacin or Doxycycline  ........................... 46 
5.3.1.2.  Special Meals for Participants on Days with PK Sessions  ................................ ......... 46 
5.3.2.  Activity Restrict ions ................................ ................................ ................................ ...46 
5.4. Screen Failures  ................................ ................................ ................................ ............ 47 
6. TREATMENTS  ................................ ................................ ................................ .......... 48 
6.1. Treatment Administration  ................................ ................................ ........................... 48 
6.1.1.  AV7909 Description  ................................ ................................ ................................ ...48 
6.1.2.  Ciprofloxacin Description  ................................ ................................ .......................... 48 
6.1.3.  Doxycycline Description  ................................ ................................ ............................ 48 
6.1.4.  Administration of AV7909  ................................ ................................ ......................... 49 
6.1.5.  Administration of Ciprofloxacin  ................................ ................................ ................. 49 
6.1.6.  Administration of Doxycycline  ................................ ................................ .................. 50 
6.2. Acquisition/Preparation/Handling/Storage/Accountability  ................................ ........ 51 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 6 of 139 
  
6.2.1.  Acquisition  ................................ ................................ ................................ .................. 51 
6.2.2.  Preparation of Investigational Product for Injection  ................................ .................. 51 
6.2.3.  Handling  ................................ ................................ ................................ ..................... 51 
6.2.4.  Product Storage and Stability  ................................ ................................ ..................... 52 
6.2.4.1.  AV7909  ................................ ................................ ................................ ....................... 52 
6.2.4.2.  Ciproflox acin ................................ ................................ ................................ .............. 52 
6.2.4.3.  Doxycycline  ................................ ................................ ................................ ................ 52 
6.2.5.  Investigational Product Experiencing Any Temperature Excursions  ......................... 52 
6.2.6.  Accountability  ................................ ................................ ................................ ............. 52 
6.3. Measure s to Minimize Bias  ................................ ................................ ........................ 53 
6.3.1.  Method of Treatment Assignment  ................................ ................................ .............. 53 
6.3.2.  Blinding  ................................ ................................ ................................ ...................... 53 
6.4. Treatment Compliance  ................................ ................................ ................................ 54 
6.5. Concomitant Therapy  ................................ ................................ ................................ .54 
6.5.1.  Prohibited Medications  ................................ ................................ ............................... 55 
6.5.1.1.  Medications Prohibited Due to Effects on Inflammation or the Immune 
System ................................ ................................ ................................ ......................... 55 
6.5.1.2.  Medications Known to Interact with Ciprofloxacin  ................................ ................... 56 
6.5.1.3.  Medications Known to Interact with Doxycycline  ................................ ..................... 56 
7. STOPPING RULES, DISC ONTINUATION/WITHDRAW AL CRITERIA 
AND PROCEDURES  ................................ ................................ ................................ .57 
7.1. Entire Study  ................................ ................................ ................................ ................ 57 
7.2. Individual Site  ................................ ................................ ................................ ............. 57 
7.3. Individual Participants  ................................ ................................ ................................ 57 
7.3.1.  Discontinuation of Study Treatment  ................................ ................................ ........... 58 
7.3.2.  Withdrawal from the Study  ................................ ................................ ........................ 59 
7.4. Lost to Follow -up ................................ ................................ ................................ .......60 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 61 
8.1. Schedule of Assessments  ................................ ................................ ............................ 61 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 7 of 139 
  
8.1.1. Screening, Randomization/Enrollment and Initial Blood Draws for TNA and 
Autoantibodies  ................................ ................................ ................................ ............ 61 
8.1.1.1.  Screening (Days -28 to -2) ................................ ................................ .......................... 61 
8.1.1.2.  Randomization/Enrollment and Initial Blood Draws for TNA and 
Autoantibodies: Day 1  ................................ ................................ ................................ 62 
8.1.2.  Group 1A: Ciprofloxacin + AV7909 with Ciprofloxacin PK Sessions  ...................... 63 
8.1.2.1.  Group 1A: Day 3 – Overnight Stay # 1  ................................ ................................ ......65 
8.1.2.2.  Group 1A: Day 4 – Pre-vaccine Single Dose Ciprofloxacin PK Session  ................... 65 
8.1.2.3.  Group 1A: Days 5, 6 and 7 – Morning  ................................ ................................ .......66 
8.1.2.4.  Group 1A: Day 7 – Evening & Overn ight Stay # 2  ................................ .................... 67 
8.1.2.5.  Group 1A: Day 8 – Pre-vaccine Steady -State Ciprofloxacin PK Session & 
Vaccination #1  ................................ ................................ ................................ ............ 67 
8.1.2.6.  Group 1A: Days 9, 22 and 24 (At home)  ................................ ................................ ....68 
8.1.2.7.  Group 1A: Day 23 (± 1d) – Vaccination # 2  ................................ .............................. 68 
8.1.2.8.  Group 1A: Day 30 – Evenin g & Overnight Stay # 3  ................................ .................. 69 
8.1.2.9.  Group 1A: Day 31 – Post-vaccine Single Dose Ciprofloxacin PK Session  ............... 69 
8.1.2.10.  Group 1A: Days 32, 33 and 34 – Morning  ................................ ................................ .70 
8.1.2.11.  Group 1A: Day 34 – Evening & Overnight Stay # 4  ................................ .................. 70 
8.1.2.12.  Group 1A: Day 35: – Post-vaccine Steady -State Ciprofloxacin PK Session  ............. 71 
8.1.2.13.  Group 1A: Day 36 (At home)  ................................ ................................ ..................... 71 
8.1.2.14.  Group 1A: Day 37 (± 1d) – Blood Draw for TNA  ................................ ..................... 71 
8.1.2.15.  Group 1A: Day 51 (± 1d) – Final In -Clinic Study Visit  ................................ ............. 72 
8.1.3.  Group 1B: Ciprofloxacin + AV7909 without Ciprofloxacin PK ................................ 72 
8.1.3.1.  Group 1B: Days 4 to 7 (At home)  ................................ ................................ .............. 74 
8.1.3.2.  Group 1B: Day 8 – Vaccination #1  ................................ ................................ ............ 74 
8.1.3.3.  Group 1B:Days 9, 22 and 24 (At home)  ................................ ................................ .....75 
8.1.3.4.  Group 1B: Day 23 (± 1  d) – Vaccination #2  ................................ ............................... 75 
8.1.3.5.  Group 1B: Days 31 to 36 (At home)  ................................ ................................ .......... 76 
8.1.3.6.  Group 1B: Day 37 (± 1  d) – Blood Draw for TNA  ................................ .................... 76 
8.1.3.7.  Group 1B: Day 51 (± 1  d) – Final In -Clinic Study Visit  ................................ ............ 77 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 8 of 139 
  
8.1.4.  Group 2A: Doxycycline + AV7909 with Doxycycline PK Sessions  ......................... 77 
8.1.4.1.  Group 2A: Day 1 – Overnight Stay # 1  ................................ ................................ ......79 
8.1.4.2.  Group 2A: Day 2 – Pre-vaccine Single Dose Doxycycline PK Session  .................... 79 
8.1.4.3.  Group 2A: Days 3, 4, 5, 6 and 7 – Morning  ................................ ............................... 80 
8.1.4.4.  Group 2A: Day 7 – Evening & Overnight Stay # 2  ................................ .................... 80 
8.1.4.5.  Group 2A: Day 8 – Pre-vaccine Steady -State Doxycycline PK Session & 
Vaccination #1  ................................ ................................ ................................ ............ 81 
8.1.4.6.  Group 2A: Days 9, 22 and 24 (At home)  ................................ ................................ ....82 
8.1.4.7.  Group 2A: Day 2 3 (± 1d) – Vaccination # 2  ................................ .............................. 82 
8.1.4.8.  Group 2A: Day 31 (+ 1d) – Evening & Overnight Stay # 3  ................................ .......83 
8.1.4.9.  Group 2A: Day 32 – Post-vaccine Single Dose Doxycycline PK Session  ................. 83 
8.1.4.10.  Group 2A: Days 33, 34, 35, and 36 – Morning  ................................ .......................... 84 
8.1.4.11.  Group 2A: Day 37 – Blood  Draw for TNA  ................................ ................................ 84 
8.1.4.12.  Group 2A: Day 37 – Evening & Overnight Stay # 4  ................................ .................. 84 
8.1.4.13.  Group 2A: Day 38: – Post-vaccine Steady -State Doxycycline PK Session  ............... 85 
8.1.4.14.  Group 2A: Day 51 (± 1d) – Final In -Clinic Study Visit  ................................ ............. 85 
8.1.5.  Group 2B: Dox ycycline + AV7909 without Doxycycline PK Sessions  .................... 86 
8.1.5.1.  Group 2B: Days 2 to 7 (At home)  ................................ ................................ .............. 87 
8.1.5.2.  Group 2B: Day 8 – Vaccination #1  ................................ ................................ ............ 87 
8.1.5.3.  Group 2B: Days 9, 22 and 24 (At home)  ................................ ................................ ....88 
8.1.5.4.  Group 2B: Day 23 (± 1 day) – Vaccination #2  ................................ ........................... 88 
8.1.5.5.  Group 2B: Days 32 to 37 (At home)  ................................ ................................ .......... 89 
8.1.5.6.  Group 2B: Day 37 (± 1) – Blood Draw for TNA  ................................ ....................... 89 
8.1.5.7.  Group 2B: Day 51 (± 1d) – Final Study  Visit  ................................ ............................. 90 
8.1.6.  Group 3: AV7909 Alone  ................................ ................................ ............................ 90 
8.1.6.1.  Group 3: Day 8 – Vaccination #1  ................................ ................................ ............... 92 
8.1.6.2.  Group 3: Day 23 (± 1 d) Vaccination #2  ................................ ................................ ....92 
8.1.6.3.  Group 3: Day 37 (± 1 d) – Blood Draw for TNA  ................................ ....................... 93 
8.1.6.4.  Group 3: Day 51 (± 1  d) – Final In -Clinic Study Visit  ................................ ............... 93 
8.1.7.  Quarterly Safety Follow -up Phone Calls  ................................ ................................ ....94 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 9 of 139 
  
8.1.8.  Early Withdrawal Visit  ................................ ................................ ............................... 95 
8.1.9.  Unscheduled Visits  ................................ ................................ ................................ .....95 
8.2. Immunogenicity/Efficacy Assessments  ................................ ................................ ......96 
8.3. Safety Assessments  ................................ ................................ ................................ .....96 
8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 96 
8.3.2.  Clinical Laboratory Tests  ................................ ................................ ........................... 96 
8.3.3.  Physical Examination  ................................ ................................ ................................ .99 
8.3.4.  Vital Signs  ................................ ................................ ................................ .................. 99 
8.3.5.  Other Safety Assessments  ................................ ................................ ........................... 99 
8.3.5.1.  E-diary Records  ................................ ................................ ................................ .......... 99 
8.4. Pharmacokinetics Sessions and Trough Concentrations of Antibiotics  ................... 102 
8.4.1.  Ciprofloxacin  ................................ ................................ ................................ ............ 102 
8.4.2.  Doxycycline  ................................ ................................ ................................ .............. 102 
8.4.3.  Specimen Collection, Preparation, Handling, and Shipping  ................................ ....102 
8.5. Data Safety Monitoring Board  ................................ ................................ .................. 102 
9. REPORTING ADVERSE EV ENTS  ................................ ................................ ........ 104 
9.1. Definitions  ................................ ................................ ................................ ................ 104 
9.1.1.  Adverse Event  ................................ ................................ ................................ ........... 104 
9.1.2.  Serio us Adverse Event  ................................ ................................ .............................. 104 
9.1.3.  Adverse Events of Special Interest  ................................ ................................ ........... 104 
9.2. Eliciting and Reporting Adverse Events  ................................ ................................ ...104 
9.2.1.  Rating the Severity of Adverse Events  ................................ ................................ .....105 
9.2.2.  Rating the Causality of Adverse Events  ................................ ................................ ...105 
9.2.3.  Eliciting Adverse Events from Other Safety Assessments  ................................ .......106 
9.3. Immediately Reportable Events  ................................ ................................ ................ 107 
9.3.1.  Principal Investigator’s Responsibilities  ................................ ................................ ..107 
9.3.2.  Sponsor’s Reporting Requirements  ................................ ................................ .......... 107 
9.4. Pregnancy  ................................ ................................ ................................ ................. 108 
9.5. Reporting of Other Information – Unanticipated Problems  ................................ .....109 
9.6. Procedure for Breaking the Blind for Individual Participants  ................................ ..109 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 10 of 139 
  
9.7. Follow -up of Adverse Events  ................................ ................................ ................... 109 
9.7.1.  Follow -up of Nonserious Adverse Events  ................................ ................................ 109 
9.7.2.  Follow -up of Serious Adverse Events or Adverse Events of Special Interest  ......... 110 
10. STATISTICAL ANALYSIS  ................................ ................................ .................... 111 
10.1.  Study Endpoints and Statistical Hypotheses  ................................ ............................. 111 
10.1.1.  Primary Endpoints  ................................ ................................ ................................ ....111 
10.1.2.  Secondary Endpoints  ................................ ................................ ................................ 111 
10.1.2.1.  Secondary Safety Endpoints  ................................ ................................ ..................... 111 
10.1.2.2.  Secondary Pharmacokinetic Endpoints  ................................ ................................ ....112 
10.1.2.3.  Secondary Immunogenicity Endpoints  ................................ ................................ .....112 
10.2.  Sample Size and Power  ................................ ................................ ............................ 112 
10.3.  Analysis Populations  ................................ ................................ ................................ 113 
10.4.  Handling of Outliers and Missing Data  ................................ ................................ ....114 
10.5.  Statistical Methods  ................................ ................................ ................................ ....114 
10.5.1.  PK Analyses  ................................ ................................ ................................ .............. 114 
10.5.1.1.  Summary of Concentrations and PK Parameters  ................................ ...................... 114 
10.5.1.2.  Equivalence Testing for Primary PK Endpoints  ................................ ....................... 115 
10.5.1.3.  Equivalence Testing for Secondary PK Endpoints  ................................ ................... 115 
10.5.2.  Non-Inferiority Testing for Secondary Immunogenicity Endpoints  ........................ 115 
10.5.3.  Exploratory Analysis for Immunogenicity  ................................ ............................... 115 
10.6.  Safety Analysis  ................................ ................................ ................................ ......... 116 
10.6.1.  Adverse Events  ................................ ................................ ................................ ......... 116 
10.6.2.  Clinical Laboratory Data  ................................ ................................ .......................... 116 
10.6.3.  Physical Examination  ................................ ................................ ............................... 117 
10.6.4.  Vital Signs  ................................ ................................ ................................ ................ 117 
10.6.5.  Prior and Concomitant Medications  ................................ ................................ ......... 117 
10.6.6.  Other Safety Variables  ................................ ................................ .............................. 117 
10.6.6.1.  Reactogenicity  ................................ ................................ ................................ .......... 117 
10.6.6.2 . Autoantibody Testing and TSH Assessment  ................................ ............................ 117 
10.7.  Interim Analysis  ................................ ................................ ................................ ........ 118 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 11 of 139 
  
10.8.  Multiplicity  ................................ ................................ ................................ ............... 118 
10.9.  Final Analysis Plan  ................................ ................................ ................................ ...118 
11. DATA HANDLING AND RECO RDKEEPING  ................................ ..................... 119 
11.1.  Source Documents and Access  ................................ ................................ ................. 119 
11.2.  Data Management  ................................ ................................ ................................ .....119 
11.3.  Data  Collection and Discrepancy Management  ................................ ....................... 119 
11.4.  File Management at the Investigational Site  ................................ ............................ 119 
11.5.  Record Retention at the Investigational Site  ................................ ............................ 120 
11.6.  Protocol Deviations  ................................ ................................ ................................ ..120 
12. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ .......122 
12.1.  Monitoring  ................................ ................................ ................................ ................ 122 
12.2.  Auditing  ................................ ................................ ................................ .................... 123 
13. ETHICS  ................................ ................................ ................................ .................... 124 
13.1.  Informed Consent  ................................ ................................ ................................ .....124 
13.2.  Institutional Review Board  ................................ ................................ ....................... 124 
13.3.  Future Use of Stored Specimens  ................................ ................................ ............... 125 
13.4.  Confidentiality  ................................ ................................ ................................ .......... 125 
14. AMENDMENT POLICY  ................................ ................................ ......................... 126 
15. PUBLICATION POLICY  ................................ ................................ ........................ 127 
16. LIST O F REFERENCES  ................................ ................................ .......................... 128 
17. APPENDICES  ................................ ................................ ................................ .......... 132 
APPENDIX  A. TOXICITY GRADING SCA LE FOR HEALTHY ADULT  AND 
ADOLESCENT VOLUNTEER S ENROLLED IN PREVEN TIVE 
VACCINE CLINICAL TRI ALS  ................................ ................................ .....133 
APPENDIX  B. ADVERSE EVENTS OF SP ECIAL INTEREST  ................................ ........... 137 
APPENDIX  C. SPONSOR’S GUIDANCE O N CHRONIC CONDITIONS  FOR 
INVESTIGATORS  ................................ ................................ .......................... 139 
  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 12 of 139 
  
LIST OF TABLES  
Table 1:  Abbreviations/Specialist Terms  ................................ ................................ .................. 14 
Table  2: Study Groups  ................................ ................................ ................................ .............. 35 
Table 3:  Medications Prohibited for all Participants  ................................ ................................ 55 
Table  4: Criteria for Discontinuation of Treatment in Individual Participants  ......................... 58 
Table 5  Schedule of Events for Group 1A: Ciprofloxacin + AV7909 with 
Ciprofloxacin PK  ................................ ................................ ................................ ........ 63 
Table  6: Schedule of Events for Group 1B: Ciprofloxacin + AV7909 without 
Ciprofloxacin PK  ................................ ................................ ................................ ........ 73 
Table 7:  Schedule of Events for Group 2A: Doxycycline + AV7909 with 
Doxycycline PK  ................................ ................................ ................................ .......... 77 
Table 8:  Schedule of Events for Group 2B: Doxycycline + AV7909 without 
Doxycycline PK  ................................ ................................ ................................ .......... 86 
Table  9: Schedule of Events for Group 3: AV7909 Alone  ................................ ....................... 90 
Table 10:  Screening/Safe ty Clinical Laboratory Tests  ................................ ............................... 98 
Table 11  Antibiotic Pharmacokinetic Parameters  ................................ ................................ ...114 
Table  12: Toxicity Grading Scale for Clinical Abnormalities in Healthy Adult and 
Adolescent Volunteers  ................................ ................................ .............................. 133 
Table  13: Toxicity Grading of Laboratory Abnormalities  ................................ ........................ 135 
Table 14:  List of Adverse Events of Special Interest*  ................................ ............................. 137 
 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 13 of 139 
  
LIST OF FIGURES  
Figure 1:   Study Design for EBS.AVA.210  ................................ ................................ ............... 37 
Figure 2:   Event Schematic for EBS.AVA.210 Groups 1 to 3  ................................ ................... 38 
 
  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 14 of 139 
  
LIST OF ABBREVIATION S/SPECIALIST TERMS  
The following abbreviations and specialist terms are used in this study protocol.  
Table 1: Abbreviations /Specialist Terms   
Abbreviation /Specialist 
Term   Definition  
ACC  American College of Cardiologists  
ACIP  Advisory Committee on Immunization Practices  
ADHD  Attention Deficit Hyperactivity Disorder  
AE Adverse event  
AESI  Adverse event  of special interest  
AHA  American Heart Association  
aIG Animal  derived immune globulin  
ALP  Alkaline phosphatase  
ALT  Alanine aminotransferase  
ANA  Antinuclear antibody  
ANCA  Anti-neutrophil cytoplasmic antibody  
ANOVA  Analysis of variance  
AST  Aspartate aminotransferase  
AUC 0-12h Area under the concentration -time curve from t=0 to 12 hours  
AUC 0-inf Area under the concentration -time curve from t=0 to infinity  
AUC 0-t Area under the concentration -time curve from t=0 to last measurable 
concentration  
AUMC  Area under the first moment curve  
AVA  Anthrax vaccine adsorbed, BioThrax.  
AV7909  AVA plus CPG 7909, an investigational product  
B. anthracis  Bacillus anthracis  
BARDA  Biomedical Advanced Research and Development Authority  
BioThrax  BioThrax® (Anthrax  Vaccine Adsorbed)  
BMI  Body mass index  
BUN  Blood urea nitrogen  
CBC  Complete blood cell count  
CBER  Center for Biologics Evaluation and Research  
CDC  Centers for Disease Control and Prevention  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 15 of 139 
  
Abbreviation /Specialist 
Term   Definition  
CFR  Code of Federal Regulations  
CI Confidence interval  
Cipro  Ciprofloxacin  
Cmax Maximum concentration  
CNS  Central nervous system  
CPG 7909  A synthetic oligonucleotide used as an adjuvant  
CRO  Contract research organization  
Ct Last measurable concentration  
CV Coefficient of variation  
d Day(s)  
dL Deciliter  
DM Diabetes mellitus  
DMP  Data Management Plan  
Doxy  Doxycycline  
DRESS  Drug reaction with eosinophilia and systemic symptoms  
dsDNA  Double -stranded deoxyribonucleic acid  
DSMB  Data Safety Monitoring  Board  
  
ECG  Electrocardiogram  
eCRF  Electronic case  report form  
EDC  Electronic data capture  
e-diary  Electronic diary  
  
ER Emergency room  
EWV  Early withdrawal visit  
FDA  Food and Drug Administration  
FSH Follicle -stimulating hormone  
GCP  Good Clinical Practices  
GERD  Gastroesophageal reflux disease  
GLP  Good Laboratory Practices  
GMC  Geometric mean concentration  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 16 of 139 
  
Abbreviation /Specialist 
Term   Definition  
GMT  Geometric mean titer  
GUP  General use prophylaxis  
HBsAg  Hepatitis B virus surface antigen  
HCVAb  Hepatitis C virus antibody  
hhIG  Human hyperimmune globulins  
h/hr Hour(s)  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HIVAb  Antibody to human immunodeficiency virus  
ICF  Informed consent form  
ICH International Council for  Harmonisation  
IEC Independent Ethics Committee  
IgG Immunoglobulin G  
IGIM  Human immunoglobulins for intravenous injection  
IGIV  Human immunoglobulins for intravenous injection  
IGSC  Human immunoglobulins for subcutaneous  injection  
IH Intracranial hypertension  
IM Intramuscular  
IND Investigational New Drug (application)  
IP Investigational product  
IRB Institutional Review Board  
ITT Intent -to-treat 
IUD  Intrauterine device  
IUS Intrauterine system  
IV Intravenous  
IXRS  Interactive voice/web re sponse  system  
kDa Kilodalton  
Kel Elimination rate constant  
LD 50 Dose at which 50% mortality is observed  
LLOQ  Lower limit of quantification  
MedDRA  Medical Dictionary for Regulatory  Activities  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 17 of 139 
  
Abbreviation /Specialist 
Term   Definition  
mEq  MilliEquivalents  
mg Milligram  
min Minute(s)  
mIU/mL  Milli -international units per milliliter  
MM Medical Monitor  
MRT  Mean residence time  
NB Note well (nota bene)  
NF 50 50% neutralization factor  
NHP  Nonhuman primate  
NOSTASOT  No statistical significance of trend  
NSAID  Non-steroidal anti -inflammatory drug  
ODN  Oligodeoxynucleotide  
OHRP  Office of Human Research Protection  
PA Protective antigen  
PE Physical examination  
PEP Post-exposure prophylaxis  
PI Principal Investigator  
PK Pharmacokinetic(s)  
po Per os (orally)  
PRBC  Packed red blood cells  
PT Preferred term (MedDRA)  
PV  Pharmacovigilance  
q 12 hr  Every 12 hours  
QA Quality Assurance  
QC Quality Control  
RBC/hpf  Red blood cells/high powered field  
RF Rheumatoid factor  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Statistical Analysis Software  
SC Subcutaneous  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 18 of 139 
  
Abbreviation /Specialist 
Term   Definition  
SOC  System Organ Class level of MedDRA  
SOP Standard operating procedure  
Subject ID  A unique identifier assigned to each study participant  
SUSAR  Suspected unexpected serious adverse reaction  
SV Study visit  
t1/2 Elimination half-life 
TBD  To be determined  
TEAE  Treatment emergent adverse event  
tmax Time to maximum concentration  
TNA  Toxin neutralizing antibody  
TOST  Two one -sided t -tests  
TSH  Thyroid stimulating hormone  
UAT  User acceptability testing  
ULN  Upper limit of normal  
UPT  Urine pregnancy test  
USP United States Pharmacopeia  
USV  Unscheduled Visit  
UVA/UVB  Ultraviolet radiation A/B  
Vac Vaccination  
WBC  White blood cell count  
WHO  World Health Organization  
WOCBP  Woman of childbearing potential  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 19 of 139 
  
1. SYNOPSIS  
Name of Sponsor/Company:  
Name of Investigational Product: AV7909  
Name of Active Ingredient: AVA drug substance  and CPG  7909 as adjuvant  
Name of Co -Administered Product s: Ciprofloxacin hydrochloride ; Doxycycline hyclate  
Title of Study: A Phase 2 Drug -Vaccine Interaction Study to Examine Whether Co -
administering AV7909 with Ciprofloxacin or Doxycycline Affects Antibiotic 
Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults  
Short Title: PEP Antibiotic -AV7909 Interaction  Study  
Study center(s): Up to five sites in the United States (US)  
Studied period ( month s): 
Individual participants enroll ment  in the study 
from the screening visit to  the last visit and all 
safety follow -up calls will be approximately 14 .5 
months. Screening will be from Day -28 to Day -2 
followed by either 19 (Group 2A ), 17 (Group 1A ) 
or 6 (Groups 1B, 2B and 3) in-clinic visits 
occurring over six weeks. Safety follow -up phone 
calls will be conducted 3, 6, 9 a nd 12 months after 
the last vaccination.  
Overall study duration from the first participant 
first visit to last participant last visit is anticipated 
to be approximately 1 8 months.  Phase of Development: Phase 2 
 
Objectives:  
Primary:  
 To evaluate the pharmacokinetic (PK) profile s of ciprofloxacin or doxycycline when 
administered orally, prior to, and following, the intramuscular (IM) administration of 
a two -dose schedule  of AV7909 administered two weeks apart.  
Secondary:  
 To assess the safety of concurr ent administration of oral ciprofloxacin  or doxycycline  
and two doses of AV7909 administered IM.  
 To evaluate the Day 37 immune response using the toxin -neutralizing antibody 
(TNA) assay following two IM doses of AV7909 with and without the concurrent 
oral administration of ciprofloxacin  or doxycycline . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 20 of 139 
  
Study Design:  
This is a randomized, open -label, phase 2, multicenter trial to investigate the potential 
interactions of AV7909 and ciprofloxacin or doxycycline when administered concomitantly. 
Healthy males and females between 18 and 45 years of age, inclusive, will read, sign and 
date an informed consent form and then be screened for eligibility for participation in the 
study. Participants (N= 210) meeting the entry criteria on Day 1 will be randomized 1:1:1 into 
one of three investigational product (IP) groups  as shown in the table below.  
IP Group  Treatment  
Group  Treatment  Sample 
Size 
 (N) 
1 Cipro  1A AV7909 + ciprofloxacin (with PK assessment)  ≈40 
≈70 
1B AV7909 + ciprofloxacin (without PK assessment)  30 
2 Doxy  2A AV7909 + doxycycline (with PK assessment)  ≈40 
≈70 
2B AV7909 + doxycycline (without PK assessment)  30 
3 AV7909  3 AV7909 only  70 
  TOTAL  ≈210 
Approximate ly the first 40 participants who are randomized for either  IP Groups 1 and 2 , ie, 
the first 80 participant s randomized across all sites to either antibiotic group,  will be assigned 
to Treatment Group s 1A or 2A while those randomized into IP Groups 1 and 2 thereafter will 
be assigned to Treatment  Group s 1B or 2B. Randomization will be stratified by site. A 
representative racial distribution will be sought among recruited participants and sites will be 
asked to recruit populations that are gender - and age -balanced (ie, between 40 -60% male 
with 40 -60% of participants  in the two age ranges of 18 to 30 years of age and 31 to 45 years 
of age).  
Figure 1 displays the overall design used for this study.  
Ciprofloxacin (500  mg by mouth [per os] every 12 hours [ po q 12 hr]) will be administered to 
Group 1  on Days 4 -9, Days  22-24 and Days 31 -37, and doxycycline (100 mg by mouth [per 
os] every 12 hours [ po q 12 hr]) will be administered to Group 2 on Days 2 -9, Days 2 2-24, 
and Days 32 -38. Antibiotics will be administered in three courses that will be used both by 
site staff for in -clinic visits and by participants when they are at home. The exact format of 
the courses in terms of number of  tablets and when participants will rece ive each course will 
be described in the Pharmacy Manual.  
The 40 participants in Group 1 A will self -administer approximately half ( 14/31) of the 
ciprofloxacin doses ; the remainder will be administered  by site staff  during clinic visits. The 
30 participants  in Group 1B, with far fewer clinic visits than Group 1 A due to the lack of PK 
sampling , will self -administer more than 90% ( 29/31) of ciprofloxacin doses.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 21 of 139 
  
For the doxycycline groups, the distribution s of self -administered doses are similar  to those 
planned for  the two ciprofloxacin groups  with Group 2A self-administering 15/35 doses and 
Group 2B self-administering 3 3/35 doses.  
An e vent schematic for this study is provided  in Figure 2. 
Ciprofloxacin PK session s in Group 1 A will be conducted on Days 4, 8, 31 and 35.  
Ciprofloxacin pre -dose or trough values will be measured prior to the morning doses of 
ciprofloxacin on Days 4, 5, 6, 7 and 8 and again on Days 31, 32, 33, 34 and 3 5. On the days 
with PK session s, blood samples for measurement of ciprofloxacin concentrations will be 
collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose (±  5 min 
through hr 4 , then ± 15 min thereafter ). The Schedules of Events for Group 1 A and Group 1B 
are provid ed in Table 5 and Table  6, respectively.   
Doxycycline PK session s in Group 2A  will be conducted on Days 2, 8, 32 and 3 8.  
Doxycycline  pre-dose or trough values will be measured prior to the morning doses of 
doxycycline  on Days 2, 3, 4, 5, 6, 7 and 8 and again on Days  32, 33, 34, 35, 36, 37 and 3 8.  
On the days with PK sessions , blood samples for measurement of doxycycline  concentrations 
will be collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose 
(± 5 min through hr 4 , then ± 15 min thereafter ). The Schedules of Events for Group 2A  and 
Group 2B are provid ed in  Table 7 and Table 8, respectively.  
All participants, including the 70 participants in Group 3, will receive AV7909 IM in the 
deltoid muscle  of alternate arms  on Days 8 and 23.  For Group s 1A and 2A, the first 
vaccination will occur following completion of the PK session s and after administration of 
the evening antibiotic ( ciprofloxacin  or doxycycline)  dose. The Schedule of Event s for Group 
3 is provid ed in Table  9. 
Blood draws for TNA assessments will be performed for all participants at randomization 
(Day 1) and on Day 3 7 (two weeks following the second and final vaccination).  
Safety in all groups will be assessed up to Day 51 (or the early withdrawal visit [EWV]) by 
physical examinations, vital signs, clinical laboratories (hematology, serum chemistry, and 
urinalysis), monitoring of adverse events (AEs), serious AEs (SAEs), AEs  of special interest 
(AESIs; ie, of autoimmune etiology; see  Table 14), concomitant medications, and injection 
site and systemic reactions as reported in participant electronic diaries (e -diaries). The 
severity of AEs, laboratory test results for select analytes, and vital sign results will be 
assessed based on the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult 
and Adolescent Volunte ers Enrolled in Preventive Vaccine Clinical Trials.  Reactogenicity 
(solicited systemic and local injection site reactions) will be assessed daily by the participants 
using e -diaries for at least seven days after each vaccination. If local injection site or  
systemic reactions continue beyond seven days  (d), participants will be prompted to continue 
e-diary entries until resolved for at least two consecutive days. Participants in Groups 1 and 2 
will also use the e -diary to record their self -administration of antibiotics. Site staff will 
review e -diary entries on a routine basis and will review the e -diary record with each Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 22 of 139 
  
participant at each study visit. Safety follow -up phone contacts to collect information on 
AEs, SAEs and AESIs  will occur at 3 months (Day  114 ± 14 d), 6 months (Day  205 ± 14 d), 9 
months (Day  296 ± 14 d) and 12 months (Day 38 8 ± 14 d) after the last scheduled 
vaccination.  
Blood samples will be taken at randomization (Day 1) and Day 51 (or the  EWV ) to test (if 
medically indicated  as per princi pal investigator’s discretion  based on a report of potential 
AESI ) for thyroid stimulating hormone (TSH)  levels, antinuclear antibodies (ANA), 
rheumatoid factor (RF) and anti -double stranded deoxyribonucleic acid (dsDNA) antibodies . 
Samples may also be collected at unscheduled visits following the safety follow -up phone 
contact(s) to investigate potential AESI reports.  
Independent safety oversight will be provided by a Data Safety Monitoring Board (DSMB), 
which will be notified of significant AEs [eg, SA Es, severe AEs recorded on  an electronic 
case report form  (eCRF ), potential AESIs of autoimmune etiology, or any other events the 
medical monitor deems medically relevant ] as determined by the medical monitor on an 
ongoing basis. The DSMB will comprise at least three voting members, to include one expert 
in immunology to specifically support the evaluation of potential AESIs for autoimmune 
etiology, if pre -existing or new onset, and relationship to the study product. The DSMB will 
make recommendations regar ding the safety of continuing enrollment and dosing. Study 
enrollment and dosing may be interrupted at the request of the DSMB Chair if it is believed 
that an AE represents a significant safety concern requiring suspension of dosing pending full 
DSMB evalu ation. The operations of the DSMB will be detailed in a DSMB Charter  which 
will be finalized prior to  screening the first participant . 
Number of Participants (Planned):  
Approximately 210 
Diagnosis and Main Criteria for Study Participation  
Healthy males and females aged 18 to 45 years (inclusive) with no prior history of anthrax 
disease, suspected exposure to anthrax, or vaccination with anthrax vaccine  and no h istory of 
allergic reaction or intolerance to quinolone or tetracycline antimicro bials  and as determined 
by inclusion and exclusion criteria listed below . 
Inclusion Criteria  
Individuals must meet all of the following inclusion criteria for study participation:  
1. Written informed consent obtained from the participant (dated, signed, and c aptured 
in the medical chart at the site).  
2. A male or female, aged 18 to 45 years of age, inclusive, at the time of informed 
consent.  
3. Healthy condition as established by medical history and clinical examination before 
entering into the study.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 23 of 139 
  
4. Have a body ma ss index (BMI) less than or equal to 35.0 kg/m2 at the Screening visit.  
5. Have adequate venous access for phlebotomies.  
6. For a woman of childbearing potential (WOCBP), negative pregnancy test at 
Screening and pre -randomization on Day 1, not currently breastf eeding, and no 
intention to become pregnant during the study period through 12 months after last 
receipt of any investigational product (IP).  
Every female participant is considered to be a WOCBP unless she is surgically sterile 
(ie, has had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or 
postmenopausal [which is defined as >12 consecutive months without menses and a 
Screening FSH  of >30 mIU/mL]. Adequate birth control (as defined here) must be 
initiated at least one month prior to randomization on Day 1 and used throughout the 
trial.  Adequate birth control methods are sexual abstinence, intrauterine 
device/system (IUD/IUS), birth control pills, implantable or injectable contraceptives 
(eg, Norplant® or Depo -Provera®), remo vable birth control device (eg, NuvaRing® 
or Evra® patches) or double -barrier method of birth control (diaphragm in 
combination with contraceptive jelly or condoms in conjunction with contraceptive 
jelly, cream or foam), tubal ligation, or have a monogamou s relationship with 
vasectomized partner who has been vasectomized for 6 months or more prior to the 
participant’s trial entry.  
Female participants randomized to Groups 1 or 2: be willing to add a double -barrier 
method, IUD, or abstinence as back -up forms  of birth control since ciprofloxacin and 
doxycycline may decrease the effectiveness of birth control pills, implantable or 
injectable contraceptives.  
Exclusion Criteria  
Individuals meeting any of the following exclusion criteria will be excluded from stud y 
participation:  
1. A Screening clinical laboratory test result greater than the central laboratory’s upper 
limit of normal (ULN) for aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), random glucose, total bilirubin, blood urea nitrogen (BUN),  
or creatinine . Other serum chemistry parameters that are not within the reference 
range will not be considered exclusionary , unless deemed clinically significant by the 
principal investigator.  
2. History of allergic reaction or intolerance to quinolone antimicrobials or  any medical 
condition that would contraindicate the use of ciprofloxacin, including and not limited 
to vascular disorders, tendon disorders, certain genetic connective tissue disor ders 
(eg, Marfan and Ehlers –Danlos syndrome), prolongation of QT interval, seizures, 
peripheral neuropathy, increased risk of C. difficile  infection  (see ciprofloxacin 
prescribing information in the Pharmacy Manual).  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 24 of 139 
  
3. History of allergic reaction or intole rance to tetracycline antibiotics or any medical 
condition that would contraindicate the use of doxycycline including an increased risk 
of C. difficile  infection, increases in BUN or an increased sensitivity to direct sunlight 
or ultraviolet radiation resu lting in erythema (see doxycycline prescribing information 
in the Pharmacy Manual).   
4. Has a need for any of the prohibited medications in Section 6.5.1  or requires the 
medications/foods within the prohibited times in Section 5.3.1.1 .  
5. Have a tattoo/scar/birthmark or any other skin condition affect ing the deltoid area that 
may interfere with injection site assessments.  
6. History of anthrax disease, suspected exposure to anthrax, or previous vaccination 
with any anthrax vaccine.  
7. Have previously served in the military any time after 1990 or plan to enl ist in the 
military any time from Screening through the final telephone contact.  
8. Previous anaphylactic reaction, severe systemic response, or serious hypersensitivity 
to a prior immunization or a known allergy to synthetic ODNs, aluminum, 
formaldehyde, be nzethonium chloride (phemerol).  
9. Plan to have an elective surgery at any point during the study until after the final 
safety phone contact.  
10. Have donated or plan to donate blood within one month prior to enrollment or at any 
point during the study until afte r the final safety phone contact.  
11. Use of any investigational or non -registered product (drug, vaccine or biologic) 
within 30 days preceding the dose of study vaccine, or planned use during the study 
until after the final safety phone contact.  
12. Planned admi nistration of any commercially -available vaccine from one week prior to 
the first study vaccination through two weeks after the last vaccination.  
13. Have experienced chronic dosing (defined as more than 14 days) with any immune -
modifying drugs within six mon ths of study enrollment. This includes oral, 
intramuscular, intra -articular, intravenous, or inhalation corticosteroids except in the 
case of inhaled or intranasal medications for seasonal allergies (see Table 3).  
14. Receipt of immunoglobulins and/or any blood products within the three months 
preceding study enrollment or at any point during the study period until after the final 
safety visit on Day 51.  
15. An abnormal electrocardiogram (ECG) at screening interpreted as ‘Abnormal, 
Significant’. Inclusion of participants with ‘Abnormal, Insignificant’ ECGs will be 
based on the principal investigator’s discretion.  
16. Have an active malignancy or history of metastati c or hematologic malignancy.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 25 of 139 
  
17. Have a history of an autoimmune, inflammatory, vasculitic or rheumaticor rheumatic 
disease including but not limited to systemic lupus erythematosus, Guillain -Barré 
syndrome, myasthenia gravis, polymyalgia rheumatica, diabetes  mellitus type I, 
rheumatoid arthritis or scleroderma.  
18. A positive laboratory evidence of hepatitis B, hepatitis C, or human 
immunodeficiency virus (HIV) HIV -1 or HIV -2 infection.  
19. Positive result on urine drug screen, any evidence of ongoing drug abuse or 
dependence (including alcohol), or recent history (over the past five years) of 
treatment for alcohol or drug abuse.  
20. Has an acute disease at the time of enrollment.  
Note that screening lab tests may be delayed to allow the resolution of a transient 
acute c ondition or the subject may be rescreened according to procedures under 
Section 5.4.  
21. Any medical condition that, in the opinion of the investigator, could adversely impact 
the participant’s involvement or the conduct of the study.  
22. Have a significant chronic condition (see Sponsor’s guidance on significant chronic 
conditions in Appendix  C), eg, serious cardiovascular, pulmonary, hepatic, type II 
diabetes mellitus or renal disease that, in the opinion of the investigator, would render 
treatment unsafe or would interfere with trial evaluati ons or completion of the study.  
23. An opinion of the investigator that it would be unwise to allow the participant to be 
randomized into the study.  
24. Member or immediate family member of an investigator site team . 
Investigational Product s (IP) , Dosage , Schedul e and Mode of Administration:  
 AV7909 ( containing 0.5 mL AVA + 0.25 mg CPG 7909  adjuvant per dose ) will be 
administered IM in the deltoid muscle  of alternating arms  to all (Groups 1 to 3) on Day 
8 and Day 23. 
 Ciprofloxacin (500 mg  po q 12 hr) will be administered to participants in Group 1 on 
Days 4-9, Days 2 2-24, and Days 31-37. 
 Doxycycline  (100 mg po q 12 hr) will be administered to participants in Group 2 on 
Days 2-9, Days 2 2-24, and Days 32-38. 
Duration of Treatment:  
All participants will receive two vaccinations with AV7909 two weeks apart . 
Participants in Group 1 will be intermittently dosed with ciprofloxacin over 33 days and 
participants in Group  2 will be intermittently dosed with doxycycline over 36 days.  
Endpoints  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 26 of 139 
  
Primary  Endpoints : 
 Area under the curve from 0 to 12 hours (AUC 0-12h) and maximum concentration 
(Cmax) for ciprofloxacin on Days 8 and 35 
 Area under the curve from 0 to 12 hours (AUC 0-12h) and maximum concentration 
(Cmax) for doxycycline  on Days 8 and 38  
Secondary  Endpoints : 
Safety  
 Incidence of AEs from the first dose of any IP through the Final Study Visit 
(Day 51 ± 1 d) 
 Incidence of serious AEs (SAEs) from the first dose of any IP until the 12 -month 
follow -up (Day  388 ± 14d) 
 Incidence of solicited systemic and injection site reactions reported in participant e-
diaries following each vaccination  
 Incidence of AESIs  from the first dose of any IP until the 12 -month follow -up 
(Day  388 ± 14 d) 
 Incidence of clinical laboratory abnormalities  
Pharmacokinetics and Immunogenicity  
 AUC 0-12h and C max for ciprofloxacin on Days 4 and 31 and for doxycycline on 
Days  2 and 32 
 Geometric mean TNA  50% neutralizing factor  (NF 50) values 2 weeks after the 
second vaccination (Day 37 ± 1 d) 
Statistical Methods:  
Statistical Analysis  
To characterize the PK profile s of ciprofloxacin  and doxycycline , the following PK 
parameters will be calculated using noncompartmental analytic methods:  
 Maximum observed concentration: C max 
 Time of Cmax: tmax  
 Elimination half-life: t 1/2 
 Elimination rate  constant : Kel 
 Area under the serum concentration -time curve (12 hours): AUC 0-12h 
 Area under the first moment curve: AUMC  
  Mean residence time: MRT  
 Area under the serum concentration -time curve extrapolated to infi nity: AUC 0-inf  
Effect of AV7909 on Ciprofloxacin Pharmacokinetics  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 27 of 139 
  
To examine the effect of AV7909 vaccination on the steady state pharmacokinetics of 
ciprofloxacin, the trough values for Days 4 through 8 and Days 31 through 35 will be 
analyzed to demonstrate that ciprofloxacin concentrations have achieved steady state on Day 
8 and Day 35. Then the C max and AUC 0-12h values for ciprofloxacin determined for Group 1 A 
participants on Day 35 (following two doses of AV7909) will be com pared to those 
determined on Day 8 (prior to AV7909 vaccination).  Point estimates and 90% confidence 
intervals (CIs) will be calculated for the geometric mean ratios. If the CIs are all within 0.80 
and 1.25, then it can be concluded that AV7909 vaccinatio n does not significantly influence  
the steady state C max and AUC 0-12h values of ciprofloxacin.  
Effect of AV7909 on Doxycycline Pharmacokinetics  
To examine the effect of AV7909 vaccination on the steady state pharmacokinetics of 
doxycycline , the trough values for Days 2 through 8 and Days 32 through 3 8 will be analyzed 
to demonstrate that doxycycline  concentrations have achieved steady state on Day 8 and 
Day 38. Then the C max and AUC 0-12h values for doxycycline  determined for Group 2A 
participants on Day 3 8 (following two doses of AV7909) will be compared to those 
determined on Day 8 (prior to AV7909 vaccination).  Point estimates and 90% CIs will be 
calculated for the geometric mean ratios. If the CIs are all within 0.80 and 1.25, the n it can be 
concluded that AV7909 vaccination does not significantly influence  the steady state C max and 
AUC 0-12h values of doxycycline .  
For the secondary endpoints, a similar comparison will be conducted for the C max and 
AUC 0-12h values for ciprofloxacin  from Day 31 vs Day 4 to determine if these single -dose PK 
values of ciprofloxacin are affected by AV7909 vaccination  and a similar comparison will be 
conducted for the C max and AUC 0-12h values for doxycycline  from Day 32 vs Day 2 to 
determine if these single -dose PK values of doxycycline  are affected by AV7909 vaccination . 
Effect of Ciprofloxacin  or Doxycycline  on AV7909 Immunogenicity  
To evaluate whether the administration of ciprofloxacin affects the immunogenicity of 
AV7909, TN A NF 50 values two weeks after the second dose of AV7909 will be compared 
between the cohort of participants that received both ciprofloxacin and AV7909, ie, Group 1 , 
also known as the ciprofloxacin test cohort, and the cohort who received AV7909 only, ie, 
Group 3 or the reference cohort. Point estimates and two -sided 95% lower CIs will be 
constructed for the ratio (test: reference) of geometric means. If the lower bound  of the two -
sided 95% lower CI is greater than 0.5 (the non -inferiority margin) it can be  concluded that 
the immune response in the cohort who received AV7909 plus ciprofloxacin is non -inferior 
to the cohort which received AV7909 alone and thus that ciprofloxacin did not  demonstrably  
affect the immunogenicity of AV7909.  
The same evaluation wil l be conducted to determine if the administration of doxycycline  
affects the immunogenicity of AV7909  in that  TNA NF 50 values two weeks after the second 
dose of AV7909 will be compared between the cohort of participants that received both 
doxycycline  and A V7909, ie, Group 2, the doxycycline test cohort, and the cohort who 
received AV7909 only (ie, Group 3 or the reference cohort ). Point estimates and two -sided 
95% lower CIs will be constructed for the ratio (test: reference) of geometric means. If the Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 28 of 139 
  
lower  bound  of the two -sided 95% lower CI is greater than 0.5 (the non -inferiority margin) it 
can be concluded that the immune response in the cohort who received AV7909 plus 
doxycycline  is non -inferior to the cohort which received AV7909 alone and thus that 
doxycycline  did not  demonstrably  affect the immunogenicity of AV7909.  
Sample Size Considerations  
Antibiotic  PK: Assessment of the effect of vaccination with AV7909 on the PK of either 
antibiotic  will be made using the geometric mean of the within -participa nt ratio of C max and 
AUC 0-12h for either ciprofloxacin or doxycycline before (Day 8) vs after (Day 35 or Day 38 ) 
AV7909 vaccination. The equivalence (no interaction) margin for the ratio is [0.80, 1.25] , 
which will be compared with the 90% CI for the geome tric mean ratio . Assuming  that the  
coefficient  of variation (CV) with the within -participant ratio is 30% and the true ratio is 
0.95, 27 participants allow s for 90% power at significance level 0.05 while 34 participants 
would provide 95% power. A group size of 40 participants  in each of the antibiotic PK 
groups (Group 1 A and Group  2A) is planned to allow for up to 30% participants being 
excluded from the PK p opulation.  
Immunogenicity:  Sample sizes of 53 in each cohort (AV7909 alone vs AV7909 + antibiotic 
[either ciprofloxacin or doxycycline] ) provide 9 0% power at the 2.5% one -sided significance  
level for the non -inferiority test (defined as the lower bound of the two -sided 95% CI of the 
ratio greater than  0.5), if the true ratio of geometric means is 0.85 and the CV of NF 50 values 
between participants in the same group is 100%. A cohort size of 70 is planned to allow for 
up to 25% of participants to be excluded  from the immunogenicity population.  
 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 29 of 139 
  
2. INTRODUCTION  
2.1. Study Rationale  
Antimicrobial therapy is an important component of post -exposure prophylaxis (PEP) following 
exposure to aerosolized Bacillus  anthracis  spores.  According to  the Centers for Disease Control 
and Prevention’s (CDC)  Advisory Committee on Immunization Practices ( ACIP ) 
recommendations for PEP of inhalation anthrax, BioThrax® (Anthrax Vaccine Adsorbed; AVA) 
administered subcutaneously at 0, 2, and 4 weeks , combined with appropriate antimicrobial 
therapy, is currently licensed for this indication in previo usly unvaccinated adults { Wright  et al,  
2010 }.  While a two -dose vaccination schedule  with AV7909 for PEP would have clear logistical 
advantages over  the three -dose schedule  with BioThrax, antimicrobial therapy would still be a 
required component of the PEP schedule . The purpose of this study is to identify any potential 
effects of AV7909 vaccination on the PK of the antibiotics ciprofloxacin or doxycy cline and any 
potential effects of ciprofloxacin  or doxycycline  therapy on the immunogenicity of AV7909. 
Both c iprofloxacin  and doxycycline have been chosen for use in this study because they are first-
line therapies recommended by the ACIP for PEP {Wright  et al, 2010}.    
2.2. Background  
Anthrax is an acute non -communicable infectious disease caused by B. anthracis , a spore -
forming, gram -positive bact erium that occurs globally { Brachman  et al, 2008; WHO , 2008 }. 
While human cases are rare in the United States (US), the bioterrorist use of B. anthracis  spores 
as a biological weapon resulted in the exposure of tens of thousands of individuals across six 
states and the District of Columbia in 2001 { CDC , 2001 }. The CDC considers  B. anthracis  to be  
one of the most likely biological agents to be used in any future terrorism activities {CDC , 
2014}.   
While vaccination prior  to exposure offers the optimal protection against anthrax, mass 
vaccination is  neither practical nor feasible as a defense against bioterrorism {CDC , 2000 }. At 
the time of the bioterrorist events in 2001, the only Food and Drug Administration (FDA) -
approved post -exposure treatments for anthrax were the antimicrobials: ciprofloxacin, ofloxacin, 
doxycycline, penicillin VK and amoxicillin { CDC,  2000}.  In the event of an aerosol exposure , 
the CDC’s ACIP recommended at the time that PEP consist of a minimum of 30 days of 
antibiotics and possibly a longer course of 42-60 days. The ACIP recommendations  from 2000  
also stated that if a vaccine w as available , three  doses of vaccine should be administered  (at 0, 2, 
and 4 weeks)  with discontinuation of antibiotic after the third vaccination { CDC,  2000}.    
In response to the 2001 attacks, approximately 9300 individuals were initially prescribed 
antimicrobial prophylaxis for at least 60 days; however, a subsequent study determined that 
compli ance with this schedule  was poor. Based on interviews with 6178 persons, 86% (n=5343) 
took at least one dose of antimicrobial prophylaxis but fewer than half (44%, n=2712) reported 
taking antimicrobial prophylaxis for at least 60 days { Shepard  et al, 2002 }.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 30 of 139 
  
The CDC subsequently offered an additional antimicrobial treatment in a voluntary treatment 
continuation program with or without three doses of the BioThrax vaccine; about 200 opted to 
receive the supply of antimicrobials plus three doses of BioThrax { Tierney  et al, 2003 }.  
Ultimately, the attack s resulted in  22 cases of anthrax ; 11 cutaneous and 11 inhalation , five of 
which (all inhalation cases) resulted in mortality { Jerniga n et al, 2002 }. No cas es of anthrax were 
identified among persons recommended to take antimicrobial prophylaxis after the bioterrorist 
attacks of 2001 {Tierney  et al, 2003 }. 
In November of 2015 , the FDA approved  BioThrax for PEP given in three doses (administered at 
0, 2, and 4 weeks) along with a post -exposure regimen of appropriate antimicrobial prophylaxis. 
{Wright  et al, 2010 } However, in contrast to the ACIP’s earlier recommendation, which 
indicated that antimicrobial prophylaxis could cease after the third dose of vaccine 
{CDC , 2002}, the ACIP  updated their recommendations  to reflect a 60-day antimicrobial  
treatment period and to continue with the antimicrobial for 14 days following the third dose of 
vaccine , which could result in the antimicrobial being used for more than 60 days , if the 
initiation of the vaccination series was delayed .   
Given the poor compliance with an antimicrobial regimen of 60 days as observed in 2001, there 
is a demonstrated medical ne ed for a vaccine that can induce a rapid and robust immune 
response. AV7909, a vaccine consisting of AVA  plus the adjuvant CPG 7909, is under 
development to meet this need.  CPG 7909 is  a synthetic immunostimulatory oligonucleotide 
(short DNA sequence). It  has been shown to be  a toll -like receptor 9 (TLR9) agonist that induce s 
both an enhanced antigen -specific antibody response and a natural killer (NK) T -cell immune 
response when used in combination with prophylactic (preventative) or therapeutic vaccines 
{Krieg , 1996 ; Pisetsky , 1996 ; Kim et al, 1999 ; Stewart  et al, 2008 }. 
By combining AVA  with CPG 7909, the AV7909 product development program aims to create a 
new vaccine that will accelerate the development of the immune response to the B. anthracis  
antigens, reducing the number of doses required to induce full protection, thereby reducing the 
amount of antigen required to establish protective immunity. From the three clinical studies 
conducted to date , Study V011, Study EBS.AVA.201 and Study EBS.AVA.208  {Rynkiewicz et 
al, 2011 ; Hopk ins et al, 2013 ; Hopkins  et al, 2016 }, a formulation consisting of 0.5 mL of AVA 
plus 0.25 mg CPG 7909 administered intramuscularly (IM) on a 0, 2 week schedule has been 
selected as the candidate formulation for Phase 3.  
Based on the results of the last study, vaccination of healthy adults with 2 doses of AV7909 can 
potentially accelerate the development of a protective level of immunity by one or two weeks (in 
comparison to the time required with the 3 -dose schedule  of BioThrax ) depending on whether 
AV7909 doses are administered four weeks or two weeks apart  {Hopkins  et al, 2016}. This 
study also demonstrated  that AV7909 given in a 3-dose schedule  (as per the BioThrax label) 
resulted in a greater percentage  of individuals achieving a  potentially protective antibody level 
one week after the last vaccination and at all subsequent time points evaluated.   
A clini cal trial conducted with BioThrax and ciprofloxacin { EPDG , 2014 } as part of the process 
of PEP licensure found no evidence of any interaction between vaccinati on with BioThrax and 
the pharmacokinetics  (PK)  of ciprofloxacin or between dosing with ciprofloxacin and the 
immunogenicity of BioThrax. It is the goal of this trial to demonstrate that vaccination with Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 31 of 139 
  
AV7909 does not affect the PK profile s of either ciprofloxacin or doxycycline and that  neither 
ciprofloxacin nor doxycycline  impair the immunogenicity of AV7909.  
2.3. Benefit/Risk Assessment  
2.3.1.  Benefits  
No benefits can be guaranteed to individuals participating in this study. However, by joining this 
study, partici pants will be contributing to research that may result in the licensure of the next 
generation anthrax vaccine for PEP  (ie, AV7909) .   
2.3.2.  Risks  
2.3.2.1.  BioThrax  
More than 14 million doses of BioThrax have been administered to over 3.3 million people since 
it was appr oved in the U.S. in 1970  for pre -exposure prophylaxis { BioThrax.com  }. BioThrax is 
approved by the  Food and Drug Administration  (FDA ) and indicated for active immunization for 
the prevention of disease caused by B. anthracis  in persons 18 through 65 years of age.  Details 
with respect to the potential risks of administration of BioThrax can be found in the BioThrax 
prescribing information {BioThrax® Prescribing Infor mation, 2015 }. The most common 
injection -site reactions observed in clinical studies included  tenderness, pain, erythema/redness, 
edema/swelling, and arm motion limitation.  The most common systemic reactions were muscle 
aches, fatigue, and headache.  Other side effects include d bruising, warmth, itching, or nodules at 
the injection site, nasopharyngitis, back pain, nausea and diarrhea.  See the AV7909 
Investigator’s Brochure for more information.  
In a 200 -person trial designed to evaluate the BioThrax P EP schedule, the most common 
solicited injection site reactions were lump, tenderness and erythema, and the common systemic 
reactions were fatigue, headache and myalgia. Of those individuals who reported solicited 
reactions, ≥ 98% percent required minimal to no treatment and reported little to no interference 
with activities of daily living { BioThrax ® Prescribing Information, 2015}.  
2.3.2.2.  CPG 7909  
CPG 7909 has been inve stigated clinically since the mid -1990s for indications that have included 
cancer monotherapy, combination use with anti -cancer therapies, and as an adjuvant in vaccines 
against infectious diseases and cancers.  The most relevant risk data for this trial co me from 
clinical  studies of CPG 7909 used as an adjuvant  in vaccine trials for hepatitis B, influenza, 
anthrax, malaria, gram negative sepsis, pneumococcal disease, and cytomegalovirus  in normal 
participants. Safety data from such trials indicated that the  most commonly  reported 
reactogenicities were  increases in the frequency and severity of injection site reactions and 
systemic AEs including fatigue, headache, flu -like symptoms, transient decreases in neutrophil 
and lymphocyte counts, and myalgia have bee n reported with the addition of CPG 7909 to 
vaccine antigens {Coley , 2006 ; Cooper  et al, 200 4; Sagara  et al, 2009 ; Mullen  et al, 2008}. 
While immune activation by CPG 7909 is designed to be transient and localized to vaccine -
exposed draining lymphatics, the possibility exists for pathologic and sustained non -specific Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 32 of 139 
  
activation of either T or B lymphocytes. Because of the potential for CpG ODN adjuvants to 
trigger autoimmune disease in susceptible individuals { Segal  et al, 2000 }, all participant s should 
be monitored for a minimum of 12 months after the last vaccination. Participant s who 
discontinue study treatment should be encouraged to attend all subsequent clinic visits and safety 
follow -up contacts to facilitate this monitoring.  See the Investigator’s Brochure for additional 
details on the relationship of CPG 7909 to adverse events of special interest  (AESIs ; events with 
autoimmune etiology ).  
2.3.2.3.  AV7909  
The risks associated with AV7909 are similar to th ose described for BioThrax and CPG 7909 
since AV7909 is a combination of the two products. In the three clinical trials completed to date 
as a part of the AV7909 clinical development program, 241 healthy participants were immunized 
with the combination of AVA + CPG  7909. Across these three trials, most participant s have  
experienced mild to moderate injection site reactions following vaccination with between 40% 
and 90% of participants reporting tenderness, pain, and arm motion limitation in their diary 
responses. Participant s reporting these latter reactions experienced predominantly mild reactions, 
with generally less than 10% experienc ing moderate or severe reactions. The most common 
systemic adverse reactions (observed in ≥5% of participants) were muscle aches, fatigue, and 
headache.  See the AV7909 Investigator’s Brochure for more information.  
Hypersensitivity and Anaphylactic/Anaphylactoid Reactions  
Acute allergic reactions  have occurred in the AV7909 program with a report of urticaria after the 
second of two 0.5 mL dose s of AV7909  (AV7909 Arm 1; Study EBS.AVA.208) that resolved 
with diphenhydramine hydrochloride . This arm received two doses of AV7909 containing 
0.5 mL AVA +0.25 m g CPG 7909 given 2 weeks apart  {Hopkins  et al,  2016}. The participant  
had a history of urticaria and this event was considered by the investigator as unrelated to the 
study product administration . In Study EBS.AVA.201, urticaria wa s reported in a participant in 
the AV7909 Formulation 1 arm, which was treated and resolved after 2 days and considered 
possibly related to study product administration. The Formulation 1 arm participants received 
two 0.5 mL doses formulated to contain 0.5 mL AVA + 0.5  mg CPG 7909 that  were delivered 
IM two weeks apart.  
Two participants in Study EBS.AVA.208 discontinued vaccination because of mild generalized 
pruritus and rash (AV7909 Arm 2) and moderate rash (AV7909 Arm 1), all events considered to 
be related to study product administration . Both Arm 1 and Arm 2 received two doses of 
AV7909 containing 0 .5 mL AVA +  0.25 mg CPG 7909; however, for Arm 1, the doses were 
delivered two weeks apart and for Arm 2, the doses were delivered 4 weeks apart  {Hopkins  et al, 
2016}. In Study V011,  which consisted of three treatment groups [AVA  (0.5 mL)  alone, CPG 
7909  (1.0 mg) -alone and AVA (0.5 mL) + CPG 7909 (1.0 mg )] all administered as  three doses 
two weeks apart , two participants in the AVA + CPG 7909 arm had hypersensitivity reactions . 
Both of these were  considered by the investigator to be unlikely related to study product 
administration . An additional  participant i n the AVA + CPG 7909 group discontinued 
vaccination after the second injection due to the development of moderate generalized rash 
(accompanied by pruritus) that was considered to be related to study product administration 
{Coley , 2006 }. Appropriate medical treatment and supervision must be available to manage 
possible anaphylactic reactions following administration of the vaccine.   Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 33 of 139 
  
AV7909 is not to be administer ed to participant s with known sensitivity to any of the vaccine 
components, eg, synthetic ODNs, formaldehyde, benz ethonium chloride (phemerol), or 
aluminum , or a sensitivity to latex . 
No participant s in the completed AV7909 clinical trials or in CPG 7909 -adjuvanted infectious 
disease trials have reported AEs related to autoimmune disorders, although several have reported 
positive, transient and/or non -symptomatic findings for clinical laboratory markers of disease 
such as anti-nuclear antibodies ( ANA ), anti -double -stranded deoxyribonucleic acid 
(anti-dsDNA)  antibodies , and rheumatoid factor (RF). In oncology trials of CPG 7909 (reviewed 
in the AV7909 Investigator’s Brochure) that typically use higher doses and treatment durations 
than expected with AV7909 va ccine exposure, autoimmune disease has been reported in multiple 
participant s, although causal attribution to the study product is complicated by comorbi dities and 
concomitant products/therapies. Autoimmune conditions have included polyarthralgia, arthriti s, 
Sjögren’s s yndrome, autoimmune thyroiditis, vitiligo, Guillain -Barré syndrome, and ulcerative 
colitis.  
2.3.2.4.  Study Procedures (IM injections and Venipuncture)  
Potential risks associated with IM injections include accidental injection of a vein instead of 
muscle, dizziness, fainting, or infection, as well as pain associated with a needle stick. Potential 
risks associated with venipuncture include pain, bruising, dizziness, and infection.  
2.3.2.5.  Ciprofloxacin  
Ciprofloxacin , a fluoroquinolone  antimicrobial agent, belongs to the class of quinolone 
antibiotics which target bacterial DNA gyrase and topoisomerase IV. The fluoroquino lones 
including ciprofloxacin have potent bactericidal activities again st a broad range of gram -negative 
and gram -positive bacteria including B. anthracis  {MacDougall , 2018 }.  
Fluoroquinolones, including ciprofloxacin , have been associated with disabling and potentia lly 
irreversible serious adverse reactions that have occurred together including:  
 Tendinitis and tendon rupture  
 Peripheral neuropathy  
 Central nervous system effects  
For additional safety  information on ciprofloxacin , please refer to the prescribing information  
provided in the Pharmacy Manual . 
2.3.2.6.  Doxycycline   
Doxycycline hyclate is a broad -spectrum antibiotic synthetically derived from oxytetracycline.  
As a member of the tetracycline class of antibiotics, doxycycline functions primarily through a 
bacteri ostatic mechanism which is thought to occur via the inhibition of protein synthesis. The 
tetracyclines, including doxycycline, are active across a broad range of gram negative and gram -
positive bacteria including B. anthracis . Details with respect to the p otential risks associated with 
the administration  of doxycycline hyclate  can be found in the prescribing information  provided 
in the Pharmacy Manual .  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 34 of 139 
  
3. STUDY OBJECTIVES & E NDPOINTS  
3.1. Study Objectives  
3.1.1.  Primary Objective  
To evaluate the pharmacokinetic (PK) prof iles of ciprofloxacin or doxycycline when 
administered orally, prior to, and following, the intramuscular (IM) administration of a two -dose 
schedule  of AV7909 administered two weeks apart.  
3.1.2.  Secondary Objectives  
 To assess the safety of concurrent administrat ion of oral ciprofloxacin  or doxycycline  and 
two doses of AV7909 administered IM.  
 To evaluate the Day 3 7 immune response using the toxin -neutralizing antibody (TNA) 
assay following two IM doses of AV7909 with and without the concurrent oral 
administration  of ciprofloxacin  or doxycycline . 
3.2. Study Endpoints  
3.2.1.  Primary Endpoints  
 Area under the curve from 0 to 12 hours (AUC 0-12h) and maximum concentration (C max) 
for ciprofloxacin on Days 8 and 3 5 
 Area under the curve from 0 to 12 hours (AUC 0-12h) and maximum concen tration (C max) 
for doxycycline on Days 8 and 38  
3.2.2.  Secondary Endpoints  
Safety  
 Incidence of AEs from the first dose of any IP  through the Final Study Visit ( Day 
51 ± 1 d)  
 Incidence of serious AEs (SAEs) from the first dose of any IP until the 12 -month follow -
up (Day 38 8 ± 14 d) 
 Incidence of solicited systemic and injection site reactions reported in participant e-
diaries following each vaccination  
 Incidence of AESIs  from the first dose of any IP until the 12 -month follow -up 
(Day  388 ± 14 d) 
 Incidence of  clinical laboratory abnormalities  
Pharmacokinetics and Immunogenicity  
 AUC 0-12h and C max for ciprofloxacin on Days 4 and 31 and for doxycycline on Days 2 and 
32 
 Geometric mean TNA 50% neutralizing factor (NF 50) values 2 weeks after the second 
vaccination ( Day 37  ± 1 d) Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 35 of 139 
  
4. STUDY DESIGN  
4.1. Overall Study Design  
This is a randomized, open -label, phase 2, multicenter trial to investigate the potential 
interactions of AV7909 and ciprofloxacin  or doxycycline when administered concomitantly . The 
potential effect of AV7909 vaccination on ciprofloxacin or doxycycline serum levels will be 
investigated by evaluating the changes in the single dose and steady -state PK profiles of 
ciprofloxacin or doxycycline before and after vaccination with a two -dose series of AV7909.  
The effect of ciprofloxacin or doxycycline dosing on the immunogenicity of AV7909 will be 
investigated by evaluating whether TNA levels two weeks following the final dose of a two -dose 
vaccination series is affected by concomitant dosing with oral ciproflox acin or doxycycline . 
Healthy males and females  18 to 45 years of age , inclusive,  will read, sign and date an informed 
consent form  (ICF)  explaining the study and then be screened  (2 to 28 days prior to 
randomization)  for eligibility to participa te in the s tudy.   Participants (N= 210) meeting the entry 
criteria will be evenly randomized 1:1:1 to one of the  three  investigational product (IP) groups 
shown in Table  2. Approximately t he first 40 participants who are randomized into IP Groups 1 
and 2 will be assigned to Treatment Group s 1A or 2A while the remaining 30 participants  
randomized into IP Groups 1 and 2 thereafter will be assigned to Treatment Group s 1B or 2B.   
Randomization will be stratified by site.  A representative racial distribution will be sought 
among participants and sites will be asked to recruit populations that are gender - and age -
balanced (ie, between 40 -60% male with 40 -60% of particip ants in the two age ranges of 18 -30 
years of age  and 31 -45 years of age ). 
Table  2: Study Groups  
IP Group  Treatment  
Group  Treatment  Sample Size  
 (N) 
1 Cipro  1A AV7909 + ciprofloxacin  (with PK assessment)  ≈40 
≈70 
1B AV7909 + ciprofloxacin  (without PK assessment)  30 
2 Doxy  2A AV7909 + doxycycline (with PK assessment)  ≈40 ≈70 
2B AV7909 + doxycycline (without PK assessment)  30 
3 AV7909  3 AV7909 only  70 
  TOTAL  ≈210 
Figure 1 shows the design for this study , with an event schematic for the entire study being 
presented in  Figure 2 followed by brief discussions of each group’s schedule. Detailed schedules 
are presented in Section  8.1.2  through Section  8.1.6.   
Safety in all groups will be assessed up to Day 51 by in -clinic recording of vital signs, adverse 
events (AEs, SAEs, and potential AESIs), concomitant medications, physical examination 
results, and by clinical laboratory outcomes recorded at screening and at Day 51 or the Early 
Withdrawal Visit (EWV), if applicab le. Adverse events of special interest are AEs associated 
with autoimmune disease as defined by the Center for Biologics Evaluation and Research Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary   Page 36 of 139 
  
(CBER ); refer to Appendix  B; these may represent a safety signal for vaccine -associated 
autoimmunity. The severity of AEs, laboratory test results for select analytes, and vital sign 
results will be assessed based on th e FDA Guidance for Industry: Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials  (refer to 
Appendix  A). 
Additionally, an elect ronic  diary (e -diary) will be used following each vaccination  to collect 
daily information on  reactogenicity events including systemic and local ( injection site ) reactions  
and any changes in concomitant medications . For participants in Group 1 and 2, a separate 
antibiotic compliance e-diary will be used to record the  dates and times of self -administered 
ciprofloxacin or doxycycline dose s. This information will be evaluated on a routine basis and 
used by  the site staff to identify additional AEs, SAEs, potential AESIs, and  changes in  
concomitant medications as well as to document ciprofloxacin  or doxycycline compliance. Blood 
samples for autoimmunity assessment will be taken at randomization (Day 1) and Day 51 (or 
EWV) f or testing (if medically indicated  as per PI’s discretion  based on report of potential AESI ) 
of TSH levels, and RF, ANA and anti -dsDNA autoantibodies.   
Safety follow -up phone contacts to collect information on SAEs and any potential AESIs will 
occur 3 months (Day 114  ± 14 d), 6 months (Day 205  ± 14 d), 9 months (Day 296  ± 14 d) and 12 
months (Day 388  ± 14 d) after the second vaccination. Samples may also be collected at 
unscheduled visits following the safety follow -up phone contact(s) to investigate re ports of 
potential AESIs . 
Independent safety oversight will be provided by a Data Safety Monitoring Board (DSMB), 
which will be notified of significant AEs (refer to Section  8.5) as determined by the medical 
monitor  (MM)  on an ongoing basis. The DSMB will comprise at least three voting members, to 
include one expert in immunology to specifically support the evaluation of potential AESIs for 
autoimmune etiology, if pre -existing or new onset, and relationship to the study product.  The 
DSMB will make recommendations regarding the safety of continuing enrollment and dosing. 
Study enrollment and dosing may be interrupted at the request of the DSMB Chair if it is 
believed that an AE represents a significant safety concern requiring suspension of dosing 
pending full DSMB evaluation. The operations of the DSMB will be detailed in a DSMB 
Charter.Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 (28 Oct 2019)     
 
Confidential & Proprietary   Page 37 of 139 
  
Figure 1:  Study Des ign for EBS.AVA.210  
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 (28 Oct 2019)     
 
Confidential & Proprietary   Page 38 of 139 
  
Figure 2:  Event Schematic for EBS.AVA.210 Groups 1 to 3 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 39 of 139 
  
4.1.1.  Group 1 A Schedule  
The 40 participants in Group 1 A will have blood drawn at randomization (Day 1) for TNA  
testing , and TSH and autoantibody testing. These  participants will  receive both ciprofloxacin and 
AV7909  and undergo four ciprofloxacin PK sessions . They will have a final blood draw for TNA 
on Day 37 and will complete their final visit for safety  including a blood draw for TSH and 
autoantibodies  on Day 51. Note: testing of samples for TSH levels and autoantibodies will be 
performed only if medically indicated (ie, as per PI’s discretion based on a report of a potential 
AESI).  
Ciprofloxacin (500 mg by mouth [per os] every 12 hours [q 12 hr]) will be administered  
intermittently, ie, on D ays 4 -9, Days 22 -24 and Days 31 -37. Participants will use the same 
supply of ciprofloxacin in the clinic and for self -administration at home.  
AV7909 (0.5 mL) will be administered by IM injection delivered on:  
 Day 8 (Note: this will be administered in the evening following completion of the PK 
session  and administration of the evening antibiotic )  
 Day 23  
Ciprofloxacin PK session s will be performed on Days 4, 8, 31, and 35. On days  with PK 
sessions , blood samples for measurement of ciprofloxacin concentratio ns will be collected at 
0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose (±  5 min through hr 4 , 
then ± 15 min thereafter ). Ciprofloxacin pre -dose or trough values (all samples collected prior to 
the morning dose of ciprofloxacin) w ill be measured on Days, 4, 5, 6, 7 and 8 ; and again on Days 
31, 32, 33, 34 and 35. The ciprofloxacin pre -dose values on Days 4, 8, 31 and 35 serve as the t=0 
values for the PK session s on those days as well as contributing to the two trough  value  analyses  
used to evaluate achievement of steady state  before and after vaccination .  
4.1.2.  Group 1B Schedule  
As shown in  Figure 2 except for clinic visits for PK and trough value sampling, the 30 
participants in Group 1B will receive otherwise identical treatment to those in Group 1 A. They 
will have blood drawn at randomization (Day 1) for TNA, TSH and autoantibody testing  and will  
receive a supply of  ciprofloxacin after they have been randomized into Group 1 . They will begin 
taking ciprofloxacin on Day  4, self-administering the antibiotic intermittently on Days 4 -9, Days 
22-24, and Days 31 -37. Following randomization,  they will have f our scheduled clinic visits. 
The first two will be on Day 8 and Day 23, when they receive their first and second vaccinations 
with AV7909 . Their third clinic visit will be  on Da y 37 when they will have a final blood draw 
for TNA and their fourth and final planned clinic visit will occur on Day 51 and includes  a blood 
draw for TSH and autoantibodies .  
4.1.3.  Group 2A  Schedule  
The 40 participants in Group 2A will have blood drawn at randomization (Day 1) for TNA, TSH 
and autoantibody testing.  These participant s will receive both doxycycline  and AV7909  and will 
undergo four PK sessions . They will have a blood draw for TNA on Day 37  and will complete 
their final visit for safety including a blood draw for TSH and autoantibodies on Day 51.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 40 of 139 
  
Doxycycline  (100 mg by m outh [per os] every 12 hours [ po q 12 hr]) will be administered 
intermittently  ie, on Days 2 -9, Days 22 -24 and Days 32 -38, in three courses , the exact format for 
which will be provid ed in the Pharmacy Manual.  Participa nts will use the same supply of 
doxycycline in the clinic and for self -administration at home.  
AV7909 (0.5 mL) will be administered  by IM  injection  on:  
 Day 8 (Note: this will be administered in the evening following completion of the PK 
session)  
 Day 23  
Doxycycline PK session s will be p erformed on Days 2, 8, 32 and 38. On days  with PK session s, 
blood samples for measurement of doxycycline  concentrations will be collected at 0.25, 0.5, 
0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose (±  5 min through hr 4 , then ± 15 min 
thereafter ).  Doxycycline  pre-dose or trough values (all samples collected prior to the morning 
dose of doxycycline ) will be measured on Days 2, 3, 4, 5, 6, 7 and 8 ; and again on Days 32, 33, 
34, 35, 36, 37  and 3 8. The doxycycline  pre-dose values on Days 2, 8, 32 and 3 8 serve as the t=0 
values for the PK session s on those days as well as contributing to the two trough analyses used 
to evaluate achievement of steady state  before and after vaccination .  
4.1.4.  Group 2B Schedule  
As shown in  Figure 2 except for clinic visits for PK and trough value sampling, the 30 
participants in Group 2B  will receive otherwise identical treatment to those in Group 2A . They 
will have blood drawn at randomi zation (Day 1) for TNA, TSH and autoantibody testing and will 
receive a supply of  doxycycline after they have been randomized into Group  2. They will begin 
taking doxycycline  on Day 2,  self-administering  the antibiotic intermittently on Days 2 -9, Days 
22-24 and Days 32 -38. Following randomization, they will have four scheduled clinic visits. The 
first two will be on Day 8 and Day 23, when they receive their first and second vaccinations with 
AV7909. Their third clinic visit will be on Day 37 when they will have a final blood draw for 
TNA and their fourth and final planned clinic visit will occur on Day 51 and includes a blood 
draw for TSH and autoantibodies.  
4.1.5.  Group 3 Schedule  
The 70 participants in Group 3 will have blood drawn at randomization (Day 1) for TN A, TSH 
and autoantibody testing . They receive two doses of  AV7909 , the first on Day 8 and the second 
on Day 23.  They will have a final blood draw for TNA on Day 37  and will complete their final 
visit for safety including a blood draw for TSH and autoantibodies on Day 51. 
4.2. Scientific Rationale for Study Design  
The study design is similar to that of an earlier trial (EBS.AVA.009: [STUDY_ID_REMOVED] ; Longstreth  
et al, 2018 ) conducted with the predecessor anthrax vaccine, BioThrax.  As was done in that trial, 
antibiotic  administration will be intermittent rather than continuous in order to reduce antibiotic 
exposure thereby presumably  reducing  the risks of adverse effects  from these antibiotics  in the se 
healthy participants .  In this trial, as in the previous trial, the aim is to charac terize the single 
dose and steady state PK profiles of ciprofloxacin or doxycycline before and after vaccination to Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 41 of 139 
  
determine whether vaccination affects antibiotic  PK. Additionally, a second aim is to evaluate 
whether administration of either of these ant ibiotics  affect s the immunogenicity of AV7909 
when evaluated with the TNA assay two weeks after the last vaccination of a 0 -, 2-week 
schedule .  
4.3. Justification of the Dose and Schedule  
4.3.1.  AV7909  
The AV7909 formulation, dose, route of administration and dosing schedule being used in this 
study are the same as those being used in the licensure -enabling clinical trial being conducted 
concurrently  (Study EBS.AVA.212 ). The formulation of 0.5 mL AVA and  0.25 mg CPG 7909, 
administered IM as two 0.5 mL doses, 2 weeks apart , was selected for further development based 
on the following observations in two previously conducted AV7909 clinical trials { Hopk ins et al, 
2013 ; Hopkins  et al, 2016 }. 
 Keeping  the AVA content at 0.5 mL (compared to  0.25 mL ) maintained 
immu nogenicity  
 Increasing the CPG 7909 content beyond  0.25 mg to 0.5 mg increased the incidence 
and severity of both local and systemic reactions as assessed with a participant  
e-diary without enhancing immunogenicity  
 Injection site reactogenicity was similar to that  observed  for BioThrax  
 At 0.25 mg CPG 7909, a  lower amount of unbound CPG could potentially reduce the 
risk of off -target immune activation  
4.3.2.  Ciprofloxacin  
The ciprofloxacin dose  (500 mg) , dosing schedule [twice a day (q 12 hr) ] and route of 
administr ation  [by mouth  (po)] being used in this study are those that would be used for PEP in 
the event of anthrax exposure and similar  to those  that were used in the prior PEP study 
conducted with ciprofloxacin and BioThrax { EPDG , 2014 }.  In this study and the prior BioThrax 
study  (Study EBS.AVA.009) , ciprofloxacin administration occurs on an intermittent daily rather 
than a continuous daily dosing schedule , with the assumption that intermittent dosing would 
achieve the required single dose and steady state  concentrations needed prior to and following 
the vaccination schedule , as well as the immunogenicity endpoints while restricting the 
antibiotics administer ed to the minimum to achieve these ends.  
Ciprofloxacin will be admin istered i ntermittently in  three courses  that will be used both by site 
staff for in -clinic visits and by participants when they are at home. The course  format in terms of 
number of tablets  and when participants will receive each course will be described in the 
Pharmacy Manual.   
In addition to ensuring the achievement of steady state concentrations before and after the 
complete  two-dose series  of the vaccine,  the selected ciprofloxacin dosin g periods reflect the 
time when the inflammatory and immunosuppressive effects of ciprofloxacin  are most likely to   
affect the antibody response to AV7909  {Takahashi  et al, 2005 ; Kaminski  et al, 2010 }. The Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 42 of 139 
  
intermittent dosing schedule was chosen in the hopes of minimizing any adverse effects from 
ciprofloxacin. This strategy appeared to have been successful in the BioThrax plus  ciprofloxacin 
study in that ciprofloxacin -related AEs were low in number, frequently reported as related to 
both ciprofloxacin and BioThrax, generally mild in severity and resolved without sequelae by the 
end of the study { EPDG , 2014 }.  
4.3.3.  Doxycycline  
The doxycycline dose  (100 mg ), dosing schedule [twice a day (q 12 hr)] and route of 
administration  [by mouth ( po)] being used in this study are those that would be used for PEP in 
the event of inhalation exposure  to anthrax . As with ciprofloxacin, doxycycline administration  
will occur on an intermittent daily rather than a continuous daily dosing schedule  for the same 
reason this approach is used for ciprofloxacin .  This schedule  will provide  the required single 
dose and steady state PK dosing regimens needed and , in addition to achieving the needed 
steady -state concentrations before and after vaccination, is designed to achieve the 
immunogenicity  end-points while restricting the antibiotics administered to the minimum 
required to achieve these ends.   
However, since the half -life of doxycycline is considerably longer than that of ciprofloxacin (15-
16 hours after a single dose and 22 or more  hours  after multiple doses compared to 3 -7 hours for 
ciprofloxacin ), participants in Group 2 will receive a few more doses of antibiotic than those in 
Group 1. This is because we believe more days of dosing will be required to achieve steady state. 
Thus , Group 2 will receive seven days of dosing with doxycycline  compared to five days used 
for ciprofloxacin  before tests for steady state are applied . 
Doxycycline will also be administered in three courses  that will be used both by site staff for in -
clinic visits and by participants when they are at home. The format of the courses in terms of 
number of tablets and when participants will receive each course will be described in the 
Pharmacy Manual.  
The doxycy cline dosing periods were chosen because they have been shown to have an effect  on 
humoral immunity  in mice  {Woo  et al, 1999 } and to affect post -vaccination cell -mediated 
immunity in swine { Pomorska -Mól et al. 2014 }, suggesting it could  also affect the antibody 
response to AV7909. The intermittent dosing schedule was chosen in the hopes of minimizing 
any adverse effects from doxycycline .  
4.4. End of Study Definition  
A participant is considered to have completed the study if he or she  has completed all phases of 
this study through the 12-month final safety follow -up phone contact (ie, Day 388  ± 14 d). 
Participants who do not comple te the study are considered to have been withdrawn from the trial  
(refer to Section  7.3). 
The End of Study Date is defined as the date of the last participant ’s final safety follow -up call, 
or earlier if the participant ’s last follow -up contact occurs before this time point . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 43 of 139 
  
5. STUDY POPULATION  
Participants will be recruited at up to five clinical research centers  in the U nited States. At least  
210 healthy adults meeting the eligibility criteria will be randomized 1:1:1 to one of the three IP  
groups : 70 in Group 1  (AV7909 + ciprofloxacin), 70 in Group 2  (AV7909 + doxycycline ) and 70 
in Group 3  (AV7909 alone) . Groups 1 and 2 will each have two subgrou ps; the A subgroup 
(N=40) will undergo PK session s while the B subgroup (N = 30) will not. Approximately t he 
first 40 participants who are randomized into Groups 1 and 2 will be assigned to Treatment 
Group 1A or Group 2A , while those who are randomized int o Groups 1 and 2 thereafter will be 
assigned to Groups 1B or 2B.   
No waivers of inclusion and/or exclusion criteria will be permitted in the trial. The sites will be 
asked to implement  procedures  that will  ensure a representative racial distribution among  
recruited participant s and result in populatio ns that are gender - and age -balanced (ie, between 
40-60% male with 40 -60% of participants in the two age ranges of 18 -30 years of age  and 31 -45 
years of age).  
5.1. Inclusion Criteria  
Individuals must meet all of the following inclusion criteria for study participation:  
1. Written informed consent obtained from the participant (dated, signed, and captured in  
the medical chart at the site) . 
2. A male or female , aged 18 to 45 years of age,  inclusive,  at the time of informed consent . 
3. Healthy condition  as established by medical history and clinical examination  before 
entering into the study . 
4. Have a body mass index (BMI) less than  or equal to  35.0 kg/m2 at the Screening visit . 
5. Have adequate venous access for phlebotomie s.  
6. For a woman of childbearing potential (WOCBP), negative pregnancy test at Screening 
and pre -randomization  on Day 1, not currently breastfeeding, and no int ention to become 
pregnant  during the study period through 12 months after last receipt of any 
investigational product (IP) .  
Every female participant is considered to be a WOCBP  unless she is surgically sterile ( ie, 
has had a hysterectomy , bilateral salpingectomy or bilateral oophorectomy ) or 
postmenopausal [which is defined as >12 consecutive months without menses and  a 
Screening FSH  of >30 mIU/mL ].  Adequate birth control (as defined here) must be 
initiated at least one month  prior to randomization on Day 1 and  used throughout the trial.  
Adequate birth control meth ods are sexual abstinence, intrauterine device /system  
(IUD /IUS ), birth control pills, implantable or injectable contraceptives ( eg, Norplant® or 
Depo -Provera®), removable birth control device ( eg, NuvaRing® or Evra® patches) or 
double -barrier method of bir th control (diaphragm in combination with contraceptive 
jelly or condoms in conjunction with contraceptive jelly, cream or foam), tubal ligation, 
or have a monogamous relationship with vasectomized partner who has been 
vasectomized for 6 months or more pri or to the participant’s trial entry .  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 44 of 139 
  
Female participants randomized to Groups  1 or 2: be willing to add a double -barrier 
method, IUD , or abstinence as back -up forms of birth control since ciprofloxacin and 
doxycycline may decrease the effectiveness of bir th control pills, implantable or 
injectable contraceptives .  
5.2. Exclusion Criteria  
Individuals meeting any of the following exclusion criteria will be excluded from study 
participation : 
1. A Screening clinical laboratory test result greater than the central labo ratory’s upper limit 
of normal (ULN) for aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
random glucose, total bilirubin, blood urea nitrogen (BUN), or creatinine . Other serum 
chemistry parameters that are not within the reference range will not be considered 
exclusionary  unless deemed clinically significant by the principal investigator . 
2. History of allergic reaction or intolerance to quinolone antimicrobials  or any medical 
condition that would contraindicate the use of ciprofloxacin, including and not limited to 
vascular di sorders , tendon disorders, certain genetic connective tissue disorders (eg, 
Marfan and Ehlers –Danlos syndrome ), prolongation of QT interval, seizures, peripheral 
neuropathy , increased risk of C. difficile  infection  (see ciprofloxacin  prescribing 
information  in the Pharmacy Manual ). 
3. History of allergic reaction or intolerance to tetracycline antibiotics or any medical 
condition that would contrai ndicate the use of  doxycycline  including an increased  risk of 
C. difficile  infection , increase s in BUN  or an increased sensitivity to direct sunlight or 
ultraviolet radiation resulting in erythema  (see doxycycline prescribing information  in the 
Pharmacy Manual ).   
4. Has a need for any of the prohibited medications in Section  6.5.1  or requires the 
medications/foods within the prohibited times in Sectio n 5.3.1.1 .  
5. Have a tattoo/scar/birthmark or any other skin condition affecting the deltoid area that 
may interfere with injection site assessments . 
6. History of anthrax disease, suspected exposure to anthrax, or previous vaccination with 
any anthrax vaccine .  
7. Have previously served in the military any time after 1990 or plan to enlist in the military 
any time from Screening through the final telephone contact .  
8. Previous anaphylactic reaction, severe systemic response, or serious hypersensitivity to a 
prior immunization or a known allergy to synthetic ODNs , aluminum, formaldehyde, 
benzethonium chloride  (phemerol) . 
9. Plan to have an elective surgery at an y point during the study until after  the final safety 
phone contact . 
10. Have donated or plan to donate blood within one month prior to enrollment or at any 
point during the study until after  the final safety phone contact . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 45 of 139 
  
11. Use of any investigational or non-registered product (drug, vaccine or biologic)  within 30 
days preceding the dose of study vaccine, or planned use during the study until after  the 
final safety phone contact .  
12. Planned administration of any commercially -available vaccine from one  week p rior to the 
first study vaccination through two weeks after the last vaccination .  
13. Have experienced chronic dosing (defined as more than 14 days) with any immune -
modifying drugs within six months of study enrollment. This includes oral, 
intramuscular,  intra-articular,  intravenous,  or inhalation corticosteroids  except in the case 
of inhaled  or intranasal  medications for seasonal allergies (see Table 3).  
14. Receipt of immunoglobulins and/or any blood products within the three months 
preceding study enrollment or at any point during the study period until after the final 
safety visit on Day 51 . 
15. An abnormal electrocardiogram (ECG) at screening interpreted as ‘A bnormal, 
Significant’. Inclusion of participant s with ‘Abnormal, Insignificant’ ECG s will be based 
on the principal investigator’s discretion . 
16. Have an active malignancy or history of metastatic or hematologic malignancy .  
17. Have a history of an autoimmune, i nflammatory, vasculitic or rheumaticor rheumatic 
disease including but not limited to systemic lupus erythematosus, Guillain -Barré 
syndrome, myasthenia gravis, polymyalgia rheumatica, diabetes mellitus type I, 
rheumatoid arthritis or scleroderma . 
18. A positiv e laboratory evidence of hepatitis B, hepatitis C, or human immunodeficiency 
virus (HIV) HIV -1 or HIV -2 infection . 
19. Positive result on urine drug screen, any evidence of ongoing drug abuse or dependence 
(including alcohol), or recent history (over the past five years) of treatment for alcohol or 
drug abuse .  
20. Has an acute disease at the time of enrollment . 
Note that screening lab tests may be delayed to allow the resolution of a transient acute 
condition or the subject may be rescreened according to procedure s under  Section  5.4.  
21. Any medical condition that, in the opinion of the investigator, could adversely impact the 
participan t’s involvement or the conduct of the study . 
22. Have a significant chronic condition  (see Sponsor’s guidance on  significant chronic 
conditions in  Appendix  C), eg, serious cardiov ascular, pulmonary, hepatic,  type II 
diabetes  mellitus or renal disease that, in the opinion of the investigator, would render 
treatment unsafe or would interfere with trial evaluations or completion of the study . 
23. An opinion of the investigator that it wou ld be unwise to allow the participant to be 
randomized into the study . 
24. Member or immediate family member of an investigator site team.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 46 of 139 
  
5.3. Lifestyle Restrictions  
Participants in the two antibiotic groups  will have certain lifestyle restrictions with which  they 
will need to comply and that the site staff will need to remind them on an on -going basis.  In 
addition, for Group 1A and 2A participants, meals served during PK sessions need to observe 
these same limitations. Details of these restrictions are provi ded below.  
5.3.1.  Meals and Dietary Restrictions  
5.3.1.1.  Precautions for Participants Taking Ciprofloxacin  or Doxycycline  
Participants in Groups 1  and 2 should be informed that these antibiotics  may be taken with or 
without food, but antacids containing magnesium or alum inum and multivitamin /supplement  
preparations with calcium, zinc or other metals, eg, iron, should be taken at least two hours 
before or six hours after  antibiotic  administration. Furthermore, the same schedule should be 
used for the consumption of dairy p roducts (like milk or yogurt) or calcium -fortified juices and 
the timing of antibiotic  dosing since absorption of antibiotic  may be significantly reduced  by 
consumption of dairy products.  However, these antibiotics  may be taken with a meal that 
contains th ese products.  In addition, participants in Group  2 should avoid taking bismuth 
subsalicylate (Pepto Bismol®) within 2 -3 hours of their doxycycline dose . 
Participants should also be asked to limit their consumption of caffeine  to 400 mg /day 
(equivalent to a bout 4 cups of coffee).   
5.3.1.2.  Special Meals for Participants on Days with PK Sessions  
On their PK session days [Days 4, 8, 31 and 35 for Group 1A  (ciprofloxacin)  and Days 2, 8, 32 
and 38 for Group 2A  (doxycycline )], participants  are to be provided a non -dairy breakfast , 30 to 
60 min prior to dosing. This is to be followed over the course of the day with a light lunch and a 
light dinner/snack.  
5.3.2.  Activity  Restrictions  
Participants should be asked to limit their time in the sun  and to avoid the use of sunlamps  and 
tanning beds . Ciprofloxacin and doxycycline  increase  the sensitivity of the skin to the ultraviolet 
radiation both from the sun  and from artificial sources such as sunlamps and tanning beds. All 
such exposures while on these medications can result in severe sunburn s, blisters or swelling of 
the skin.  
Participants should be reminded to avoid sun exposure but if they must go out to avoid the high 
UV hours of 10 am to 2 pm, to wear sunscreen and protective gear (hats, sunglasses  and 
protective clothes ) when they do go outside . If they develop any of the  signs or symptom s of 
sunburn while on  antibiotic , participants must  be instructed to  notify the site staff.   
Participants  in Group 1 should be advised against engaging in strenuous  physical activity as this 
may independently increase the risk of tendon rupture from ciprofloxacin.  
During each PK session, participants should remain  in a seated or semi -recumbent position for 2 
hours post -dose and then maintain  a light activity level throughout the course of the day . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 47 of 139 
  
5.4. Screen Failures  
A screen failure is a participant from whom informed consent is obtained and documented in 
writing, but who is not subsequently randomized to study treatment. Reasons for screen fail ure 
are to be recorded in the electronic case report forms (eCRFs).  
All screening procedures must occur 2 to 28 days before the Day 1 study visit, at which time 
participants are allocated to a treatment group. During the initial Screening visit, the Princi pal 
Investigator ( PI) or designee will confirm, by documentation of the evaluation, any transient 
acute condition that may affect the participant’s Screening clinical laboratory results  (which 
should meet the criteria specified in Exclusion criterion  1). The clinical laboratory assessment 
can be performed at the same visit or delayed, allowing time for resolution of the transient acute 
condition (eg, dela yed screening until resolution of febrile illness, delayed urine occult blood in a 
menstruating woman). The clinical laboratory testing for Screening will not be performed more 
than twice (one initial and one  repeat test for a total of two times). If the l aboratory results are 
abnormal due to a processing or handling error, the test will be repeated without counting 
towards the not -to-exceed total of twice performed.  
Participants who are screen failures are permitted to be rescreened one time (only) accord ing to 
the PI’s discretion. In the event that the participant is rescreened for trial participation, a new 
informed consent form (ICF) must be signed. For example, if there are any delays between 
Screening and enrollment that cause eligible participants to  fall outside the Screening window, 
these participants may be re -consented and rescreened. Participants who complete the 
rescreening and are randomized in the study will not be considered screen failures.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 48 of 139 
  
6. TREATMENTS  
6.1. Treatment Administration  
6.1.1.  AV7909 Descript ion 
AV7909 is a preformulated, sterile, milky -white suspension for IM injection consisting of the 
AVA drug substance  (AVA) and CPG 7909 adjuvant.  All p articipants will receive one dose of 
AV7909 0.5 mL IM, consisting of 0.5 mL AVA and 0.25 mg CPG 7909, on Day 8 and one dose 
IM on Day 23. 
The AV7909 vaccine, manufactured by  
, will be supplied in 6 mL (nominal fill volume) clear  borosilicate glass multi -dose 
vials with rubber stoppers and flip -top aluminum seals for storage. A single vial is filled with 
approximately 6.1 mL. For purposes of this trial, only a single dose (0.5 mL) will be used from 
each vial.  
Each vial  will be labeled with the name, main constituents and volume of study product; route of 
administration; manufacturer name; characterization as “sterile” product and “multi -dose vial”; 
storage conditions; manufacturing (fill) date and lot number; and approp riate federal caution 
statement for investigational use product.  
6.1.2.  Ciprofloxacin Description  
Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is a synthetic broad -spectrum  
antimicrobial agent for oral administration. It is the monohydrochloride monohydra te salt of 1 -
cyclopropyl -6-fluoro -1, 4-dihydro -4-oxo-7-(1-piperazinyl) -3-quinolinecarboxylic acid. It is a 
faintly yellowish to light yellow crystalline substance with a molecular weight of 385.8. Its 
empirical formula is C 17H18FN 3O3•HCl•H 2O.  
Ciprofloxaci n will be provided as tablets of ciprofloxacin hydrochloride at strength of 500 mg 
ciprofloxacin equivalent. The manufacturer  and exact formulation, ie, excipients, and format for 
the tablets will be specified in the Pharmacy Manual . 
6.1.3.  Doxycycline Descriptio n 
Doxycycline hyclate, USP, is a broad -spectrum  antibiotic synthetically derived from 
oxytetracycline. The chemical designation is 4 -(Dimethylamino) -1,4,4a,5,5a,6,11,12a -octahydro - 
3,5,10,12,12a -pentahydroxy -6-methyl -1,11-dioxo -2-naphthacenecarboxamide 
monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline is a light -
yellow crystalline powder . The hyclate has a molecular weight  1025. 9 with an empiric formula 
of (C22H24N2O8•HCl) 2 • C 2H6O • H 20. 
Doxycycline  will be provided as tablets of doxycycline hyclate  at strength of 100 mg 
doxycycline  equivalent. The manufacturer  and exact formulation, ie, excipien ts, and format for 
the tablets will be specified in the Pharmacy Manual . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 49 of 139 
  
6.1.4.  Administration of AV7909  
AV7909 w ill be administered to all participants in all groups as a 0.5 mL IM vaccination in 
alternate arms on Days 8 and 2 3. Vaccinations will be administered in the clinic by authorized 
personnel  once AEs have been assessed, vitals have been taken and  a symptom -directed PE  
conducted .  Females who have not demonstrated an FSH level >30 mIU/mL must also pass a 
urine pregnancy test  (see Section  8.3.2 ).   
Partici pants in Group s 1A and 2A will receive their first vaccination after the 12 -hour PK sample 
in the evening of Day 8, and their second vaccination on Day 2 3. Site personnel who administer 
the vaccine should be trained in the early recognition of symptoms of anaphylactic reactions, a 
rare but potentially serious reaction to parenteral injections.   
Sites should be prepared to treat participant s experiencing clinically significant dyspnea or 
hypotension,  wheezing or generalized urticarial reactions.  Appropriate medical therapy for 
anaphylaxis should be administered, if indicated, which should include IM or subcutaneous 
epinephrine 1:1000, and may include corticosteroids, diphenhydramine, bronchodilators,  
intravenous volume expansion, and/or oxygen.  Participant s will be evaluated and carefully 
monitored until complete resolution of any signs and symptoms, should they occur.  
If a participant in Groups 1or 2 has a moderate or severe illness and/or an oral t emperature 
greater than 100.4°F within three  days before vaccination 1, or any condition that, in the opinion 
of the Investigator, would render vaccination unsafe or wou ld interfere with evaluations, t hese 
participants will be withdrawn from the  study and will be considered ineligible for rescreening . 
These  participants will be instructed to cease taking antibiotics  but to continue with their e -diary 
for an additional 7 days  beyond the day they ceased taking antibiotics  at which point they will be 
asked to return to the site and complete the EWV procedures. If the reason for not receiving 
vaccine is an AE/SAE/AESI, the participants will be followed until the event has resolved, 
stabilized or the participant has been referred to another physician. These parti cipants, having not 
received any vaccine, will not be included in the long -term follow -up nor will they have 
additional blood samples taken for TNA , TSH  or autoantibodies.   
Any p articipant in Group 3  who has a moderate or severe illness and/or an oral tem perature 
greater than 100.4°F within three  days before vaccination 1, or any condition that, in the opinion 
of the Investigator, would render vaccination unsafe or that would interfere with evaluations may 
be re -screen ed and re -randomized with the event wh ich precluded vaccination being added to 
that participant’s medical history.  If such an event were to occur within three  days of vaccination 
2, the vaccination must be delayed but should still occur within the 1-day study window. 
Partic ipants unable to rec eive vaccination 2  within the allowed study visit window will remain in 
the study  and be followed for safety . 
6.1.5.  Administration of Ciprofloxacin  
Ciprofloxacin (500 mg  po q 12 hr) will be administered only to participant s in Group 1. A total 
of 31 ± 2 doses will be administered in three courses , the exact format  for which will be 
presented in the Pharmacy Manual.   
Group 1A  participants will nominally receive 1 7 of their 3 1 ciprofloxacin  doses in the clinic 
whereas Group 1B  will nominally receive two of their 31 ciprofloxacin doses in the clinic.   The Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 50 of 139 
  
remaining doses will be taken at home.  Doses should be taken at the same times  ± 30 min each 
day. Doses administered in the clinic will be recorded by the staff with the date and time of 
administration in each par ticipant’s source documents  and eCRF . Dose s self -administered at 
home will be recorded by the participant  with time of administration in their e -diary.  Refer to 
Section  8.3.5.1  for additional details on the e-diary. If a participant misses a dose, they should be 
instructed to take the dose as soon as remembered, but no later than within 4 hours of its 
scheduled time . The participant should then wait until the next scheduled dose. The participant 
should not take two doses at the same time.  
Exact details regarding the format in which the doses will be provided to  the participant s will be 
provided in the Pharmacy Manual .   
Certain foods and over -the-counter products can interfere with the absorption of ciprofloxacin so 
prior to administration of doses in the clinic, site staff should ask each participant if they have 
eaten certain dairy products (such as milk or yogurt) or taken magnesium/aluminum antacids, 
other highly buffered drugs, or other products containing calcium, iron or zinc  since their last 
dose and if so record this information along with the timing of intake, eg, 6 hours since their last 
dose. This informati on along with other precautions that need to be followed when taking 
ciprofloxacin will be provided to participants when they are given their supplies of ciprofloxacin 
for self -administration (see Section  5.3.1 ). 
6.1.6.  Administration of Doxycycline  
Doxycycline (1 00 mg  po q 12 hr) will be administered only to participant s in Group 2. A total of 
35 ± 2 doses will be administered in three courses as shown in  Figure 2.  
Group 2A  participants will  nominally  receive 20 of their 35 doxycycline  doses in the clinic 
whereas Group 2 B will nominally receive two of their 35 doxycycline  doses in the clinic.   The 
remaining doses will be taken at home.  Doses should be taken at the same times  ± 30 min each 
day. Doses administered in the clinic will be recorded by the staff with the date and time of 
administration in each parti cipant’s source documents  and eCRF . Dose s self -administered at 
home will be recorded by the participant  with the time of administration in their e -diary.  Refer to 
Section  8.3.5.1  for additional details on the e -diary. If a participant misses a dose, they should be  
instructed to take the dose as soon as remembered, but no later than 4 hours of its scheduled 
time. The p articipant should then wait until the next scheduled dose. The participant should not 
take two doses at the same time.  
Exact details regarding the format in which the doses will be provided to  the participant s will be 
provided in the Pharmacy Manual .   
Certain foods and over -the-counter products can interfere with the absorption of doxycycline  so 
prior to administration of doses in the clinic, site staff should ask each participant if they have 
eaten certain dairy products (such as milk or yogurt) or taken magnesium/aluminum antacids, 
other highly buffered drugs, or other products containing calcium, iron or zinc  since their last 
dose and if so record this information along with the timing of intake (eg, 6 hours since their last 
dose). This information along  with other precautions that need to be followed when taking 
doxycycline  will be provided to participants when they are given their supplies of doxycycline  
for self -administration (see Section  5.3.1 ). Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 51 of 139 
  
6.2. Acquisition/Preparation/Handling/Storage/Accountability  
6.2.1.  Acquisition  
AV7909 liquid suspension for injection and oral antibiotics [ciprofloxacin  and doxycycline  
(exact format s will be specified in the Pharmacy Manual )] will be shipped to investigational sites 
from the drug depot following institutional review board/independent ethics committee 
(IRB/IEC ) and Emergent approval. All shipments will be accompanied by TempTale® 
temperature monitors to record any excursions outside of required storage conditions, ie, 
refrigerated storage [ 36 to 46ºF ( 2-8 ºC)] for the vaccine and room temperature [ 68° to 77°F (20 -
25 ºC)] for the antibiotics ( ciprofloxacin  or doxycycline) . Detailed instructions for inventory 
receipt, temperature excursions, and IP resupply will b e provided in the Pharmacy Manual.  
6.2.2.  Preparation of Investigational Product for Injection  
Vaccine vials should be removed from the storage unit and allowed to sit at room temperature for 
approximately 15 min utes before administration. Vaccine doses should be drawn into a syringe 
only when administration  is eminent . The stability of the vaccine stored in the syringes has not 
been determined. A site staff member, licensed to administer medication/vaccination, w ill 
prepare each dose of AV7909  into a syringe  according to the following instructions:  
 A separate 1 - or 1½ -inch 23 - or 25 -gauge sterile needle and separate 1.0 mL syringe will 
be used for each participant.  
 Gently roll the vial of AV7909 between the hands to ensure that the suspension is 
homogeneous.   
 Visually inspect the product for particulate matter and discoloration prior to preparing 
into the syringe. If the product appears discolored or has visible particulate matter, DO 
NOT USE the contents of the v ial.  THE VIAL SHOULD BE QUARANTINED and 
reported to the CRO according to the instructions in the Pharmacy Manual.  
 Wipe the rubber stopper with an alcohol swab and allow to air dry before inserting the 
needle.   
 Withdraw 0.5 mL of investigational product  from the vial  into a sterile syringe for 
administration.  The volume and contents of the syringe will be verified by a second 
person before administration.  
 Reseal  the vial  and cover  it with tamper -evident tape to indicate no additional doses may 
be withd rawn  from the vial . 
AV7909 should not be mixed with any other product in the syringe.  
6.2.3.  Handling  
Detailed instructions for packaging, labeling, and shipping as well as inventory receipt, and IP 
resupply will be  provided in the Pharmacy Manual.   Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 52 of 139 
  
6.2.4.  Product  Storage and Stability  
6.2.4.1.  AV7909  
Each shipment of AV7909 will arrive in a refrigerated carton containing vaccine and a 
TempTale™ temperature recorder that will be reviewed before use of the vaccine.  Immediately 
upon receipt of each shipment of vaccine, vials are to be refrigerated at 36 to 46ºF (2 to 8ºC).  
AV7909 should not be frozen. Storage temperature must be continuously monitored and 
recorded. To  guarantee proper storage conditions, the minimum, actual and maximum 
temperature in the storage refrigerator shal l be continuously monitored for correct temperature. 
A back -up power source for the refrigerator is required.  The study vaccine should be stored in a 
locked room, with access restricted to necessary site personnel.  
6.2.4.2.  Ciprofloxacin  
Each shipment of ciprofloxa cin will arrive in an insulated container with a temperature 
monitoring device which at a minimum displays the minimum and maximum temperature 
encountered while in transit. Ciprofloxacin is to be stored at room temperature [ 68° to 77°F (20° 
to 25°C) ]. The ciprofloxacin should be stored with access restricted to necessary site personnel 
with temperature log for recording ambient temperature daily.  
6.2.4.3.  Doxycycline  
Each shipment of doxycycline will arrive in an insulated container with a temperature 
monitoring dev ice that at a minimum displays the minimum and maximum temperature 
encountered while in transit. Doxycycline is to be stored at room temperature [ 68° to 77°F (20° 
to 25°C) ]. The doxycycline should be stored with access restricted to necessary site personne l 
with a temperature log for recording ambient temperature daily.  
6.2.5.  Investigational Product Experiencing Any Temperature Excursions  
AV7909 , ciprofloxacin or doxycycline which have been delivered/received at the site with 
temperature recorders indicating temp erature excursions above or below their storage ranges will 
be immediately quarantined and not used by the site until the CRO study monitor has been 
informed and can determine an appropriate path forward. Similarly, if any IP is subjected to such 
temperatu re excursions while held at the site, the CRO study monitor must be contacted for 
further instructions.  
6.2.6.  Accountability  
The Investigator will maintain complete records of receipt, storage and administration of 
investigational products  at the investigator si te. For the AV7909 vaccine, this will include lot 
number, the dose/volume administered, and the time, date, and site of administration. The latter 
information will be recorded in the participant’s source documents along with the initials of the 
administeri ng individual. NO VIALS OF VACCINE, including empty, damaged or partially 
used vials are to be destroyed or discarded during the conduct of the study.  At the completion of 
the study, once all vaccine accountability is complete and queries resolved, the si te will be 
responsible for discardin g all remaining vials of IP  per the instructions in the site Pharmacy Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 53 of 139 
  
Manual. For  ciprofloxacin and doxycycline, the Investigator will record number of tablets 
received , lot number(s),  and the number of tablets dispensed . For those tablets  administered on 
site, the site will also record the date and time of administration  on the appropriate eCRF page . 
The latter information will be recorded in the participant’s source documents along with the 
initials of the administering  individual. For antibiotic tablets dispensed to participants, 
participants will record in an e -diary the time of self -administration of these antibiotics at home 
and the sites will check e -diary records regularly as well as collect the antibiotic supplies  at each 
applicable in-clinic visit and do a tablet count to check compliance. At the completion of the 
treatment period , once all antibiotic dose accountability is complete and queries resolved, the site 
will be responsible for discarding  all remaining an tibiotic doses per the instructions in the 
Pharmacy Manual.  
6.3. Measures to Minimize Bias  
6.3.1.  Method of Treatment Assignment  
After the ICF has been signed and dated by the participant and PI/designee but before any 
screening procedures are performed, the participa nt will be assigned a unique subject 
identification (ID) number by the site. To maintain confidentiality, the subject ID will be used to 
identify the participant for data collected in eCRFs throughout the trial and for all clinical 
laboratory samples. The investigational site will retain a master list linking the subject ID with 
the name, date of birth, and contact information of the participant. The master list is to be 
retained by the site only and is not to be collected by Emergent or its agents.  
If a pa rticipant is rescreened, a new subject ID will be assigned. To link records to the same 
participant, the participant’s previous subject ID will be recorded in the eCRF along with the 
new subject ID.  
At the Randomization visit (Day 1), after the PI has conf irmed that the participant meets all the 
inclusion criteria and none of the exclusion criteria, a central randomization process will be used 
to assign each participant to one of the three  open -label IP groups. The sites will be asked to the 
extent possible  to execute a recruitment process that achieves a representative racial/ethnic 
distribution in populations that are reasonably gender - and age -balanced (ie, at least 40% male 
with 40% of participants in the two age ranges of 18 -30 years of age and 31 -45 ye ars of age).  
A randomization plan will be prepared and finalized prior to randomization of the first 
participant . The specific instructions for randomizing participants will be provided in the 
Pharmacy Manual.  
If a participant signs and dates the ICF but is not randomized within the screening period 
window, that participant is considered a screen failure unless he or she  signs a new ICF, is re -
screened and is randomized within the allowable window (refer to Section 5.4). 
6.3.2.  Blinding  
Not applicable; this is an open -label study.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 54 of 139 
  
6.4. Treatment Compliance  
Each dose of AV7909 vaccine will be administered by site personnel at the investigator site.  The 
date and time of the vaccine administration will be recorded in the participant ’s source 
documents and on the eCRFs.  
The antibiotics, c iprofloxacin or doxycycline , will be administered in -clinic by staff and self -
administered by participants at home.  Each dose of ciprofloxacin  or doxycycline  administered 
by the site personnel will be recorded in the participant’s source documents and the eCRF  with 
the dat e and time of administration.  
Each dose of ciprofloxacin  or doxycycline  self-administered at home will be recorded by the 
participant in the e -diary along with  the date.  The investigator site personnel will review the 
compliance data recorded in the e -diary on a routine basis  and will call or talk to any participants 
who fail to record their antibioti c doses  on two or more occasions. Repeated non -compliance 
may warrant discontinuation  although such participants will be followed for safety.   
If a participant misses a dose of antibiotic ( ciprofloxacin or doxycycline) at home, the missed 
dose should be do cumented in the e -diary. Participants missing an at -home dose of antibiotic will 
remain in the study. Participants will be reminded that they have a 4 -hour window within which 
to take a forgotten dose and that the time they record in the e -diary should be the time the dose is 
actually taken rather than the time it should be taken.  They will also be reminded that a late dose 
should not reset the schedule, ie , that even if they take one dose late, their next dose should be 
taken on their original dosing sche dule, and that they should continue to maintain 12 hours 
between doses  thereafter  and never take two doses at the same time.  Thus, if a participant 
normally takes doses at 7 am and 7 pm but forgets to take the 7 am dose until 10 am, he or she  
should still take the second dose at 7 pm.  
Participants will be asked to bring their antibiotic  supplies with them to the clinic  at each visit  so 
that staff can confirm the remaining number of doses to document compliance.  Site staff will 
collect any doses remaining on ce a course is complete and supply the next course  when it is 
needed.   
Additionally, for Group s 1A and 2A, compliance will also be tracked via the individual 
ciprofloxacin  or doxycycline  serum concentrations that will be recorded in the pre -dose and 
trough values, which are being collected to demonstrate achievement of the steady state 
concentrations of these antibiotics before and after vaccination with AV7909.  
6.5. Concomitant Therapy  
Prior and concomitant medication information (medications used 30 days prior to Screening or 
medications used since the last study visit) will be recorded in the eCRF  at screening , 
randomization  and at each study visit  when applicable .  
The medication name, dose , route, frequency, indication , and stop and start days/times  for each 
new medication will be recorded. For the purposes of this trial, concomitant medications will be  
defined to include prescription drugs and biologics, over -the-counter drugs as well as h erbal and 
nutritional supplements.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 55 of 139 
  
6.5.1.  Prohibited Medications  
Prohibited and restricted medications for this study fall into two categories: those that are 
restricted because of their effect on inflammation, immunity and vaccination and those known to 
interact  with either ciprofloxacin or doxycycline .    
6.5.1.1.  Medications Prohibited Due to Effects on Inflammation or the Immune System  
Prohibited and restricted medications  for all participants  include anti -inflammatory or antipyretic 
medications, topical antihistamine eye drops, nasal steroids, vaccines, immunosuppressive 
therapy, cytotoxic therapy  and any experimental treatments (see  Table 3). 
Table 3: Medications Prohibited for all Participants  
Category  Generic Name and Examples of Associated Brand Names  
Anti-inflammatory or 
antipyretic medication: 
prohibited within 24 
hours prior to or after 
vaccination  Glucocorticoids, aspirin -containing medication, NSAIDs, acetaminophen -
containing medication  
Motrin, Advil®, Co-Advil®, Bayer®, Tylenol® Excedrin® 
Topical hydrocortisone  
Note:  NSAIDs should be used (if medically indicated) with caution 
(outside 24 hours prior to or after vaccination) by parti cipants in Group 1 , 
because in pre -clinical studies and post -marketing the combination of high 
doses of quinolones with NSAIDs has been shown to provoke convulsions  
(see ciprofloxacin prescribing information  in the Pharmacy Manual ). 
Aspirin withheld on 
each day of vaccination, 
but may be resumed the 
following day  Low-dose aspirin (≤ 81 mg/day)  
Any commercially -
available vaccine 
(except that for anthrax) 
through two weeks after 
the last vaccination  Including but not limited to vaccines for influenza, shi ngles, hepatitis B, 
pneumococcal, tetanus, yellow fever, pertussis, cholera, adenovirus, 
diphtheria, rabies virus haemophilus b, hepatitis A, human papillomavirus, 
measles, mumps, Japanese encephalitis virus, meningococcal vaccine, polio 
virus, plague, rot avirus, zoster vaccine, smallpox  
Immuno modulatory 
agents  through the final 
follow -up phone call.  
Note: inhalation use (eg, 
for seasonal allergies) is 
permitted.   Any systemic corticosteroids including, but not limited to, generic and 
brand names of: beta methasone, budesonide, cortisone acetate, 
dexamethasone, hydrocortisone, methylprednisolone, prednisolone, 
prednisone, triamcinolone.  
Cytotoxic Therapy  Any of the alkylating agents, platinum coordinating complexes, 
antimetabolites or natural products used  in current therapeutic regimens for 
cancer or rheumatic diseases including but not limited to generic and brand 
names of: m ethotrexate , cyclophosphamide, azathioprine, methotrexate, 
mercaptopurine , bendamustine, streptozocin, cisplatin, chlorambucil  and 
hydroxyurea.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 56 of 139 
  
Category  Generic Name and Examples of Associated Brand Names  
Investigational 
Medicinal Product  Product that is used in a clinical investigation.  
Blood thinners and anti -
coagulants  (Groups 1A 
and 2A)   Any medication that might increase the risk of bleeding including but not 
limited to heparin and its derivatives, warfarin and other vitamin K 
antagonists,  oral factor Ax inhibitors, any reversible or irreversible inhibitor 
of coagulation receptor P2Y 12, any glycoprotein IIa/IIIa antagonist, or any 
PAR -1 antagonist  
Parenteral 
Immunoglobulins or 
Blood Pro ducts  Any of the approved intravenous (IV), subcutaneous (SC), or intramuscular 
(IM) human immune globulins (IG) or the human hyperimmune globulins 
(hhIG) or animal derived immune globulin (aIG) products including but not 
limited to: any IGIV, IGIM or IGSC ; any anthrax hhIG, botulism hhIG, 
cytomegalovirus hhIG, hepatitis B hhIG, Rho(D) hIG, vaccinia hIG, or 
rabies hhIG; or any anti -thymocyte aIG, anti -scorpion venom aIG, anti -
snake venom aIG, anti -spider venom aIG, anti -digoxin aIG, anti -botulinum 
toxin aIG, or anti -thymoglobulin aIG.  
6.5.1.2.  Medications Known to Interact with Ciprofloxacin  
Prohibited and restricted medications  for participants in Group 1 include those that are primarily 
metabolized by human cytochrome 450 P1A2 (CYP1A2) , but also those that are m etabolized by 
CYP3A4 since ciprofloxacin is a strong inhibitor of CYP1A2 and a moderate inhibitor of 
CYP3A4 , as well as products that can affect the absorption of ciprofloxacin such as antacids, 
multivitamins, or supplements that contain magnesium, aluminu m, calcium, iron or zinc. If 
required, the latter medications should be taken 2 hours before or 6 hours after a ciprofloxacin 
dose. Refer to the ciprofloxacin prescribing information  (in the Pharmacy Manual) where 
medications which  are known  to interact wi th ciprofloxacin are listed  and should not be taken by 
participants in Group 1 of this study.   
A more extensive list of medications is provided at the following URL: 
https://o nline.epocrates.com/drugs/50110/ciprofloxacin/Monograph  {Athenahealth  2019 a}. With 
the exception of those indicated to be contraceptives and those  which may be components of  
antacids, multivitamins, or supplements that contain magnesium, aluminum, calcium, iron, or 
zinc, all medications, vaccines and supplements found at the above URL are also prohibited for 
participants in Group 1 of this study.  
6.5.1.3.  Medications Known to Interact with Doxycycline  
Prohibited and restricted medications  for participants in Group  2 can be found in the doxycycline 
prescribing information (provided in the Pharmacy Manual )Error! Reference source not 
found. . A more extensive list of medications is provided at the following URL: 
https://online.epocrates.com/drugs/20310 /doxycycline/Monograph  {Athenahealth  2019b }. With 
the exception of those indicated to be contraceptives and those which may be components of  
antacids, multivitamins, or supplements that contain magnesium, aluminum, calcium, iron, or 
zinc, all medications, vaccines and supplements found at the above URL are also prohibited for 
participants in Group 2 of this study.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 57 of 139 
  
7. STOPPING RULES, DISC ONTINUATIO N/WITHDRAWAL 
CRITERIA AND PROCEDU RES  
7.1. Entire Study  
Study enrollment and vaccinations may be temporarily halted by the DSMB or the Sponsor if 
any of the following occur, pending further evaluation:  
 three  or more dosed  participants having the same Grade 3 or higher  AE 
 three suspected unexpected serious adverse reactions (SUSARs) within the same 
body system as assessed by the Sponsor  
 five potential AESIs considered related to the IP, as assessed by the Sponsor  
 a single DSMB -assessed  AESI , considered to be  related to the IP  by the PI   
These events will be reviewed by the DSMB and a recommendation will be made regarding 
vaccinations, continuation of study, or study termination. The procedures for DSMB notification 
and review of SUSARs, AESIs, and other significant  events will be outlined in the DSMB 
Charter (refer to  Section  8.5).  
Emergent, BARDA, the IRB/IEC and/or FDA reserve the right to terminate the study at any time 
for clinical or administrative reasons. This study may be terminated due to safety concerns, 
failure to meet expected enrollment goals, administrative reasons or at Emergent’s discretion. If 
the study is terminated prematurely, Emergent w ill provide written notification to all 
investigators and regulatory authorities and will specify the reason(s) for early termination.  The 
investigator must inform the IRB/IEC promptly and provide the reason(s) for the termination.  
7.2. Individual Site  
The CRO  will promptly notify Emergent if the trial is terminated by the PI or the IRB/IEC at the 
site.  
Any particular site may be terminated from the trial at the discretion of the PI, Emergent, or 
IRB/IEC, eg, for non -enrollment of participants  or non -complianc e with the protocol. Emergen t 
may decide to replace  a terminated site . 
7.3. Individual Participants  
All participants have the right to withdraw at any point during treatment without prejudice. The 
PI can also discontinue a participant from a trial at any time i f medically necessary  or for reasons 
of noncompliance .  
Every attempt will be made to follow participants for safety for the entire duration of the trial 
through the Month 12 safety follow -up providing they have received at least one vaccination. 
Participa nts in Groups 1 and 2 who discontinue treatment prematurely for any reason after 
receiving the first dose of  antibiotic  but prior to receipt of the first vaccination will be 
encouraged to return to the clinic for the Early Withdrawal procedures minus the b lood draws for 
autoantibodies , TSH  and TNA. Participants who discontinue treatment prematurely for any 
reason after receiving the first vaccination will be encouraged to continue in the study for any Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 58 of 139 
  
remaining study visits (for safety assessments only) and  the safety follow -up phone calls at 
Months 3, 6, 9 and 12 (post -vaccination).  
If a participant discontinues treatment and/or involvement in the study, the reason(s) must be 
fully evaluated and recorded appropriately in source documents and eCRFs. Reason for 
discontinuation of treatment and reason for withdrawal from the study are to be recorded 
separately on eCRFs. If the participant is being discontinued because of an AE, that AE will be 
indicated as the reason for discontinuation and/or study withdrawal . 
Randomized participant s who withdraw for any reason will not be replaced  in this trial . 
7.3.1.  Discontinuation of Study Treatment  
Study treatment, either administration of antibiotic ( ciprofloxacin  or doxycycline)  or vaccination 
with AV7909, will be permanently  discontinued in any participants if they meet any of the 
individual participant halting rules described in Table  4. The date when the event occurred or 
was detected  and the  specific  reason , ie, which criterion was met,  for discontinuation of 
treatment,  is to be recorded on the eCRF.  
Table  4: Criteria for Discontinuation of Treatment in Individual Participants  
No. Item  
1.  Participants ex periencing any of the AEs described in the  WARNINGS AND 
PRECAUTIONS sections of the  ciprofloxacin and doxycycline  package insert s (provided 
in the Pharmacy Manual ) will be discontinued .  
In the case of ciprofloxacin,  these include, but are not limited to, tendinitis and tendon 
rupture, hypersensitivity reactions (including rash and jaundice), peripheral neuropathy, 
central nervous system effects, exacerbation of myasthenia gravis, hepatotoxicity, 
Clostridium difficile -associated diarrhea, prolongation of the QT interval, and a variety of 
other serious adverse reactions including severe dermatologic reactions, eg, toxic 
epidermal necrolysis, Stevens -Johnson syndrome ; anemia, including hemolytic and 
aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; 
agranulocytosis; pancytopenia; and/or other hematologic abnormalities  and inflammatory 
responses, eg, i nterstitial nephritis; acute renal insufficiency or failure;  allergic 
pneumo nitis;  hepatitis; jaundice; acute hepatic necrosis or failure . 
In the case of doxycycline , these include, but are not limited to,  Clostridium difficile -
associated diarrhea,  photosensitivity manifesting as an exaggerated sunburn reaction ; super 
infection an d overgrowth of non -susceptible organisms including fungi ; severe skin 
reactions, such as exfoliative dermatitis, erythema multiforme, Stevens -Johnson syndrome,  
toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms 
(DRESS) ; intracranial hypertension (IH, pseudotumor cerebri)  manifesting as headache, 
blurred vision, diplopia, and vision loss has been observed with papilledema detectable on 
fundoscopy ; delayed skeletal development in the fetuses of pregnant wom en [tetracyc lines/ 
however, data for doxycycline are limited ]. NB: Pregnancy would require discontinu ation 
from the trial  (refer to Section  9.4).  
2.  Grade 2 or greater hypersensitivity , ie, anaphylaxis, allergic reaction (such as, but not 
limited to difficulty breathing, rapid increase in heart rate, dizziness, nausea, evidence of 
rash, or periorbital swelling) believed by the PI to b e associated with receipt  of any of the  
IPs  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 59 of 139 
  
No. Item  
3.  Any Grade 3 or higher systemic reactogenicity symptom  assessed by e-diary  and 
confirmed by the PI   
4.  Any AE that would pose a risk to the participant  as determined by the PI if continued 
administration of IP were to occur . 
5.  Any viola tion of eligibility criteria  discovered after randomization  that would pose a risk to 
the participant , as determined by the PI and agreed to by the Medical Monitor ( MM) 
6.  Febrile illness (fever > 100.4 °F) within three days prior to either vaccination (Exception: 
For the second vaccination , the visit may be rescheduled to another day outside this three -
day period providing it will not fall outside the required visit window for vaccination two 
[Section  8.1].) 
7.  Receipt of AV7909  associated with loss of cold chain  
8.  Suspected or confirmed pregnancy (refer to Section  9.4). (Exception: In the case of 
suspected pregnancy, if the subsequent serum pregnancy test is negative, the antibiotic  
dosing may be  resumed and the vaccination visit (second vaccination only) may  be 
rescheduled to another da y providing it does not fall outside the required visit window for 
the visit  [Refer to Section  8.1].) 
9.  Schedulin g or other conflict results in the second  vaccination visit falling outside the 
required window  
10.  Recei pt of prohibited medication  (see Section  6.5.1 ) as determined by the PI and agreed by 
the MM  
11.  Causally -related Grade 3 or higher unsolicited AE as assessed by the PIa 
12.  Causally -related SAE or potential AESI as assessed by the Sponsor  
AE=adverse event; AESI = adverse event of special interest; IP=investigational product; MM = medical monitor; PI=principal 
investigator, SAE = serious adverse event , 
aAny AE is considered to be related to the vaccine administration if assessed by the PI as being “possibly” or “probably” or 
“definitely” related .  
All participant s who have received at least one vaccination will be encouraged to continue with 
the scheduled study safety evaluations, including any remaining study visits (safety assessments 
only), collection of samples for TSH and autoantibodies (only if medically indic ated) and the 
safety follow -up calls.  Participants who decline will be encouraged to complete the EWV (see 
Section  8.1.8 ) and followed for safety  through the 12 -Month (Day 388 ± 14d) Safety Follow -up 
phone call. If the discontinuation was due to an  AE, participants  will be followed until the event 
has resolved or stabilized or the participant has been referred to an outside physician.   
7.3.2.  Withdrawal from  the Study  
A participant  may withdraw from the study at any time , for any reason.  The PI may withdraw a  
participant  from the study for the following reasons:  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 60 of 139 
  
1. Occurrence of an AE  that in the opinion of the PI, warrants the participant ’s permanent 
disconti nuation from treatment (if having received at least one vaccination, the 
participant will be encouraged to continue in the study for safety follow -up only). 
2. Death . 
3. Lost to follow -up.  
4. Non-compliance with IP . 
5. Physician decision . 
6. Withdrawal of consent by par ticipant .  
7. Study terminated by Sponsor.  
8. Other (eg, if Sponsor requests withdrawal of a participant, ceases dosing due to 
unacceptable toxicity ). 
If the PI determines a participant has been noncompliant with study procedures, the PI will 
document the reason  for noncompliance, and the participant will be withdrawn from the study.  
Reason(s) for study withdrawal will be recorded on the End of Study eCRF page. Participants 
who withdraw from the study treatment will be asked to continue with the scheduled study s afety 
evaluations, including any remaining study visits (safety assessments only),  collection of 
samples for autoantibodies and the safety follow -up calls details of which are provided in 
Section  8.1.6.3 , Section  8.1.6.4 , and Section  8.1.7 .  Participants who decline will be encouraged 
to complete the EWV.  The EWV procedures are discussed in Section  8.1.8 .  
7.4. Lost to Follow -up 
Participant s who cannot be contacted during the in -clinic evaluation period through the Day 51  
(Final In-clinic Visit ) or at the final 12 -month ( 388 ± 14 d) safety follow -up phone contact s and 
who do not have a known reason for study withdrawal  (eg, withdrew consent or AE) will be 
classified as “lost to follow -up” as the reason for study discontinuation in the eCRFs. The site 
will make three attempts to contact the participant  by telephone.  In the event the site is unable to 
reach the participant  by telephone, the site will attempt to contact the participant  via certified 
mail or an alternative similar met hod where appropriate. The time -period between contact 
attempts will be greater than on e week apart.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 61 of 139 
  
8. STUDY ASSESSMENTS AN D PROCEDURES  
8.1. Schedule of Assessments  
Involvement for the individual participant in this study from first visit to last visit inclusive of the 
screening visit and the safety follow -up phone calls will be approximately 14 .5 months. 
Screening will occur within approximately one month (Day -28 to Day -2) of study start. Eligible 
participants will be randomized into one of the three groups shown in Table  2. All participants 
undergo the same assessments and procedures during screening and immediately following 
randomization; however, thereafter each group has its own schedule of assessments. The 
following sections provide deta iled lists of assessments to be performed by visit, first starting 
with a section on the Screening and Randomization visits which are common to all participants 
and then followed with sections for each of the  five groups.  
8.1.1.  Screening, Randomization/Enrollmen t and Initial Blood Draws for TNA and 
Autoantibodies  
8.1.1.1.  Screening (Days -28 to -2) 
Participants will be screened for participation in the trial from 2 to 28 days prior to the Day 1 
(randomization) visit. The Screening period begins once the participant signs and dates the ICF. 
The following activities will occur during the Screening visit or period:  
1. Ensure r eview  and completion of all required information on the ICF and capture in site 
source documentation and eCRF . 
2. Assign subject ID number .  
3. Record  demographics . 
4. Record complete medical history including current signs and symptom s which  will be 
recorded as AEs only if the y result from a study -related procedure (s). 
5. (For WOCBP only) document in the participant’s chart about counsel received for the 
requirements around type and timing of an adequate method of contraception, including 
the participant’s preferred method . 
6. Perform complete physical examination  including an ECG.  
7. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respirat ory rate and 
temperature), height and weight  and determine BMI . 
8. Record medications  taken in last 30 days . 
9. Collect blood and urine samples for clinical laboratory tests (see Section  8.3.2 ) 
a. Depending on a woman’s fertility status conduct a serum pregnancy test  (for 
WOCBP)  or an FSH test  (for postmenopausal women ). Any  female participant whose 
FSH test returns a value ≤30  mIU/mL  will need to take a serum pregnancy test .  
b. Hematology . 
c. Serum chemistry .  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 62 of 139 
  
d. Viral serology ( human immunodeficiency virus [HIV] antibodies, hepatitis B surface 
antigen [HBsAg], and hepatitis C antibody) . 
e. Urinalysis . 
f. Urine drug screen .  
10. Review for study eligib ility against inclusion/exclusion criteria .  
8.1.1.2.  Randomization/Enrollment and Initial Blood Draws for TNA and Autoantibodies: 
Day 1  
Day 1: Morning  
The following will occur on Day 1 prior to randomization:  
1. Update medical history  including signs and symptoms, wh ich will be recorded as AEs 
only if the event results from a study -related procedure . 
2. Assess vital signs . 
3. Conduct symptom -directed PE . 
5. Record medications taken since screening visit .  
6. Confirm continued use of an adequate method of contraception and collect  urine sample 
for pregnancy test for WOCBP (if positive, the participant must not be randomized; upon 
receipt of a confirmatory negative serum pregnant test result, the participant may be 
rescheduled for the Day 1 visit , providing the visit falls within th e required window of the 
screening procedures ). 
7. Review for study  eligibility against inclusion/exclusion criteria, to include a review of all 
safety and screening laboratory test results and status of ongoing AEs since the prior 
visit. 
After the PI has confirmed that the participant  meets all the inclusion criteria and none of the 
exclusion criteria , the participant  will be randomized  into one of the three IP groups .  
1. Randomize eligible participants . 
2. For participants  who are WOCBP and  randomized to Group 1 or 2:  Re-educate 
participants  that ciprofloxacin and doxycycline may decrease the effectiveness of birth 
control pills, implantable or injectable contraceptives . Instruct  the participant to add a 
double -barrier method, IUD , or abstin ence as back -up forms of birth control .   
3. All randomized participant s will have blood samples taken for TNA , TSH and 
autoantibodies.  
4. Participants randomized to  Group 2A  will be instructed to return the same evening so that 
they can enter the first doxycycl ine PK session the following morning  (See 
Section  8.1.4 ). 
5. Participants randomized to Group 1A  will be instructed to return to the site the evening of 
Day 3  so that they can enter the first ciprofloxacin PK session on Day 4  (See 
Section  8.1.2 ). Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 63 of 139 
  
6. Partici pants randomized to Group 1B  or 2B  will be : 
 provided their antibiotic s [ciprofloxacin  (Group 1B)  or doxycycline  (Group 2B )],  
 provided  instructions on the dosing regimen (twice daily at 12 -hour interval s), 
beginning on the following day  (Day 2)  for those t aking doxycycline ( Group 2B ) and 
beginning on Day 4 for those taking ciprofloxacin ( Group 1B ). 
 informed about the dietary and lifestyle precautions required when taking each 
antibiotic  (see Section  5.3).  
 introduced to the e -diary  for antibiotic compliance  (see Section  8.3.5.1 ) and give 
instructions on how the e -diary  should be used to record self-administered antibiotic  
doses.  
 instructed to return on Day 8 to receive their first vaccination (See Section s 8.1.3  and 
Section  8.1.5 ).  
Any participant who does not have or who does not wish to use their own personal device 
to access the e -diary will at this time be supplied a hand -held device by the site . 
7. Participants rando mized to Group 3  will be instructed to return  on Day 8 to receive their 
first vaccination ( Section  8.1.6 ). 
8.1.2.  Group 1 A: Ciprofloxacin + AV7909 with Cip rofloxacin PK Sessions  
Shown in  Table 5 is a schedule of events for Group 1A  participants from screening until the end 
of the study. Following  the table are detailed descriptions of the daily activities that the sites are 
expected to conduct for each of the column headings identified in the table. Note that this detail 
starts with PM Admit (Evening Admission) as the detailed activities during Sc reening and Group 
Assign (Randomization) were covered previously in Section  8.1.1 .  
Table 5 Schedule of Events for Group 1 A: Ciprofloxacin + AV7909 with Ciprofloxacin 
PK  
 Screening  Group  
Assign  PMa 
Admit  PKb  AMa 
Visits  Vac  At 
 Home † TNA  Final 
Visit  Safety 
Calls  EWV  
USV ‡ 
Study Day(s)  -28 to -2 1 3, 7, 
30, 34 4, 8, 
31, 35 5-7 
32-34 8 
23* 9, 22, 24, 
36, 37  37 51 114, 205, 
 296, 388 NA 
Visit Window  NA  §TBD  NA NA ± 1 d*  ± 1 d ± 1 d ± 14 d  
Sign, date ICF & assign ID  X           
Review eligibility c X X X   X      
Medical history  & 
demographics  X X          
Physical examinationd  X        X  X 
ECGe X           
Vital signsf X X  X  X   X  X 
Pregnancy testg X X X  
(D3& D7 
only)    X   X  X 
FSH testg X           Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 64 of 139 
  
 Screening  Group  
Assign  PMa 
Admit  PKb  AMa 
Visits  Vac  At 
 Home † TNA  Final 
Visit  Safety 
Calls  EWV  
USV ‡ 
Study Day(s)  -28 to -2 1 3, 7, 
30, 34 4, 8, 
31, 35 5-7 
32-34 8 
23* 9, 22, 24, 
36, 37  37 51 114, 205, 
 296, 388 NA 
Visit Window  NA  §TBD  NA NA ± 1 d*  ± 1 d ± 1 d ± 14 d  
Collect sample for hematologyh X        X  X 
Collect sample for s erum 
chemistryi X        X  X 
Collect sample for u rinalysisj X        X  X 
Urine drug screenk X           
HIVAb/HBsAg/HCVAb  X           
Concomitant medicationsl X X X X X X X X X X X 
Randomize eligible participants   X          
Symptom -directed PEm  X    X   X  X 
Blood draws for TNAn   X      X    
Cipro dosing & complianceo,p    X X X X X X   X p 
Cipro  pre-dose or  trough     X X       
Cipro  PKq    X        
AV7909 vaccinationr      X      
Participant e -diary + toolss  x  X X X X X X  X 
Staff review of e -diariest   Xs X X X X X X  X 
AEsu, SAEs , AESIsv  X X X X  X   X X X 
Collect TSH & autoantibody  
sample sw   X       X  X w 
For the abbreviations used above please refer to Table 1 of the protocol . *The  ± 1 d window applies only to the second 
vaccination on Day 23 (note: the second course of antibiotic treatment will have to shift according ly) and needs discussion with 
CRO. †At Home Days are only those days where both doses of ciprofloxacin  are taken at home . § The TBD window only applies 
to Day 30 and can at best be +1  d but needs discussion with sites and CRO  because it will require a 1 day fo rward shift for all 
activities thereafter until Day 37 which may not need to shift because of its window.  ‡For EWV occurring within the visit 
window of Day 37 , a blood sample for TNA will be drawn.  
aPM and AM admissions must be timed so that ciprofloxacin can be administered in the clinic within a 12 hr  ± 30 min window of 
the prior AM or PM dose.  
b For each PK session, the sites will manage the meals and activity of participants as detailed in Protocol  Section  5.3.1  and 
Protocol  Section  5.3.2 . 
c Eligibility will be reviewed before each vaccination, either the evening before  (ie, on Day 7) or the morning of vaccination  (ie, 
on Day 23). 
d Physical examinations (PE) will be conducted as described in Protocol Section  8.3.3 .  
e Electrocardiogram s (ECG s) will be conducted and interpreted at screening as described in Section  8.3.3 . 
f  Vital signs will be administered as described in Protocol Section  8.3.4 .  
g Pregnancy tests (serum and/or urine) will be administered to all WOCBP  as described in Protocol Section  8.3.2 . Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy  tests for WOCBP required before  each 
vaccination will be administered either the evening before (ie, on Day 7) or the morning (ie, on  Day 23) of vaccination . Note : 
for WOCBP  in group 1A , UPT is required at Day 3 and Day 7 only  (during overnight stay visit) ; it is not required at Day  30 or 
34. FSH test will be performed a t Screenining visit only for postmenopausal women.    
h Hematology tests will be conducted as described in Protocol Section  8.3.2 .  
i Serum chemistry tests will be conducted as described Protocol Section  8.3.2.   
j Urinalyses will be conducted as described in Protocol Section  8.3.2 .    
k Urine drug screens will be conducted as described in Protocol Section  8.3.2 .  
l Concomitant medications will be identified and recorded along with their indication as described in Protocol Section  6.5.    
m Symptom -directed PEs will be conducted as described in Protocol Section  8.3.3 . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 65 of 139 
  
n Blood samples for TNA assessment on Day 1 will be collected in the morning following randomization. Those on Day 37 will 
be collected after the final dose of ciprofloxacin has been adminis tered.  A TNA sample will also be collected if EWV occurs 
within the visit window of Day 37 as described in Protocol Section  8.1.8 .  
o Ciprofloxacin doses (500 mg po q 12 hr) will be administered as described in Protocol Section  6.1.5  with the first dose being 
administered on Day 4  when the cipro PK group enters  their first PK session.  
p Ciprofloxacin dose compliance will be managed as described in Protocol Section  6.4. 
q Blood samples for assessment of ciprofloxacin concentrations will be collected as detailed in Protocol Section  8.4. 
r Vaccinations with AV7909 will be administered as described in Protocol Section  6.1.4 . 
s All Participants will be provided  with an e -diary for post vaccination follow up along with a thermometer and an injection site  
reaction measurement tool . Participants in Group 1 and 2 will be provided with an e -dairy for antibiotic compliance.  All 
participants  will be trained on the use of these tools and the e -diaries as described in Proto col Section  8.3.5.1 . 
t Staff will begin reviewing the e -diaries on Day 6 and will review them at regular intervals thereafter.  
u AEs will be collected at all clinic visits through Day 51 /EWV as described in detail in Protocol Section  9. 
v AEs, S AEs and potential AESIs will be collected during the Safety Follow -up Telephone Calls (see Protocol Section  8.1.7 ). 
w Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section  8.3.2  (ie, at Day 1 , Day 51 , and at EWV if the subject received at least one vaccination ).  Additional samples  for TSH & 
autoantibody testing may be requested  (eg, based on  participant report(s) of a potential AESI ); blood draws for additional TSH 
and/or autoantibody testing should be performed as part of an unscheduled visit . 
8.1.2.1.  Group 1 A: Day 3 – Overnight Stay # 1  
1. Admit to the clinic for overnight stay #1.  
2. Review and record A E assessments and changes in medications in participant’s medical 
history unless they are related to study procedures in which case they are recorded as 
AEs.  
3. For WOCBP , collect urine and perform a UPT.  Positive UPTs will be confirmed with a 
serum pregnanc y test. All confirmed pregnancies in participants who have received at 
least one dose of any IP and where conception occurs prior to 12 months after last receipt 
of that IP will be followed to outcome.  
8.1.2.2.  Group 1 A: Day 4 – Pre-vaccine Single Dose Ciprofloxac in PK Session   
1. Provide a non -dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.   
2. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
3. Collect blood sample for ciprofloxacin t=0 concentration determination prior to 
administration of AM dose of  ciprofloxacin.  
4. Administer AM ciprofloxacin dose following blood sample collection for t=0 antibiotic 
concentration determination  and record time o f administration in the source document  
and eCRF ; ensure the participant remains semi -recumbent for two hours after dosing and 
continues with a light activity level throughout the day.  
5. Blood samples for ciprofloxacin PK assessment are to be collected at t he following time 
points:  0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose ( ± 5 min 
through hr , 4 then  ± 15 min  thereafter ). The exact time of sample collection is to be 
recorded in the source document and eCRF.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 66 of 139 
  
6. Administer ciprofl oxacin dose (500 mg po) in the clinic after the final 12 -hour 
ciprofloxacin PK sample has been collected and 12 hours after morning dose ( ± 30 min), 
record exact time of administration in the source document  and eCRF . 
7. Record  anyAEs reported . 
8. Conduct a symptom -directed  PE (if required) .  
9. Prior to being discharged from the clinic, participants will be :  
 informed about the dietary and lifestyle precautions required when taking 
ciprofloxacin (see Section  5.3)  
 Review  the e -diary instructions on how the e -diary should be used to record  
compliance for the antibiotic doses  (see Section  8.3.5.1  e-diary).  
Any participant who does not have or who does not wish to use their own personal 
device to access the e -diary will at this time be supplied a hand -held device by the 
site;  
8.1.2.3.  Group 1 A: Days 5, 6 and 7 – Morning  
1. Review e -diary, confirm compliance with ciprofloxacin dosing (Days 6 and 7), and ask if 
there were any associated changes in concomitant medications.  
2. Collect blood samples for determination of ciprofloxacin trough concentrations prior to 
administering the AM dose of ciprofloxacin on Days 5, 6 and 7; record times of 
administration of ciprofloxacin in source document and eCRF.  
3. Prior to discharge from the clinic on Day 5, participants will  
 receive a ciprofloxacin supply  to take with them  
 be reminded to take their evening dose of ciprofloxacin approximately 12 hours 
(± 30 min) from the time their morning dose was provided and to bring their 
supply of ciprofloxacin with them when they return the following morning.  
 be reminded of  the dietary and  activity precautions associated with the use of 
ciprofloxacin (see Section  5.3).  
4. On Days 5 and 6, the evening dose (q 12 hr) of ciprofloxacin is to  be self -administered at 
home (at about the same times [ ± 30 min] each day).  The participant will to be 
instructed/reminded to record the date and time of administration of ciprofloxacin in the 
e-diary  
5. On the mornings of Days 5, 6 and 7, staff will revie w the e -diary entries with the 
participant, confirm compliance with ciprofloxacin dosing (Days 5 and 6), review and 
record any  changes in concomitant medications , and will remind participants on Days 5 
and 6 to return the next morning for another clinic vi sit. 
6. At the end of each clinic visit, participants will be reminded to take their evening dose of 
ciprofloxacin and to be aware of the dietary and activity precautions associated with the 
use of ciprofloxacin ( see Section  5.3). Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 67 of 139 
  
7. Prior to discharge on morning of Day 7, participants will be reminded to return to clinic 
that evening for the second overnight admission.   
8.1.2.4.  Group 1 A: Day 7 – Evening  & Overnigh t Stay # 2   
1. Admit to clinic for overnight stay #2.  
2. For WOCBP , collect urine and perform a UPT. Positive UPTs will be confirmed with a 
serum pregnancy test. All confirmed pregnancies in participants who have receive d at 
least one dose of any IP  and where conception occurs prior to 12 months after last receipt 
of that IP will be followed to outcome.  
3. Staff will review  ciprofloxacin supply with participant, checking  the remaining content 
against the dosing records in the e -diary to document compli ance and using this supply to 
provide the evening ciprofloxacin dose which is to be administered 12 hours ( ± 30 min) 
after morning dose ; record time of administration of ciprofloxacin in source document  
and the eCRF . 
8.1.2.5.  Group 1 A: Day 8 – Pre-vaccine Steady -State Ciprofloxacin PK Session & 
Vaccination #1  
1. Provide a non -dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.  
2. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respi ratory rate and 
temperature).  
3. Review eligibility for vaccination.  
4. Review and record AEs.  
5. Reassess  concomitant medications.  
6. Perform symptom -directed  PE, if required . 
7. Collect blood sample for cipro floxacin t=0 concentration determination prior to 
administration of AM dose of cipro floxacin . 
8. Administer AM dose of cipro floxacin  following blood sample collection for t=0 
antibiotic concentration determination  and record time of administration in the source 
document  and the eCRF ; ensure the participant  remains semi -recumbent for two hours 
after dosing and continues with a light activity level throughout the day.  
9. Blood samples for cipro floxacin  PK assessment are to be collected at the following time 
points: 0.25, 0.5,  0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose ( ± 5 min 
through hr 4 , then ± 15 min  thereafter ).  
10. Administer ciprofloxacin 500 mg  po in the clinic after the final 12 -hour cipro floxacin  PK 
sample has been collected and 12 hours after mornin g dose ( ± 30 min).  
11. Administer AV7909  vaccination #1 after the 12 hr blood sample for cipro floxacin  PK has 
been collected  and after the PM dose of ciprofloxacin has been administered . Participants Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 68 of 139 
  
will be monitored for at least 30 minutes following vaccine administration for any 
adverse effects especially anaphylaxis.  
12. Assess  vital signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature)  at 30  ± 5 minutes  post-vaccination . 
13. At some point during the day but p rior to being discharged from the clinic, the 
participant ’s ciprofloxacin supply  will be re viewed, checking the remaining content 
against the dosing records.   
14.  Prior to discharge from the clinic, t he participant will be  provided and  trained on an e -
diary  to capture local and systemic reactogenicity events  (ie, reactogenicity e -diary) and 
to record daily  for at least seven  days following each vaccination . If a reaction is not 
resolved at seven days postvaccination, the participant is to continue completing the e -
diary da ily until they are symptom free for two consecutive days . Participants will be 
provided with  an injection site reaction measurement tool and shown how to use it to 
measure the size of certain reactogenicity events associated with vaccination , rate the 
intensity and where to enter this  information  in the e-diary (see Section  8.3.5.1 ).  
15. When the participants are discharged from the clinic, they will be reminded : 
 about the diet and activity precautions that must be followed when taking 
ciprofloxacin (see Section  5.3).  
 to continue to  use the antibio tic e-diary  to record the times they take their 
ciprofloxacin doses each day, and to use their reactogenicity  e-diary to record any 
vaccination reactions,  if applicable . 
8.1.2.6.  Group 1 A: Days  9, 22 and 24 (At home)  
On Days  9, 22 and 24 , the participant is to self -administer ciprofloxacin (500 mg po q 12 hr) at 
home [at about the same times (± 30 min) each day]. The participant will continue with the e -
diary as described in Section  8.3.5.1 .  
It is required that participants self -administer ciprofloxacin  on the day before (morning and 
evening, the day of (evening), and the day after vaccination (morning and evening) . The site 
must con tact the participant to remind them to begin their second course of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the scheduled second vaccinati on date).A ny participant who  
needs to shift the day they come for their second vaccination  must be reminded by the site to 
start their ciprofloxacin dosing on the appropriate day, eg, if the second vaccination shifts to Day 
22, then the participant will  need to  be reminded to start taking ciprofloxacin on the morning and 
evening of Day 21 in order to meet the dosing requirement.    
8.1.2.7.  Group 1 A: Day 2 3 (± 1d) – Vaccination # 2  
1. Review e-diary entries with the participant, recording of ciprofloxacin dosing, reminding 
the participant of the precautions in Section  5.3. 
2. Review and record AEs , including any ongoing since the prior visit . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 69 of 139 
  
3. Reassess  concomitant medications.  
4. Perform symptom -directed  PE, if required . 
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect urine and perform a UPT  (prior to  AV7909  vaccination).   Positive 
UPT s will be confirmed with a serum pregnancy test. All confirmed pregnancies in 
participant s who receive at least one dose of any IP  and where conception occurs prior to 
12 months  after last receipt of any IP  will be followed to outcome.  
7. Review eligibility  for continuing vaccination.  
8. Administer AM cipro floxacin  dose; record time of administration  in source document  
and the eCRF .  
9. Administer AV7909  vaccination #2 ; this should occur after ciprofloxacin dosing . 
Participants should be monitore d for at least 30 minutes following vaccine administration  
for any adverse effects especially anaphylaxis . 
10. Assess  vital signs  at 30  ± 5 min post-vaccination  (seated/semi -recumbent blood pressure, 
heart rate, respiratory rate, and temperature).  
11. After vaccination , participants will be reminded to continue to use the e -diary  and 
injection site reaction measurement tool to capture the adverse events associated with 
vaccination,  and to record the dates and times they take their self -administered 
ciprofloxa cin doses.  (See Section  8.3.5.1  e-diary ). 
12. Prior to discharge on Day 2 3 ± 1d, participants will be reminded to continue to take their 
ciprofloxacin on the following day (Day 24) and to return to clinic in seven  days for the 
third  overnight admission.    
8.1.2.8.  Group 1 A: Day 30 – Evening & Overnight Stay # 3  
1. Admit to the clinic for overnight stay # 3.  
2. Staff will review e -diary entries with participant, discussing the use of concomitant 
medication as well as any vaccination reactions .  
3. Staff will review ciprofloxacin supply from participant, cross -referencing the content 
against the dosing records in the e -diary to document compliance .  
8.1.2.9.  Group 1 A: Day 31 – Post-vaccine Single Dose Ciprofloxacin PK Session  
1. Provide a non -dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.  
2. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
3. Collect blood sample for ciprofloxacin t=0 concentration determination prior to 
administration of AM dose of ciprofloxacin .  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 70 of 139 
  
4. Administer AM dose of cipro floxacin  following blood sample collection for t=0 
concentration determination  and record time of administration in the  source document  
and the eCRF ; ensure the participant  remains semi -recumbent for two hours after dosing 
and continues with a light activity level throughout the day.  
5. Blood samples for cipro floxacin  PK assessment are to be collected at the following time 
points:  0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose ( ± 5 min 
through hr 4 , then ± 15 min  thereafter ). 
6. Administer cipro floxacin  500 mg  po in the clinic after the final 12 -hour cipro floxacin  PK 
sample has been collected and 12 ho urs after morning dose ( ± 30 min).  
7. Following the PK session, staff will review any changes in concomitant medications.  
8. When the participant s are discharged from the clinic, they will be reminded : 
 about the diet and activity precautions that must be followed when taking 
ciprofloxacin (see Section  5.3).  
 to continue to  use the antibiotic e-diary  to record their ciprofloxacin doses ea ch 
day, and to use the reactogenicity e -diary to record any vaccination reactions,  if 
applicable , see Section  8.3.5.1  (Participant  e-diary ). 
8.1.2.10.  Group 1 A: Days  32, 33 and 34 – Morning   
1. Review e -diary , confirm compliance with ciprofloxacin dosing to document compliance, 
discuss  any changes in  concomitant medicat ions, as well as any vaccination reactions if 
still ongoing and remind participants about the dietary and activity precautions that must 
be followed when taking ciprofloxacin (see Section  5.3).  
2. Collect blood samples for determination of cipro floxacin  trough concentrations prior to 
the in -clinic administration of the AM dose of cipro floxacin  on Days 32, 33 and 34; 
record times of administration of ciprofloxacin in source document  and the eCRF . 
3. On Days 32 and 33, the evening dose (q 12 hr) of ciprofloxacin is to be self -administered 
at home (at about the same times [ ± 30 min] each day).  
4. Prior to discharge on the morning of Day 34, participants will be reminded to return to 
clinic that evening for the fourth overnight admission.    
8.1.2.11.  Group 1 A: Day 34 – Evening & Overnight Stay # 4  
1. Admit to clinic for overnight stay #4.  
2. Staff will review the participant’s ciprofloxacin supply and review e-diary entries , 
conducting a compliance check of the remaining doses compared to the e -diary record. 
Staff will also ask if the participant required  the use of concomitant medication as well as 
any vaccination reactions if still ongoing.  
3. Administer ciprofloxacin 500 mg  po 12 hours after morning dose ( ± 30 min) . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 71 of 139 
  
8.1.2.12.  Group 1 A: Day 3 5: – Post-vaccine Steady -State Ciprofloxacin PK Session  
1. Provide a non -dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the cours e of the day.   
2. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
3. Collect blood sample for ciprofloxacin  t=0 concentration determination prior to 
administration of AM dose of ciprofloxacin . 
4. Administer AM dose of ciprofloxacin  (500 mg po) following blood sample collection for 
t=0 concentration determination  and record time of administration in the source 
document  and the eCRF ; ensure the participant  remains semi -recumbent for two hours 
after dosing and continues with a light activity level throughout the day.  
5. Blood samples for ciprofloxacin  PK assessment are to be collected at the following time 
points: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8,  10 and 12 hours post -dose ( ± 5 min 
through hr 4 , then ± 15 min  thereafter ).  
6. Administer ciprofloxacin  500 mg  po in the clinic after the final 12 -hour ciprofloxacin  PK 
sample has been collected and 12 hours after the morning dose ( ± 30 min).  
7. Record concomi tant medications.  
8. Return  ciprofloxacin supply to participant  
9. When the participant s are discharged from the clinic, they will be reminded : 
 about the diet and activity precautions that must be followed when taking 
ciprofloxacin (see Section  5.3).  
 to continue to  use the antibiotic e-diary to record  the times they take their 
ciprofloxacin doses each day  and to use the reactogenicity e -diary to record any 
vaccination reactions,  if applicable , see Section  8.3.5.1   (Participant  e-diary ). 
8.1.2.13.  Group 1 A: Day 3 6 (At home)  
Two cipro floxacin  doses (500 mg  po morning and evening, q 12 hr) are to be self -administered 
at home on Day 36. The participant  will continue with the e-diary  as described in Section  8.3.5.1 . 
8.1.2.14.  Group 1 A: Day 3 7 (± 1d) – Blood Draw for TNA  
The Day 3 7 visit to draw blood for immunogenicity may shift by  ± 1 d.  If such a shift in visit 
day occurs , the participant  must remain on cipro floxacin  500 mg  po every 12 hours until the 
morning of that visit.   In the event of such a shift, the participant’s required number of doses of 
ciprofloxacin will vary. The Pharmacy Manual will contain a table detailing the dosing options 
for the final course of ciprofloxacin given a one -day shift from Day 3 7. 
1. Participants will report to the clinic having taken their morning dose of ciprofloxacin  at 
home . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 72 of 139 
  
2. Review  participant’s ciprofloxacin supply ; count the number of remaining doses and 
compare to the e -diary record to document compliance; record total remaining in  source 
document and  eCRF . 
3. Review other e -diary entries with participant . Discuss any changes in the use of 
concomitant medication as well as any vaccination reactions if still ongoing. Remind 
participants that they should still use sunscreen and avoid exc essive sun exposure and 
strenuous sports until the Day 51  Final Study Visit.  
4. Record concomitant medications.  
5. Collect blood sample for TNA assessment.  
8.1.2.15.  Group 1A : Day 51  (± 1d) – Final In-Clinic Study Visit  
1. Perform complete  PE. 
2. Review e-diary  entries with pa rticipant  and collect hand -held device  if study provided .  
3. Review and record AEs.  
4. Record concomitant medications.  
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect and perform a UPT .  Positive UPT s will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participant s who receive at least one dose of 
AV7909  or cipro floxacin and where conception occurs prior to 12 months  after last 
receipt of either IP will be followed to outcome . 
7. Collect blood sample s for hematology  and serum chemistry .  
8. Collect blood sample s for TSH & autoantibod ies. 
9. Collect urine sample for urinalysis.  
8.1.3.  Group 1B: Ciprofloxacin + AV7909 with out Ciprofloxacin PK  
Shown in Table  6 is a schedule of events for Group 1B participants from screening until the end 
of the study. Following the table are detailed descriptions of the activities that the sites are 
expected to conduct for each of the column h eadings identified in the table once each participant 
has received his  or her group assignment. Note that this detail starts following randomization for 
Group 1B which is when th ey receive their first course of ciprofloxacin although the actual 
activities for the trial do not begin until Day 4 when participants self-administer their first dose Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 73 of 139 
  
of ciprofloxacin. The detailed activities during Screening and Group Assign (Randomizati on) 
were covered previously in Section  8.1.1 .  
Table  6: Schedule of Events for Group 1B: Ciprofloxacin + AV79 09 with out Ciprofloxacin 
PK 
 Screening  Group  
Assign  At 
Home † Vac At Home † TNA  Final 
Visit  Safety 
Calls  EWV  
USV‡  
Study Day(s)  -28 to -2 1 4-7 8 
23* 9, 22, 24, 
31-37 37 51 114, 205, 
 296, 388 NA 
Visit Window  NA NA  *± 1 d  ± 1 d ± 1 d ± 14 d  
Sign, date ICF & assign ID  X         
Review eligibility a X X  X      
Medical history  & demographics  X X        
Physical examinationb  X      X  X 
ECGc X         
Vital signsd X X  X   X  X 
Pregnancy teste X X  X   X  X 
FSH teste X         
Collect sample for hematologyf X      X  X 
Collect sample for s erum chemistryg X      X  X 
Collect sample for u rinalysish X      X  X 
Urine drug screeni X         
HIVAb/HBsAg/HCVAb  X         
Concomitant medicationsj X X  X  X X X X 
Randomize eligible participants   X        
Symptom -directed PEk  X  X      
Blood draws for TNAl  X    X    
Cipro dosing & compliancem,,n  X X X X X   Xn 
AV7909 vaccinationo    X      
Participant e -diary + toolsp  X X X X X X  X 
Staff review of e -diariesq   X X X X X  X 
AEsr, SAEs & AESIss X X  X   X X X 
Collect TSH & autoantibody sample st  X     X  X 
For the abbreviations used above please refer to Table 1 of the protocol . *The  ± 1 d window applies only to the second 
vaccination on Day 2 3 (note: the second course of antibiotic treatment will have to shift accordingly) . †At Home Days are only 
those days where both doses of ciprofloxacin are taken at home. ‡For EWV occurring within the visit window of Day 37, a blood 
sample for TNA will be drawn.  
a Eligibility will be reviewed before each vaccination , ie, on Day 8 and Da y 23. 
b Physical examinations  (PE) will be conducted as described in Protocol Section  8.3.3 . 
c ECG s will be conducted and interpreted at screening as described  in Protocol Section  8.3.3 .   
d Vital signs will be administered as described in Protocol Section  8.3.4 .   
e Pregnancy tests  (serum and/or urine)  will be administered to all WOCBP  as described in Protocol Section  8.3.2 . Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP will be required 
before each vaccination . At Screening visit only, FSH test will be  performed for postmenopausal women.      
f Hematology will be conducted as described in Protocol Section  8.3.2 .   Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 74 of 139 
  
g Serum chemistry will be conducted as described Protocol Section  8.3.2 .   
h Urinalysi s will be conducted as described in Protocol Section  8.3.2 . 
i Urine drug screens will be conducted as described in Protocol Section  8.3.2 . 
j Concomitant medications  will be identified and recorded as described in Protocol Section  6.5.     
k Symptom -directed PEs will be conducted as described in Protocol Section  8.3.3 . 
l Blood samples for TNA assessment on Day 1  will be collected in the morning following randomization. Those on Day 3 7 will 
be collected after the final dose of ciprofloxacin has been administered . A TNA sample will also be collected if EWV occurs 
within the visit window of Day 37 as described in Protocol Section  8.1.8 . 
m Participants receive their first course of ciprofloxacin following randomization. Format of the doses and distribution of 
subsequent courses will be described in the Pharmacy manual. Self-administration o f ciprofloxacin starts on Day 4. Ciprofloxacin 
dose compliance  will be managed as described in Protocol Section  6.4.   
n Ciprofloxacin doses (500 mg  po q 12 hr) will be administered as described in Protocol Section  6.1.2 .   
o Vaccinations with AV7909 will be administered as described  Protocol Section  6.1.4 .  
p All p articipants will be provided  with an e -diary for post vaccination follow up along with  a thermometer  and an injection site  
reaction measurement tool . Participants in Group 1 and 2 will be provided with an e -dairy for antibiotic compliance.  All 
participants  will be trained on the use of these tools and the e-diaries as described in Protocol Section  8.3.5.1 . 
q Staff will begin reviewing the e -diaries on Day 5 and will review them at regular intervals thereafter.  
r AEs will be collected at all clinic visits through Day 51 /EWV  as described in detail in Protocol Section  9.  
s AEs, S AEs and potential AESIs  will be collected during the Safety Follow -Up Telephone Calls (see Protocol Section  8.1.7 ). 
t Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section  8.3.2  (ie, at Day 1, Day 51, and at EWV  if the subject received at least one vaccination ). Additional  samples for TSH & 
autoantibody testing may be requested  (ie, based on  the participant ’s report(s) of a potential AESI ); blood draws for additional 
TSH and/or autoantibody testing should  be performed as part of  an unscheduled visit . 
8.1.3.1.  Group 1B: Days 4 to 7 (At home)  
1. On Days 4 to 7, the participant  will self-administer cipro floxacin  500 mg  po every 12 
hours at home at about the same times ( ± 30 min) each day.   
2. Participant will use the antibiotic e-diary to record the date and time of administration of 
cipro floxacin .  
8.1.3.2.  Group 1B: Day 8 – Vaccination #1  
1. Review eligibility . 
2. Staff will review  the ciprofloxacin  supply and review the e -diary entries, conducting a 
compliance check of the remaining doses compared to the e -diary record. Staff will 
record ciprofloxacin doses to document compliance . Staff will als o discuss any changes 
in the use of concomitant medication while reminding the participant of the precautions 
in Section  5.3. 
3. Review and record AEs . 
4. Conduct a symptom -directed  PE, if required . 
5. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect and perform UPT  (prior to AV7909 vaccination).  Positive UPT s 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of AV7909 or ciprofloxacin  and where conception occurs 
prior to 12 months  after last receipt of either IP  will be followed to outcome.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 75 of 139 
  
7. Administer cipro floxacin  500 mg  po in AM  prior to vaccination ; the evening dose of 
cipro floxacin  500 mg  po will be self -administered at home 12 hours after the AM dose 
[and at approximately the same time (±  30 min) each day].  
8. Administer AV7909  vaccination #1. Participants should be  monitored for at least 30 
minutes following vaccine administration for any adverse effects especially anaphylaxis.  
9. Assess  vital signs at 30  ± 5 min postvaccination . 
10. Prior to being discharged from the clinic, the participant will be  given and trained on an 
e-diary  to capture local and systemic reactogenicity events  (ie, reactogenicity e -diary)  and 
to record daily  for at least seven  days following each vaccination . If a reaction is not 
resolved at seven days postvaccination, the parti cipant is to continue completing the e -
diary daily until they are symptom free for two consecutive days . Participants will be 
given aninjection site reaction measurement tool and shown how to use it to measure the 
size and assess the severity  of certain re actogenicity events associated with vaccination . 
See Section  8.3.5.1  (e-diary)  and remind participants about the diet and activity 
precautions that must be followed when taking ciprofloxacin (see Section  5.3). 
8.1.3.3.  Group 1B:Days 9, 22 and 24  (At home)  
On Days 9, 22 and 24, the participant is to self -administer ciprofloxacin (500 mg po q 12 hr) at 
home [at about the same times (± 30  min) each day]. The participant will continue with the e -
diary as described in Section  8.3.5.1 .  
It is required that participants self -administer ciprofloxacin  on the day before (morning and 
evening), the day of (evening), and the day after (morning and evening) vaccinati on. The site 
must contact the participant to remind them to begin their second course of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the sched uled second vaccination date). A ny participant who 
schedules vaccination 2 (on Day 23) to shift within the allowable window (± 1  d) will be 
reminded to start their ciprofloxacin dosing on the appropriate day, eg, if the second vaccination 
shifts to Day 22 then the participant will be reminded to start taking ciprofloxacin on the 
morning and evening of Day 21 in order to meet the dosing requirement.  
8.1.3.4.  Group  1B: Day 2 3 (± 1 d) – Vaccination #2  
1. Staff will review ciprofloxacin supply and re view  against  e-diary entries conducting a 
compliance check of the remaining doses compared to the e -diary record. Staff will 
record ciprofloxacin doses to document compliance . Staff will discuss changes in the use 
of concomitant medication as well as any vaccination re actions if still ongoing  while 
reminding the participant of the precautions in Section  5.3.  
2. Review and record AEs.  
3. Perform symptom -directed  PE, if required . 
4. Record concomitant medications.   
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate, and 
temperature).  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 76 of 139 
  
6. Review eligibility for continuing vaccination.  
7. For female participant s not exempted due to a  screening  FSH >30 mIU/mL , collect and 
perform UPT  (prior to AV7909  vaccination).  Positive UPT s will be confirmed with a 
serum pregnancy test.  All confirmed pregnancies in participant s who receive at least one 
dose of any IP  and where conception occurs prior to 12 months  after last receipt of any IP 
will be followed to outcome.  
8. Administer cipro floxacin  500 mg po in AM; the evening dose will be self -administered at 
home.  
9. Administer AV7909  vaccination #2 ; this should occur after ciprofloxacin dosing. 
Participants sho uld be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis.   
10. Following the 30 (±  5) minutes of observation, repeat vital signs ( seated/semi -recumbent  
blood pressure, heart rate, respiratory rate , and temperature)  measur ement . 
11. After e-diary review , participants will be reminded to  continue to  use the reactogenicity 
e-diary and injection site reaction measurement tool to capture the adverse events 
associated with vaccination , and to record the dates and times they self -administer  their 
ciprofloxacin doses in the antibiotic e -diary . See  Section  8.3.5.1  (e-diary ). 
12. Prior to discharge on Day 2 3, participants will be reminded to return to clinic in two 
weeks (±  1 d) on Day 3 7 ± 1 d for the final blood draws for TNA . Again, participants are 
to continue dosing with ciprofloxacin through the even ing of Day 24 and discontinue 
dosing until Day 31. Their ciprofloxacin supply will  be returned to them before they are  
discharge d from the clinic.   
8.1.3.5.  Group 1B: Days 31 to 36 (At home)  
On Days 31 to 37, the participant  is to self -administer cipro floxacin  500 mg  po every 12 hours at 
home [at about the same times (± 30 min) each day ].  The participant  will continue with the e-
diary  as described in  Section 8.3.5 .1. The site must contact the participant to remind them to star t 
their third course of ciprofloxacin within 24 hours of Day 31.  
8.1.3.6.  Group 1B: Day 3 7 (± 1 d) – Blood Draw for TNA   
The Day 37 Visit may shift by  ± 1 d. If such a shift occurs , the participant  must remain on 
cipro floxacin  500 mg  po every 12 hours until the morning before the blood draw .  In the event of 
such a shift, the participant’s required number of doses of ciprofloxacin will vary. The Pharmacy 
Manual will contain a table detailing the dosing options for the final course of cipr ofloxacin 
given a one -day shift from Day 3 7. 
1. Participants will report to the clinic having taken their morning dose of ciprofloxacin  at 
home . 
2. Review  participant’s ciprofloxacin supply ; count the number of remaining doses and 
compare to the e -diary record to document compliance ; record total remaining in source 
document . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 77 of 139 
  
3. Review other e-diary entries with participant . Discuss  any changes in the use of 
concomitant medication as well as any vaccination reactions if still ongoing . Remind 
participants that they should still use sunscreens and avoid excessive sun exposure and 
strenuous sports until the Day 51  Final Study Visit.   
4. Record concomitant medications.  
5. Collect blood sample for TNA assessment  
8.1.3.7.  Group 1B: Day 51  (± 1 d) – Final In-Clinic Study Visit  
1. Perform complete  PE.  
2. Review e-diary  entries with participant  and collect hand -held device  if study provided .  
3. Review and record AEs.  
4. Record concomitant medications.  
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect and perform UPT .  Positive UPT s will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participant s who receive at least one dose of 
AV7909  or cipro floxacin and where conception occurs prior to 12 months  after last 
receipt of either IP will be followed to outcome . 
7. Collect blood sample for hematology.  
8. Collect blood sample for serum chemistry.  
9. Collect blood sample for TSH and autantibodies . 
10. Collect urin e sample for urinalysis.   
8.1.4.  Group 2A: Doxycycline + AV7909 with Doxycycline PK Sessions  
Shown in Table 7 is a schedule of events for Group 2A  participants  from screening until the end 
of the study. Following the table are detailed descriptions of the activities that the sites are 
expected to conduct for each of the column headings identified in the Table. Note that this detail 
starts with PM Admit (Evening Admission) as the detailed activities during Screening and Group 
Assign (Randomization) were covered previously in Section  8.1.1 . 
Table 7: Schedule of Events for Group 2A : Doxycycline + AV7909 with Doxycycline 
PK 
 Screening  Group  
Assign  PMa 
Admit  PKb  AMa 
Visits  Vac  At 
 Home † TNA  Final 
Visit  Safety 
Calls  EWV  
USV‡  
Study Day(s)  -28 to -2 1 1r, 7c,e, 
31, 37  2r, 8, 
32, 38 3-7 
33-37 8 
23e* 9, 22, 24,  37 51 114, 205, 
 296, 388 NA 
Visit Window  ±  NA  §+ 1 d NA  *± 1 d   ± 1 d ± 14 d  
Read, s ign, date ICF & receive  ID X           
Review eligibility  X X X   Xc      Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 78 of 139 
  
 Screening  Group  
Assign  PMa 
Admit  PKb  AMa 
Visits  Vac  At 
 Home † TNA  Final 
Visit  Safety 
Calls  EWV  
USV‡  
Study Day(s)  -28 to -2 1 1r, 7c,e, 
31, 37  2r, 8, 
32, 38 3-7 
33-37 8 
23e* 9, 22, 24,  37 51 114, 205, 
 296, 388 NA 
Visit Window  ±  NA  §+ 1 d NA  *± 1 d   ± 1 d ± 14 d  
Medical history  & demographics  X X          
Physical examinationd  X        X  X 
ECGe X           
Vital signsf X X  X  X   X  X 
Pregnancy testg X X X  
(D7 only)    X   X  X 
FSH testg X           
Collect sample for hematologyh X        X  X 
Collect sample for s erum 
chemistryi X        X  X 
Collect sample for u rinalysisj X        X  X 
Urine drug screenk X           
HIVAb/HBsAg/HCVAb  X           
Concomitant medicationsj X X X X X X X X X X X 
Randomize eligible participants   X          
Symptom -directed PEm  X    X   X   
Blood draws for TNAn   X      X    
Doxy dosing & complianceo,p    X X X X X X   X 
Doxy pre-dose or  trough     X X       
Doxy  PKq    X        
AV7909 vaccinationr      X      
Participant e -diary + toolsx  X  X X X X X X  X 
Staff review of e -diariest   X X X X X X X  X 
AEsu, SAEs , AESIsv  X X X X  X   X X X 
Collect TSH & autoantibody 
sample sw   X       X  X 
For the  abbreviations used above please refer to Table 1 of the protocol . *The  ± 1 d window applies only to the second 
vaccination on Day 23  (note: the second course of antibiotic treatment will have to shift accordingly) . †At Home Days are only 
those days where both doses of doxycycline are taken at home .  § The +1 d window only applies to Day 31 . ‡For EWV occurring 
within the visit window of Day 37, a blood sample for TNA will be drawn.  
a PM and AM admissions must be timed so that doxycycline  can be administered in the clinic within a 12 hr  ± 30 min window of 
the prior AM or PM dose.  
b For each PK session, the sites will manage the meals and activity of participants as detailed in Protocol  Section  5.3.1  and 
Protocol  Section  5.3.2 . 
c Eligibility will be reviewed before each vaccination, either the evening before  (ie, on Day 7) or the morning of vaccination  (ie, 
on Day 23).   
d Physical examinations (PE) will be conducted as described in Protocol Section  8.3.3 . 
e ECG s will be conducted  and interpreted  at screening as  described in Protocol Section  8.3.3 .  
f Vital signs will be administered as described in Protocol Section  8.3.4 .  
g Pregnancy tests  (serum and/or urine)  will be administered to all WOCBP  as described in Protocol Section  8.3.2 . Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP required before each 
vaccination will be performed either the evening before (ie, on Day 7) or the morning of vaccination  (ie, on Day 23). Note: for 
WOCBP  in group 2A , UPT is required only at Day 7 ( at the evening admission ); it is  not required at evening admission s at Day 
1, 31 or 37.  FSH test will be performed at Screenining visit only for  postmenopausal  women .     Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 79 of 139 
  
h Hematology tests will be conducted as described in Protocol Section  8.3.2 .   
i Serum chemistry tests will be conducted as described Protocol Se ction  8.3.2 . 
j Urinalysis will be conducted as described in Protocol Section  8.3.2 .  
k Urine drug screens will be conducted as described in Protocol Section  8.3.2 . 
l Concomitant medications  will be identified and recorded as described in Protocol Section  6.5. 
m Symptom -directed PEs will be conducted as described in Protocol Section  8.3.3 . 
n Blood samples for TNA assessment on Day 1 will be collected in the m orning following randomization. Those on Day 37 will 
be collected after the morning  dose of doxycycline  has been administered . A TNA sample will also be collected if the EWV 
occurs within the visit window of Day 37 as described in Protocol Section  8.1.8 .  
n Symptom -directed PEs will be conducted as described in Protocol Section  8.3.3 . 
o Doxycycline  dose compliance will be managed as described in Protocol Section  6.4.   
p Doxycycline  doses ( 100 mg po q 12 hr) will be administered as described in Protocol Section  6.1.6 .  
q Blood samples for assessment of doxycycline concentrations will be collected as detailed in Protocol Section  8.4. 
r Vaccinations with AV7909 will be administered as described Protocol Section  6.1.4 .  
s All p articipants will be provided with an e -diary for post vaccination follow up along with  a thermometer and an injection site  
reaction measurement tool . Participants in Group 1 and 2 will be provided with an e -dairy for antibiotic compliance.  All 
participants  will be trained on the use of these tools and the e -diaries as described in Protocol Section  8.3.5.1 . 
t Staff will begin reviewing the e -diaries on Day 3 and will review them at routine intervals  thereafter.  
u AEs will be collected at all clinic visits through Day 51 /EWV as described in detail in Protocol Section  9.  
v AEs, S AEs and potential AESIs will be collected during the Safety Follow -Up Telephone Calls (see Protocol Section  8.1.7 ). 
w Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section  8.3.2  (ie, at Day 1, Day 51, and at EWV  if the subject received at least one vaccination ). Additional  TSH & autoantibody 
testing may be requested (ie, based on  the participant ’s report(s) of a potential AESI ); additional TSH and/or autoantibody testing 
should be performed as part of an unscheduled visit . 
8.1.4.1.  Group 2A: Day 1  – Overnight Stay # 1  
1. Admit to the clinic for overnight stay #1.  
2. Review eligibility.  
3. Review and record AE asses sments and changes in concomitant medications in 
participant’s medical history unless they are related to study procedures in which case 
they are recorded as AEs.  
8.1.4.2.  Group 2A: Day 2 – Pre-vaccine Single Dose Doxycycline  PK Session   
1. Provide a non -dairy breakfa st 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.   
2. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
3. Collect blood sample for doxycycline t=0 concentration determination prior to 
administration of AM dose of  doxycycline.  
4. Administer AM dose of doxycycline following blood sample collection for t=0 antibiotic 
concentration determination and  record time of administration in the source document  
and the eCRF ; ensure the participant remains semi -recumbent for two hours after dosing 
and continues with a light activity level throughout the day.  
5. Blood samples for doxycycline PK assessment are to be collected at the following time 
points:  0.25, 0.5, 0.75 , 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose ( ± 5 min 
through hr 4 , then ± 15 min  thereafter ). The exact time of sample collection is to be 
recorded in the source document and eCRF.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 80 of 139 
  
6. Administer doxycycline dose (100 mg po) in the clinic after the final 12 -hour 
doxycycline PK sample has been collected and 12 hours after morning dose ( ± 30 min), 
record exact time of administration in the source document  and the eCRF . 
7. Record  any AEs reported . 
8. Conduct a symptom -directed  PE in response to any AEs re ported.   
9. Prior to being discharged from the clinic,  participants will :  
 Be informed about the dietary and lifestyle precautions required when taking 
doxycycline (see Section  5.3). 
 Review the instructions on the use of the antibiotic e-diary to record compliance for 
the antibiotic doses  (see Section  8.3.5.1  e-diary).  
Any participant who does not have or who does not wish to use their own personal device 
to access the e -diary will at this time be supplied a hand -held device by the site . 
8.1.4.3.  Group 2A: Days  3, 4, 5, 6 and 7 – Morning  
1. Review e -diary, confirm compliance with doxycycline dosing (Days 6 and 7)  and ask if 
there were any associated changes in concomitant medications.  
2. Collect blood samples for determination of doxycycline trough concentrations prior to 
administering the AM dose of doxycycline on Days 3, 4, 5, 6 and 7; record times of 
administration of doxycycline in  the source document s and eCRF . 
3. Prior to discharge from the clinic on Day 3, participants will receive their first course of  
doxycycline and will be introduced to the dietary and activity precautions associated with 
the use of doxycycline (see Section  5.3).  
4. On Days  3, 4, 5 and 6, the evening dose (q 12 hr) of doxycycline is to be self -
administered at home [at about the same time (± 30 min ) each day ].  The participant will 
to be inst ructed/reminded to record the date and time of administration of doxycycline in 
the e -diary . 
5. On the mornings of Days 4, 5, 6 and 7, staff will review the e -diary entries with the 
participant  and confirm compliance with doxycycline dosing (Days 3, 4, 5 and 6).  
6. At the end of each clinic visit, participants will be reminded to take their evening dose of 
doxycycline and to be aware of the dietary and activity precautions associated with the 
use of doxycycline (see Section  5.3). 
7. Prior to discharge on morning of Day 7, participants will be reminded to return to clinic 
that evening for the second overnight admission  and to bring their doxycycline supply 
with them .   
8.1.4.4.  Group 2A: Day 7 – Evening  & Overnight Stay # 2   
1. Admit to clinic for overnight stay #2.  
2. Review eligibility  for vaccination . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 81 of 139 
  
3. Staff will review the e-diary  entries with participant, confirming antibiotic dosing 
compliance. Staff will then record AEs and any changes in concomitant medications . 
4. For WOCBP , collect urine and perform a UPT.  Positive UPTs will be confirmed with a 
serum pregnancy test. All confirmed pregnancies in participants who have received at 
least one dose of any IP and where conception occurs prior to 12 months  after last receipt 
of that IP will be followed to outcome.  
5. Administer doxycycline  12 hours after morning dose ( ± 30 min); record time of 
administration of doxycycline in source docume nt and in eCRF  
8.1.4.5.  Group 2A: Day 8 – Pre-vaccine Steady -State Doxycycline  PK Session & 
Vaccination #1  
1. Provide a non -dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.  
2. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
3. Review and record AEs.  
4. Reassess  concomitant medications.  
5. Perform symptom -directed  PE, if required . 
6. Collect blood sample for doxycycline t=0 concentration determina tion prior to 
administration of AM dose of doxycycline . 
7. Administer AM dose of doxycycline  following blood sample collection for t=0 antibiotic 
concentration determination; ensure the participant  remains semi -recumbent for two 
hours after dosing and continu es with a light activity level throughout the day.   
8. Blood samples for doxycycline  PK assessment are to be collected at the following time 
points: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose ( ± 5 min 
through hr 4 , then ± 15 min  thereafter ).  
9. Administer doxycycline  100 mg  po in the clinic after the final 12 -hour doxycycline  PK 
sample has been collected and 12 hours after morning dose ( ± 30 min).  
10. Administer AV7909  vaccination #1 after the 12 hr blood sample for doxycycline  PK has 
been collected  and after the PM dose of doxycycline has been administered . Participants 
should be monitored for at least 30 minutes following vaccine administration for any 
adverse effects especially anaphylaxis.  
11. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature)  at 30  ± 5 minutes post-vaccination . 
12. At some point during the day but prior to being discharged from the clinic, the 
participants’ doxycycline supply will be returned to them .  
13. Prior to discharge  from the clinic, the p articipant s will be  given and trained on the e -diary  
to capture local and systemic reactogenicity events and to record daily  for at least seven  
days following each vaccination . If a reaction is not resolved at seven days Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 82 of 139 
  
postvaccinat ion, the participant is to continue completing the e -diary daily until they are 
symptom free for two consecutive days . Participants will be provided an injection site 
reaction measurement tool and shown how to use it to measure the size of certain 
reactogen icity events associated with vaccination , rate the intensity and where to enter 
this information  in the e-diary (see Section  8.3.5.1 ). 
14. When the participants are discharged from the clinic, they will be reminded : 
 about the diet and activity precautions that must be followed when taking 
doxycycline (see Section  5.3).  
 to continue to  use the antibiotic e-diary  to record the times they take their 
doxycycline doses each day  and to use the reactogenicity  e-diary to record any 
vaccination reactions,  if applicable; as described in Section  8.3.5.1  (Participant  e-
diary ). 
8.1.4.6.  Group 2A: Days  9, 22 and  24 (At home)  
On Days 9, 22 and 24 , the participant is to self -administer doxycycline ( 100 mg po q 12 hr) at 
home (at about the same times [ ± 30 min ] each day).  The participant will continue with the e -
diary as described in Section  8.3.5.1 .  
It is required that participants self -administer doxycycline on the day before (morning and 
evening, the day of (evening), and the day after vaccination (morning and evening) . The site 
must contact the participant to remind them to begin their second course  of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the scheduled second vaccination date). A ny participant who 
needs to shift their vaccine visit  must be reminded to start their doxycycline dosing on the 
appropriate day, eg, if the second vaccination shifts to Day 22 then the participant will be 
reminded to start taking doxycycline on the morning and evening of Day 21 in order to meet the 
dosing re quirement.  
8.1.4.7.  Group 2A: Day 2 3 (± 1d) – Vaccination # 2  
1. Review e-diary entries with the participant, recording doxycycline dosing, discussing any 
symptoms and if they required  any changes in concomitant medications   
2. Review and record AEs  including any ongoing since prior visit . 
3. Reassess  concomitant medications.  
4. Perform symptom -directed  PE, if required . 
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect and perform a UPT  (prior to  AV7909  vaccination).  Positive UPT s 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participant s 
who receive at least one dose of any IP  and where conception occurs prior to 12 months  
after last receipt of any IP  will be followed to outcome.  
7. Review eligibility  for continuing vaccination.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 83 of 139 
  
8. Administer AM doxycycline  dose; record time of administration  in source documents and 
eCRF .  
9. Administer AV7909  vaccination #2 ; this should occur after doxycycline dosing . 
Participa nts should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis.  
10. Assess vital signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate, and 
temperature)  at 30  ± 5 minutes post-vaccination . 
11. After diary review, participants will be reminded to continue to use the reactogenicity e-
diary  and injection site reaction measurement tool to capture reactogenicity  events 
associated with vaccination, any use of concomitant medications and to record the dates , 
as well as  to use the antibiotic e -diary to record times they take their self -administered 
doxycycline  doses; see Section  8.3.5.1  (e-diary ). 
12. Prior to discharge on Day 2 3, participants will be reminded  
 of the precautions in Section  5.3. 
 to continue to take their doxycycline the following day  
 to return to clinic in eight  days for the third  overnight admission.    
8.1.4.8.  Group 2A: Day 31 (+ 1d)  – Evening & Overnight Stay # 3  
1. Admit to the clinic for overnight stay # 3.  
2. Staff will review e -diary entries with participant, checking doxycycline  dosing records to 
document compliance, discuss any t vaccination reactions , as well as t he use of 
concomitant medication s, and will remind partic ipants about the precautions  associated 
with the use of doxycycline .  
8.1.4.9.  Group 2A: Day 32 – Post-vaccine Single Dose Doxycycline  PK Session  
1. Provide a non -dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.  
2. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
3. Collect blood sample for doxycycline  t=0 concentration determination prior to 
administration of AM dose of doxycycline .  
4. Administer AM dose of doxycycline  following blood sample collection for t=0 
concentration determination; ensure the participant  remains semi -recumbent  for two 
hours after dosing and continues with a light activity level throughout the day.  
5. Blood samples for doxycycline  PK assessment are to be collected at the following time 
points:  0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post -dose (± 5 min 
through hr 4 , then ± 15 min  thereafter ). 
6. Administer doxycycline  100 mg  po in the clinic after the final 12 -hour doxycycline  PK 
sample has been collected and 12 hours after morning dose ( ± 30 min).  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 84 of 139 
  
7. Following the PK session, staff will assess and  record AEs and changes in concomitant 
medications.  
8. When the participant s are discharged from the clinic, they will be reminded to  continue to  
use the  antibiotic  e-diary  to record the times they take their doxycycline doses each day  
and to use the reactogenicity e -diary to record any vaccination reactions,  if applicable.   
8.1.4.10.  Group 2A: Days  33, 34, 35, and 36 – Morning   
1. Review e -diary , confirm compliance with doxycycline dosing to document compliance, 
discuss changes in  any vaccination react ions if still ongoing , as well as the use of 
concomitant medication and remind participants about the dietary and activity 
precautions that must be followed when taking doxycycline  (see Section  5.3).  
2. Collect blood samples for determination of doxycycline  trough concentrations prior to the 
in-clinic administration of the AM dose of doxycycline  on Days 33, 34, 35  and 36; record 
times of administration of doxycycline  in source document  and eCRF.  
3. On Days 33, 34, 35 and 36, the evening dose (q 12 hr) of doxycycline  is to be self -
administered at home (at about the same times [ ± 30 min] each day).  
8.1.4.11.  Group 2A: Day 37 – Blood Draw for TNA  
1. Collect doxycycline supply, r eview e -diary  dosing entries to  confirm compliance with 
doxycycline dosing to document compliance, discuss changes in the use of concomitant 
medication s, as well as any vaccination reactions , if still ongoing , and remin d participants 
about the dietary and activity precautions that must be followed when taking doxycycline  
(see Section  5.3).  
2. Collect blood sample for  determination of doxycycline  trough concentrations prior to the 
in-clinic administration of the AM dose of doxycycline  [100 mg  po 12 hours after 
even ing dose ( ± 30 min) ]; record time of administration of doxycycline  in source 
document and eCRF . 
3. Following doxycycline dose administration, c ollect blood sample for TNA assessment.  
  
4. Prior to discharge on the morning of Day  37, return doxycycline supply and remind 
participants to return to clinic that evening for the fourth overnight admission.    
8.1.4.12.  Group 2A: Day 37 – Evening & Overnight Stay # 4  
1. Admit to clinic for overnight stay #4.  
2. Staff will review the participant’s doxycycline supply and review e -diary entries with 
participant, checking doxycycline  dosing records to document compliance, discuss if they 
required the use of concomitant medication s, as well as any vaccination reactions if still 
ongoing and will remind participants about the diet and activity precautions that must be 
followed when taking doxycycline (see Section  5.3).  
3. Administer doxycycline  100 mg  po 12 hours after morning dose ( ± 30 min) ; record time 
of administration of doxycycline in source document and e CRF . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 85 of 139 
  
8.1.4.13.  Group 2A: Day 3 8: – Post-vaccine Steady -State Doxycycline  PK Session  
1. Provide a non -dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.   
2. Assess vital  signs (seated/semi -recumbent blo od pressure, heart rate, respiratory rate and 
temperature).  
3. Collect blood sample for doxycycline  t=0 concentration determination prior to 
administration of AM dose of doxycycline . 
4. Administer AM dose of doxycycline  (100 mg po) following blood sample collect ion for 
t=0 concentration determination; ensure the participant  remains semi -recumbent for two 
hours after dosing and continues with a light activity level throughout the day.  
5. Blood samples for doxycycline  PK assessment are to be collected at the following time 
points: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post -dose ( ± 5 min 
through hr 4 then  ± 15 min ).  
6. Record any reported AEs.  
7. Record concomitant medications.  
8. Retain doxycycline s upply; dose administered before  PK session is the final dose . 
9. When the participant s are discharged from the clinic, they will be reminded to  return to 
the clinic in seven  days (nominally Day 51 ) for the final study visit.  
10. Participants should also be remind ed that they should still avoid strenuous sports  and the 
sun and  use sunscreens until the Day 51  Final In-clinic Study Visit.  
8.1.4.14.  Group 2A: Day 51  (± 1d) – Final In-Clinic Study Visit  
1. Perform complete  PE. 
2. Review e-diary  entries with participant  and collect ha nd-held device  if study provided .  
3. Review and record AEs.  
4. Record concomitant medications.  
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect and perform a UPT .  Positive UPT s will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participant s who receive at least one dose of 
AV7909  or doxycycline and where conception occurs prior to 12 months  after last receipt 
of either IP will be followed to outcome . 
7. Collect blood sample s for hematology  and serum chemistry .  
8. Collect blood sample s for TSH and autoantibodies . 
9. Collect urine sample for urinalysis.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 86 of 139 
  
8.1.5.  Group 2B: Doxycycline + AV7909 without Doxycycline PK Sessions  
Shown in  Table 8 is a schedule of events for Group 2B participants from screening until the end 
of the study. Following the table are detailed descriptions of the activities that the sites are 
expected to conduct for each of the column headings identified in the table. Note that the detailed 
activities during  Screening and Group Assign (Randomization) are covered in Section  8.1.1 . 
Table 8: Schedule of Events for Group 2B: Doxycycl ine + AV7909 without Doxycycline 
PK 
 Screening  Group  
Assign  At 
Home † Vac At Home † TNA  Final 
Visit  Safety 
Calls  EWV  
USV‡  
Study Day(s)  -28 to -2 1 2-7 8     
23* 9, 22, 24,  
32-38 37 51 114, 205, 
 296, 388 NA 
Visit Window  ±  NA NA  ± 1d  ± 1d ± 1d ± 14d  
Sign, date ICF & assign ID  X         
Review eligibility a X X  X      
Medical history  & demographics  X X        
Physical examination  b X      X  X 
ECG  c X         
Vital signs  d X X  X   X  X 
Pregnancy test  e X X  X   X  X 
FSH test  e X         
Collect sample for hematology  f X      X  X 
Collect sample for s erum chemistry  g X      X  X 
Collect sample for u rinalysis  h X      X  X 
Urine drug screen  i X         
HIVAb/HBsAg/HCVAb  X         
Concomitant medications  j X X  X  X X X X 
Randomize eligible participants   X        
Symptom -directed PE  k  X  X      
Blood draws for TNA  l  X    X    
Doxy  dosing & compliance  m,n  X X X X X   X 
AV7909 vaccination  o    X      
Participant e -diary + tools  p  X X X X X X  X 
Staff review of e -diaries  q   X X X X X  X 
AEsr, SAEs & AESIss X X  X   X X X 
Collect TSH & autoantibody sample  t  X     X  X 
For the abbreviations used above please refer to Table 1 of the protocol. *The  ± 1 d  window applies only to the second 
vaccination on Day 2 3 (note: the second course of antibiotic treatment will have to shift accordingly) . †At Home Days are only 
those days where both doses of doxycycline are taken at home . ‡For EWV occurring within the visit window of Day 37, a blood 
sample for TNA will be drawn.  
a Eligibility will be reviewed before each vaccination, ie, on Day 8 and Day 23. 
b Physical examinations  (PE) will be conducted as described in Protocol Section  8.3.3 . 
c ECG s will be conducted and interpreted at screening as  described in Protocol Section  8.3.3 . 
d Vital signs will be administered as described in Protocol Section 8.3.4 .  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 87 of 139 
  
e Pregnancy tests (serum and/or urine) will be administere d to all WOCBP  as described in Protocol Section  8.3.2 . Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP will be required 
before each vaccination . At Screening visit only, FSH test will be  performed for postmenopausal women.    
f Hematology will be conducted as described in Protocol Section  8.3.2 .   
g Serum chemistry will be conducted as described Protocol Section  8.3.2 .   
h Urinalysi s will be conducted as described in Protocol Section  8.3.2 . 
i Urine drug screens will be conducted as described in Protocol Section  8.3.2 . 
j Concomitant medications  will be identified and recorded as described in Protocol Section  6.5.   
k Symptom -directed PEs will be conducted as described in Protocol Section  8.3.3 . 
l Blood samples for TNA assessment on Day 1  will be collected in the morning following randomization. Those on Day 3 7 will 
be collected after the  morning dose of doxy  has been administered . A TNA sample will also be collected if EWV occurs within 
the visit window of Day 37 as described in Protocol Section  8.1.8 . 
m Participants receive t heir first course of doxy following randomization.  Format of the doses and distribution of subsequent 
courses  will be described in the Pharmacy manual. Self-administration of doxycycline starts the following day (Day 2). 
Doxycycline  dose compliance  will be  managed as described in Protocol Section  6.4.  
n Doxycycline  doses ( 100 mg  po q 12 hr) will be administered as described in Protocol Section 6.1.4.  
o Vaccinations with AV7909 will be administered as described  Protocol Section 6.1.3 . 
p All p articipants will be provided  with an e -diary for post vaccination follow up along with  a thermometer  and an injection site  
reaction measurement tool . Participants in Group 1 and 2 will be provided with an e -dairy for antibiotic compliance.  All 
participants  will be trained on the use of these tools and the e-diaries as described in Protocol Section 8.3.5.1.  
q Staff will begin reviewing the e -diaries on Day 3 and will  review them on a routine basis thereafter.  
r AEs will be collected at all clinic visits through Day 51 /EWV  as described in detail in Protocol Section 9.  
s SAEs and potential AESIs  will be collected during the Safety Follow -up Telephone Calls (see Protocol Section  8.1.7 ). 
t Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section  8.3.2  (ie, at Day 1, Day 51, and at EWV if the subject received at least one vaccination) . Additional  samples  for TSH & 
autoantibody testing may be requested  (ie, based on  the participant ’s report(s) of a potential AESI ); blood draws for additional 
TSH and/or autoantibody testing should be performed as part of an unscheduled visit . 
8.1.5.1.  Group  2B: Days 2 to 7 (At home)  
1. On Days 2 to 7, the participant  will self-administer doxycycline  100 mg  po every 12 
hours at home at about the same times ( ± 30 min) each day.   
2. Participant will use the e-diary to record the date and time of administration of 
doxycycline .  
8.1.5.2.  Group 2B: Day 8 – Vaccination #1  
1. Review eligibility . 
2. Staff will review the doxycycline supply and  review  the e-diary entries , conducting a 
compliance check of the remaining doses compared to the e -diary record. Staff will also 
discuss any changes in the use of concomitant medication.  
3. Review and  record AEs . 
4. Conduct a symptom -directed  PE, if required . 
5. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect and perform UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confi rmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of AV7909 or doxycycline  and where conception occurs 
prior to 12 months  after last receipt of either IP  will be followed to outcome.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 88 of 139 
  
7. Administer doxyc ycline 500 mg po in AM prior to vaccination; the evening dose of 
doxycycline 100 mg po will be self -administered at home 12 hours after the AM dose 
[and at approximately the same time ( ± 30 min) each day].  
8. Administer AV7909 vaccination #1. Participants should be monitored for at least 30 
minutes following vaccine administration for any adverse effects especially anaphylaxis.  
9. Assess vital  signs at 30  ± 5 minutes post-vaccination . 
10. Prior to discharge from the clinic, the participant will be given and traine d on an e -diary  
to capture local and systemic reactogenicity events (ie, reactogenicity e -diary) and to 
record daily  for at least seven  days following each vaccination . If a reaction is not 
resolved at seven days postvaccination, the participant is to cont inue completing the e -
diary daily until they are symptom free for two consecutive days . Participants will be 
given an injection site reaction measurement tool and shown how to use it to measure the 
size and assess the severity of certain reactogenicity eve nts associated with vaccination . 
See Section  8.3.5.1  (e-diary) and remind participants about the diet and activity 
precautions that must be followed  when taking doxycycline (see Section  5.3). 
8.1.5.3.  Group 2B: Day s 9, 22 and 24  (At home)  
On Days 9, 22 and 24, the participant is to self -administer doxycycline ( 100 mg po q 12 hr) at 
home (at about the same times [ ± 30 min) each day]).  The participant will continue with the e -
diary as described in Section  8.3.5.1 .  
It is required that participants self -administer doxycycline on the day before (morning and 
evening, the day of (evening), and the day after vaccination (morning and evening) . The site 
must contact the participant to remind them to beg in their second course of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the scheduled second vaccination date). A ny participant who 
schedules va ccination 2 (on Day 23) to shift within the allowable window ( ± 1 days) will be 
reminded to start their doxycycline dosing on the appropriate day, eg, if the second vaccination 
shifts to Day 22 then the participant will be reminded to start taking doxycycl ine on the morning 
and evening of Day 21 in order to meet the dosing requirement.  
8.1.5.4.  Group 2B: Day 23 (± 1 day) – Vaccination #2  
1. Staff will review  the participant’s doxycycline supply and review e-diary entries , 
conducting a compliance check of the remaining doses compared to the e -diary record. 
Staff will also discuss  any changes in the use of concomitant medication as well as any 
vaccination reactions if still ongoing , and reminding the participant of the precautions in 
Section  5.3.  
2. Review and record AEs.  
3. Perform symptom -directed  PE, if required . 
4. Record concomitant medications.   
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate, and 
temperature).  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 89 of 139 
  
6. Review eligibility for continuing vaccination.  
7. For WOCBP , collect and perform UPT  (prior to AV7909  vaccination).  Positive UPT s 
will be confirmed with a serum pregnancy test.  All confirmed p regnancies in participant s 
who receive at least one dose of any IP  and where conception occurs prior to 12 months  
after last receipt of any IP will be followed to outcome.  
8. Administer doxycycline  100 mg po in AM; the evening dose will be self -administered at 
home.  
9. Administer AV7909  vaccination #2 ; this should occur after doxycycline  dosing. 
Participants should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects espe cially anaphylaxis.   
10. Following the 30 (±  5) minutes of observation, repeat vital signs ( seated/semi -recumbent  
blood pressure, heart rate, respiratory rate, and temperature)  measurement . 
11. After diary review , participants will be reminded to  continue to  use the reactogenicity  e-
diary and injection site reaction measurement tool , to capture  any use of concomitant 
medications  and to record the dates and times they self -administer  their doxycycline  
doses on the antibiotic e -diary . See  Section  8.3.5.1 . 
12. Prior to discharge on Day 2 3, participants  doxycycline supply will be returned , and 
participants will be reminded to return to clinic in two weeks ( ± 1 day) on Day 37  ± 1d 
for the final bloo d draws for TNA. Again, participants are to continue dosing with 
doxycycline through the morning of Day 37.  
8.1.5.5.  Group 2B: Days 32 to 37 (At home)  
On Days 32 to 37, the participant  is to self -administer doxycycline  100 mg  po every 12 hours at 
home at about the  same times ( ± 30 min) each day.  The participant  will continue with the e-
diary  as described in Section  8.3.5.1 . The site must contact the particip ant to remind them to start 
their third course of doxycyline  within 24 hours of Day 31.   
8.1.5.6.  Group 2B : Day 37 (± 1) – Blood Draw for TNA  
The Day 3 7 Visit may shift by  ± 1 day. If such a shift occurs , the participant  must remain on 
doxycycline  100 mg  po every 12 hours until the morning before the blood draw .  In the event of 
such a shift, the participant’s required number of doses of doxycycline will vary. The Pharmacy 
Manual will contain a table detailing the dosing options for the final course of doxycy cline given 
a one -day shift from Day 37.  
1. Participants will report to the clinic having taken their morning dose of doxycycline  at 
home . 
2. Review  participant’s doxycycline supply ; count the number of remaining doses and 
compare to the e -diary record to docume nt compliance ; record total remaining in source 
document . 
3. Review other e-diary entries with participant . Discuss  any changes in the use of 
concomitant medication as well as any vaccination reactions if still ongoing . Remind Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 90 of 139 
  
participants that they should st ill use sunscreens and avoid excessive sun exposure and 
strenuous sports until the Day 51  Final Study Visit.   
4. Record concomitant medications.  
5. Collect blood sample for TNA assessment . 
8.1.5.7.  Group 2B : Day 51  (± 1d) – Final Study Visit  
1. Perform complete  PE.  
2. Review e-diary  entries with participant  and collect hand -held device  if study provided .  
3. Review and record AEs.  
4. Record concomitant medications.  
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate and 
temperature).  
6. For WOCBP , collect and perform UPT . Positive UPT s will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participant s who receive at least one dose of 
AV7909  or doxycycline and where conception occurs prior to 12 months  after last receipt 
of either IP will be followed to outcome . 
7. Collect blood sample for hematology.  
8. Collect blood sample for serum chemistry.  
9. Collect blood sample for TSH and autoantibodies .  
10. Collect urine sample for urinalysis.  
8.1.6.  Group 3 : AV7909 Alone  
Shown in Table  9 is a schedule of events for Group 3  participants from screening until the end of 
the study. Following the table are detailed descriptions of th e activities that the sites are expected 
to conduct for each of the column headings identified in the table once each participant has 
received his  or her group assignment.  Note that for Group 3  this detail only includes Days 8 and 
23 as the detailed activi ties during Screening and Group Assignment (Randomization) were 
covered previously in Section  8.1.1  and the activities for the Day 3 7 and Day 51  visits, the Safety 
Follow -up Phone calls and the EWVs are handled individually in Section  8.1.6.3 , 
Section  8.1.6.4 , Section  8.1.7 , and Section  8.1.8 , respectively .   
Table  9: Schedule of Events for Group 3 : AV7909 Alone  
 Screening  Group  
Assign  Vac TNA  Final 
Visit  Safety Calls  EWV  
USV‡  
Study Day(s)  -28 to -2 1 8  
23* 37 51 114, 205,  
 296, 388 NA 
Visit Window  ±  NA NA ±1d* ±1d ± 1d ± 14d  
Sign, date ICF & assign ID  X       
Review eligibility a X X X     Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 91 of 139 
  
 Screening  Group  
Assign  Vac TNA  Final 
Visit  Safety Calls  EWV  
USV‡  
Study Day(s)  -28 to -2 1 8  
23* 37 51 114, 205,  
 296, 388 NA 
Visit Window  ±  NA NA ±1d* ±1d ± 1d ± 14d  
Medical history  & demographics  X X      
Physical examination  b X    X  X 
ECG  c X       
Vital signs  d X X X  X  X 
Pregnancy test  e X X X  X  X 
FSH test  e X       
Collect sample for hematology  f X    X  X 
Collect sample for s erum chemistry  g X    X  X 
Collect sample for u rinalysis  h X    X  X 
Urine drug screen  i X       
HIVAb/HBsAg/HCVAb  X        
Concomitant medications  j X X X X X X X 
Randomize eligible participants   X      
Symptom -directed PE  k  X X     
Blood draws for TNA  l  X  X    
AV7909 vaccination  m   X     
Participant e -diary + tools  n   X X X  X 
AEs o, SAEs & AESIs p X X X  X X X 
Collect TSH & autoantibody sample  q  X   X  X 
For the abbreviations used above please refer to Table 1. 
*± 1 d window only applies to the second vaccination (Day 2 3). ‡For EWV occurring within the visit window of Day 37, a blood 
sample for TNA will be drawn , 
a Elibility will be reviewed before  each vaccination, ie, on Day 8 and Day 23. 
b Physical examinations  (PE) will be conducted as described in Protocol  Section  8.3.3 . 
c An ECG will be conducted at screening as  described in Protocol Section  8.3.3 .  
d Vital signs will be administered as described in Protocol  Section  8.3.4 .  
e Pregnancy tests (serum and/or urine) will be administered to all WOCBP  as described in Protocol  Section  8.3.2 . Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP will be required 
before each vaccination. At Screening visit only, FSH test will be performed for postmenopausal wome n.    
f Hematology will be conducted as described in Protocol Section  8.3.2 .   
g Serum chemistry will be conducted as described Protocol Section  8.3.2 .   
h Urinalyse s will be conducted as described in Protocol Section  8.3.2 .  
i Urine drug screens will be conducted as described in Protocol Section  8.3.2 .  
j Concomitant medications  will be identified and recorded as described in Protocol  Section  6.5.    
k Symptom -directed PEs will be conducted as described in Protocol Section  8.3.3 . 
l Blood samples for TNA assessment on Day 1  will be collected in the morning following randomization. Those on Day 3 7 will 
be collected in the morning.  A TNA sample will also be collected if EWV occurs within the visit window of Day 37 as described 
in Protocol Section  8.1.8 . 
m Vaccinations with AV7909 will be administered as described in  Protocol  Section  6.1.3 . 
n All participants will be provide d with an e -diary for post vaccination follow up along with d  a thermometer  and an injection site  
reaction measurement tool  and will be trained on the use of these tools and the e-diary  as described in Protocol  Section  8.3.5.1 . 
o AEs will be collected at all clinic visits through Day 51 /EWV  as described in detail in Protocol  Section  9. 
p SAEs and potential AESIs  will be collected during the Safety Follow -up Telephone Calls (see Protocol  Section  8.1.7 ). 
q Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol  
Section  8.1.6.3  (ie, at Day 1, Day 51, and at EWV if the subject received at least one vaccination) . Additional samples for TSH & Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 92 of 139 
  
autoantibody testing may be collected  based on  the safety follow -up phone contact if warranted from participant report(s) of a 
potential AESI ); blood draws for additional TSH and/or autoantibody testing should be performed as part of an unscheduled visit . 
8.1.6.1.  Group  3: Day 8 – Vaccination #1   
1. Review eligi bility . 
2. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate and 
temperature) . 
3. For WOCBP , collect and perform UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of AV7909 or doxycycline  and where conception occurs 
prior to 12 months  after last receipt of either IP will be followed to outcome.  
4. Perform symptom -directed  PE. 
5. Reassess concomitant medications.  
6. Administer AV7909 vaccination #1.  
7. Participants should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis.  
8. Assess  vital signs  at 30  ± 5 minutes post-vaccination . 
9.  Before the participant is discharged from the clinic, they will be trained on  the use of e-
diary (see Section  8.3.5.1 ) and given instructions on how the e -diary should be used to 
record daily temperature , and any local and systemic reactogenicity events after 
vaccination . Participants will be instr ucted to use the e -diary on a daily basis for at least 
seven days postvaccination. If a reaction is not resolved at seven days postvaccination, 
the participant is to continue completing the e -diary daily until they are symptom free for 
two consecutive days .   
10. Participant s will also be given an injection site reaction measurement tool and shown 
how to use it to measure the size and rate the intensity of certain reactogenicity events 
associated with vaccination as well as where to enter this in the e -diary.   
Any participant who does not have or who does not wish to use their own personal device to 
access the e -diary will at this time be supplied a hand -held device by the site.  
8.1.6.2.  Group 3: Day 2 3 (± 1 d) Vaccination #2  
1. Review participant  e-diary  discussing any symptoms and any use of pain  medications . 
2. Review and record AEs.  
3. Reassess  concomitant medications.  
4. Perform symptom -directed  PE. 
5. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate, and 
temperature).  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 93 of 139 
  
6. For WOC BP, collect and perform UPT  (prior to AV7909  vaccination).  Positive UPT s 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participant s 
who receive at least one dose of AV7909  and where conception occurs prior to 12 
months  after last receipt of IP will be followed to outcome.  
7. Review eligibility for continuing vaccination.  
8. Administer AV7909  vaccination #2. Participants should be monitored for at least 30 
minutes following vaccine administration for any adverse effects especially a naphylaxis.  
9. Assess vital  signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate, and 
temperature)  at 30  ± 5 minutes post-vaccination . 
10. After diary review  the participant  will be reminded to use the reactogenicity e-diary and 
injection sit e reaction measurement tool to capture the adverse events associated with 
vaccination , as well as to continue entering their temperatures every  day. See 
Section  8.3.5.1  (e-diary ). 
11. Prior to discharge following vaccination on  Day 2 3, participants will be reminded to 
return to clinic in two weeks ( ± 1 day) on Day 3 7 ± 1d for the final blood draws for TNA.     
8.1.6.3.  Group 3: Day 3 7 (± 1 d) – Blood Draw for TNA  
The Day 3 7 Visit may shift by  ± 1 d.  
1. Review e-diary entries with participant s, discuss ing any  changes in health status and the 
use of concomitant medication as well as any vaccination reactions if still ongoing .  
2. Review and record AEs.  
3. Record concomitant medications.  
4. Conduct symptom -directed  PE (if necessary) .  
5. Collect blood sample for TNA assessment . 
8.1.6.4.  Group 3: Day 51  (± 1 d) – Final In-Clinic Study Visit  
1. Perform complete  PE. 
2. Review e-diary  entries with participan t and collect hand -held device .  
3. Review and record AEs.  
4. Record concomitant medications.  
5. Measure vital signs ( seated/semi -recumbent  blood pressure, heart rate, respiratory rate 
and temperature).  
6. For WOCBP , collect and perform UPT .  Positive UPT s will be con firmed with a serum 
pregnancy test. All confirmed pregnancies in participant s who receive at least one dose of 
any IP  and where conception occurs prior to 12 months  after last receipt of any IP will be 
followed to outcome . 
7. Collect blood sample for hematolo gy. Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 94 of 139 
  
8. Collect blood sample for serum chemistry.  
9. Collect blood sample for TSH & autoantibody determination.   
10. Collect urine sample for urinalysis.  
8.1.7.  Quarterly Safety Follow -up Phone Calls  
Following the last scheduled vaccination , the site will conduct quarterly safety follow -ups in 
which participants are contacted by phone at 3 months  (Day 114 ± 14 d), 6 months  (Day 205 ± 14 
d), 9 months (Day 296 ± 14 d) and 12 months  (Day 388 ± 14 d).  These phone contacts will be 
scheduled to key  off the participant ’s actual or, if missed, target Day 2 3 visit (intended last 
vaccination day) so that all participants (even those failing to receive both vaccinations but who 
are followed for safety only) are contacted  3 months after their target Day 23.   
The following assessments will be performed over the phone at the 3 months  (Day 114 ± 14d), 6 
months  (Day 205 ± 14 d), 9 months (Day 296 ± 14 d) and 12 months  (Day 388 ± 14 d) contacts:  
 Assess and document , AEs,  SAEs a nd potential AESIs (refer to Section  9.3) 
 For WOCBP, confirm continued use of an adequate method of contraception and 
inquire about any possible pre gnancies (refer to Section  9.4) 
 If an AE, SAE and/or an AESI is reported, record any associated medications  
 Review the status of ongoing AEs/SAEs/AESIs to update the resolution status  
During the telephone calls, the staff member is to inquire about and record in source 
documentation any AEs and SAEs occurring since either the Day 51  visit or the previous phone 
contact . Any occurrence of SAE s will be reported to Emergent immediately as specified under 
Section  9.3 and followed up per procedures described in  Section  9.7.2 . If an SAE has occurred, it 
will be recorded on the AE eCRF with any medications taken also recorded on  the appropriate  
eCRF.  
During the telephone calls, the staff m ember will also attempt to elicit and record in source 
documentation any information on AEs of potential autoimmune etiology . If the condition is a 
diagnosed or suspected AESI , the staff member may refer the participant to the PI or designee 
for further phone evaluation if needed; based on initial assessment of potential AESI, the 
participant will be asked to return for an unscheduled clinic visit for evaluation (refer to  
Sectio n 8.1.9 ) and to provide a blood sample for autoantibody  testing  and/or TSH assessment (if 
applicable) . The PI or designee will obtain records confirm ing the diagnosis or refer the 
participant to a medical specialist for additional clinical and diagnostic testing and follow up 
until the diagnosis is ascertained.  The potential AESI will be reported to Emergent immediately  
as specified in Section  9.3 and followed up per procedures described in  Section  9.7.2 . Only after 
the DSMB has assessed  the case as a confirmed AESI will the  PI or designee record the 
occurrence of the AESI on the AE eCRF with any medications taken also recorded on eCRFs. 
The medical monitor  or designee will direct the completion of the AE eCRF when 
communicating the DSMB assessment  outcome(s) to the PI or designee.  
In the event the site is unable to reach the participant by telephone at any of the interim safety 
follow -up calls at  3 months  (Day 114 ± 14 d), 6 months  (Day 205 ± 14 d), 9 months (Day Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 95 of 139 
  
296 ± 14 d) and 12 months  (Day 388 ± 14 d), at least three phone contact attempts must be made 
before the site documents that the participant was unable to be reached. The contact attempts will 
be spaced at least one week apart. Failure to reach the participant at one of the interim safety 
follow -up time points does not preclude contact attempts at the next scheduled safety follow -up 
time point.  Procedures for the final  12-month  follow -up call are de scribed in  Section  7.4.  
8.1.8.  Early Withdrawal Visit  
Any participant who withdraws early or is discontinued for any reason will be asked to complete 
an EWV .  
1. For participants in Groups 1 and 2 , review  the participant’s remaining antibiotic  supply 
and count the number of remaining doses  to document compliance; record total 
remaining in source document . 
2. Perform complete physical examination.  
3. Assess vital  signs (seated/semi -recumbent blood pressure, heart rate, respiratory rate and 
temperature).  
4. For WOCBP , collect and perform serum pregnancy test.   
5. If EWV occurs within the visit window for Day 37 , collect blood sample for TNA.  
6. Collect blood sample for hemato logy.  
7. Collect blood sample for serum chemistry .  
8. Collect urine sample for urinalysis .  
9. For participants who have received at least one vaccination, collect blood sample for TSH 
& autoantibody  determination.  
10. Review entries in e -diary with participant.  
11. Revi ew and record AEs.  
12. Record concomitant medications.  
8.1.9.  Unscheduled Visits  
Unscheduled visits will occur when necessary, in the opinion of the PI or designee, to follow -up 
on an AE or abnormal laboratory test result between scheduled visits. Additionally, parti cipants 
who report a potential autoimmune -related condition at any of the safety follow -up phone calls 
will be requested to return to the clinic for an unscheduled visit to provide a blood sample for 
TSH & autoantibody  testing .  
Unscheduled visits occurring before Day 51  will include a symptom -directed PE, measurement 
of vitals, AE (includes SAE/AESI) assessment inclusive of reviewing the status of ongoing AEs 
since the prior visit, updating of medication usage since the last visi t, and (if applicable) review 
of e-diary data since the last visit.  
Unscheduled visits occurring after Day 51  will include an AE/SAE/AESI assessment including 
blood draw for TSH and autoantibody  testing  (if medically indicated)  and updating of Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 96 of 139 
  
medication u sage since the last visit/contact (only if AE/SAE/AESI -related).  Other evaluations 
performed by the PI or designee during the unscheduled visit as part of the participant’s medical 
care (eg, vital signs, symptom -directed PE, etc) and recommendations given to the participant 
(eg, referral to the participant’s personal physician or specialist for further diagnosis and/or care, 
prescribed medications) will be documented in the participant’s medical chart at the site. In the 
event of any referrals for further m edical care, the PI or designee will follow up  with the 
participant and/or personal physician/specialist to ensure the reporting of any SAEs or potential 
AESIs per the protocol (refer to  Section  9.7.2 ).  
8.2. Immunogenicity/Efficacy Assessments  
For all participants , blood samples for the determination of  TNA titers will be collected on Day  1 
and Day 37 (± 1 d) (2 weeks after the last vaccination). Blood samples will be collected at  the 
EWV only if it falls within the visit window for Day 37.  
All immunogenicity laboratory samples will be evaluated using a TNA assay. Specific 
procedures related to collection, processing , storage, and shipment of the sample s will be 
provided in a Laboratory Manual.  
The TNA assay being used in this trial has been validated by Battelle Memorial Institute 
(Columbus, Ohio) under National Institute of Allergy and Infectious Diseases sponsorship . The 
assay measures the functional ability of antisera containing anti -PA antibodies to specifically 
protect cells against B. anthracis  lethal toxin cytotoxicity  {Stinson  et al,  2005 ; Li et al., 2008 }. 
The TNA assay results will be reported as the reciprocal of a serum sample dilution that results 
in 50% neutralization of lethal toxin cytotoxicity (50% effective dilution; ED 50). To standardize 
assay results, the results are divided by the ED 50 of a serum reference standard, and the resulting 
ratio is reported as a 50% neutralization factor, NF 50. Reference standard AVR801 w ill be used.  
8.3. Safety Assessments  
8.3.1.  Adverse Events  
Refer to Section  9, Reporting Adverse Events . 
8.3.2.  Clinical Laboratory Tests  
All analytes to be tested during screening/safety /autoimmunity  clinical laboratory tests are 
specified in  Table 10. Instructions for the collection, processing, storage, and shipment of 
screening and safety clinical laboratory test samples are provided separately in the Laboratory 
Manual. All samples will  be sent to the central laboratory for analysis, except urine for 
pregnancy testing , which will be performed at the site and results documented in the eCRF.  
It is the responsibility of the PI or designee to review the results of all screening and safety 
laboratory tests (including unscheduled lab tests) as they become available, initially for the 
assessment of study eligibility and subsequently for the continuous safety monitoring of 
participants. Review of the laboratory report s must be documented.  
The fo llowing assessments will be performed at Screening only:  
 Urine drug screen (refer to Table 10 for analytes) . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 97 of 139 
  
 Serologic testing ( HIV-1/HIV -2 antibodies , HBV surface antigen, and  HCV 
antibody). Confirmatory testing will be performed on any samples that test positive 
for either HIV or HCV; no additional blood/serum will be required for this 
confirmatory testing.  
 FSH test in postmenopausal women ; refer to Section  5.1. 
Pregnancy testing will be performed at Screening, immediately following group assignment , 
before each vaccination , and at the Day 51  Final Study Visit  or at the EWV. Female participant s 
who are surgically sterile or are confirmed at Screening to have an FSH level > 30 mIU/mL ( ie, 
postmenopausal; refer to  Section  5.1) are exempt from pregnancy testing. A serum pregnancy 
test is required at Screening for all other female participant s (ie, WOCBP) . Post -screening 
pregnancy testing in all women not having an FSH level > 30 mIU/mL (ie, WOCBP) will consist 
of a UPT  at the above specified visits except for a serum pregnancy test performed at the (if 
applicable) EWV. All UPT s must be performed at the investigational site and documented to be 
negative prior to  vaccine administration . For participant s with positive UPT  results, a 
confirmatory serum pregnancy test will be performed. IP will not be administered to any 
participant  who tests positive for pregnancy . If group assignment occurs within four days of a 
negative Screening serum pregnancy test, a UPT does not have to be  performed.  
Blood and urine samples for safety clinical laboratory testing (hematology, serum chemistry, 
urinalysis) will be collected at Screening and Day 51  as well as  at the EWV if the EWV occurs 
before Day 51 . Refer to Table 10 for th e list of analytes for hematology, serum chemistry and 
urinalyses.  The laboratory test results will be evaluated against the FDA toxicity grading scale 
provided in Table  13 of Appendix  A.  
In addition, blood samples for TSH & autoantibody assessment of ANA, R F and anti -dsDNA 
will be taken at Day 1 after randomization, Day 51  or EWV  or an unscheduled visit  if the 
participant has received at least one dose of vaccine and at the time of safety follow -up phone 
contact(s) if warranted from participant report(s) of a potential AESI (see Table 10 for th e list of 
analytes for autoantibody testing).  These samples will be shipped to the central laboratory and 
will be banked ; testing for TSH and ANA, RF and anti -dsDNA autoantibodies will be performed 
only if medically indicated (as per PI’s discretion  based on a report of a potential AESI ).  
Instruction s for the collection, processing, storage, and shipment of laboratory samples will be 
provided separately in the Laboratory Manual.  
It is the PI’s responsibility to review the results of all screening and safety laboratory tests 
(including unscheduled lab tests) as they become available, initially for the assessment of study 
eligibility and subsequently for the safety monitoring of participant s. Review of the laboratory 
report must be documented.  
For each abnormal laboratory test result, the PI needs to as certain if this is a clinically significant 
change from screening level  for that individual participant . This determination, however, does 
not necessarily need to be made the first time an abnormal value is observed. The PI may repeat 
the laboratory test a nd/or request additional tests to verify the results of the original laboratory 
tests. The PI (or designee) will inform the MM of  any unscheduled clinical labo ratory testing, 
including but not limited to confirmatory testing of laboratory samples, with the  exception that 
notification is not required for confirmatory testing for pregnancy, HCV, and HIV.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 98 of 139 
  
Investigational sites will be automatically notified of any Grade 3 or higher laboratory 
abnormalities. For any Grade 3 or higher laboratory result, the test  will be repeated as soon as 
possible by the central lab using the same blood sample to confirm the result. The PI or designee 
must request the participant  return to the clinic for an unscheduled visit for an assessment of 
clinical status. The decision to redraw laboratory tests will be made by the PI (with notification 
to the MM) and/or MM and will be based on the type and severity of the laboratory abnormality 
and the clinical status of the participant . Any Grade 3 or higher neutropenia or lymphopenia mus t 
be evaluated with an unscheduled repeat complete blood count (CBC) approximately 72 hours 
after the initial specimen was drawn .  
If the original (retested sample) or repeat laboratory value is Grade 3 or higher or determined by 
the PI to be a clinically significant change from baseline for that participant , this will be 
considered an AE and will be recorded on the AE eCRF. Any other clinical laboratory 
abnormalities must also be reported as AEs if considered by the PI to be a clinically significant 
change  from baseline.  If an abnormal laboratory test result is a sign of a disease or syndrome, 
the disease or syndrome will be recorded as the AE/SAE and not the abnormal laboratory result. 
Clinical laboratory abnormalities may trigger individual participant  or study halting rules ( see 
Section  7.1 and Section  7.3) and may require discontinuation of treatment.  
Table 10: Screening/Safety Clinical Laboratory Tests  
Hematology  
-Basophils  
-Eosinophils  
-Hematocrit  
-Hemoglobin  
-Lymphocytes  
-Monocytes  
-Neutrophils  
-Platelets  
-RBC count  
-WBC count  
 
Serum Chemistry  
-ALT  
-AST  
-Bilirubin  
-BUN  
-Creatinine  
-Glucose  
 Urinalysis  
-Appearance  
-Bilirubin  
-Color  
-Glucose  
-Ketones  
-Leukocyte esterase  
-Nitrite  
-Occult blood  
-pH 
-Protein  
-Specific gravity  
-Urobilinogen  
-Microscopic examination (only if 
protein, nitrite, leukocyte esterase, or 
occult blood results are positive)  
 
Additional Tests  
-FSH (only in postmenopausal women  
at Screening ) 
-Serum/ UPT  (all WOCBP ) 
-TSH   Viral Serology:  
-anti-HCV antibody  
-anti-HIV antibody  
-HBsAg  
 
Urine Drug Screen:  
-Amphetamines  
-Barbiturates  
-Benzodiazepines  
-Cannabinoids  
-Cocaine  
-Opioids 
- 
 
Autoantibodies  
-Rheumatoid factor (RF)  
-Antinuclear antibody 
(ANA)  
-Anti-double stranded 
deoxyribonucleic acid  
(dsDNA) antibodies  
 
For the abbreviations used above refer to Table 1. Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 99 of 139 
  
8.3.3.  Physical Examination   
Complete PEs will be performed at screening, the Final Study Visit  (Day 51 ) and early 
withdrawal, if applicable.  The following will be examined: cardiovascular system  (including a  
standard 12-lead electrocardiogram at screening only , to be read at the site ); lymphatic/  
hematological, respiratory system; nervo us system; skin and appendages; 
abdominal/gastrointestinal system; metabolic/endocrine, musculoskeletal system; and ear, nose, 
and throat.  
Symptom -directed PEs will be performed  at all visits except the Screening , Final Study Visit s 
and early withdrawal (including any unscheduled visits) , only if required (ie,  in response to the 
report/ collection of AEs/SAEs/potential AESIs ).  
Abnormal PE findings are to be recorded as AEs if new or changed in severity any time after the 
first administration of any IP and P E AEs should be assessed for  severity and  causality.  Grade 3 
(or higher) PE findings could trigger individual or study halting rules if considered associated 
with IP administration  (see Section  7).  Physical examination abnormalities are not separately 
reported as AEs if the PE abnormality is part of a symptom complex that is already reported as 
an AE .  
8.3.4.  Vital Signs  
Vital signs including seated/semi -recumbent  systolic and diastolic blood pressure, heart rate, 
respiration rate, and temperature will be obtained at Screening and each subsequent clinic visit 
through Day 51 /EWV  (except at AM and PM clinic visits for groups 1A and 2A , and at Day 37 
for all groups ), including unscheduled visits. Height and weight will only be recorded at 
Screening. On vaccination days (Days 8 and 2 3), vital signs will be assessed prior to vaccination 
and at 30  ± 5 minutes post -vaccination.  
All vital sign abnormal ities determined by the PI or designee to be a clinically significant change 
from baseline for that participant should be recorded as AEs. Grade 3 or higher vital signs will be 
repeated twice to verify that the severity is a Grade 3 or higher. If two of th e three assessments 
are Grade 3 or higher, the vital sign should be reported as a Grade 3 or higher abnormality.  Vital 
sign abnormalities may trigger individual participant or study halting rules (refer to Section  7).  
8.3.5.  Other Safety Assessments  
8.3.5.1.  E-diary Records  
Participants will be asked to fill out a n electronic diary  (e-diary)  daily  for for postvaccination 
reatogenicity events (all groups) and an e-diary for antibiotic compliance  (Groups 1 and 2) . 
Participants who do not have or don’t want to use their personal electronics to access the web -
enabled e -diary will be provided a hand -held device for purposes of this study. Participants will 
receive  instructions on reactrogenicity and/or antibiotic compliance e-diary completion . 
Participants  will be asked  to complete the reactogenicity e-diary at the same time each day to 
capture observations on the previous 24 -hour period. Staff at the clinical site will follow up 
participant’s reactogenicity and/or antibiotic e-diary noncompliance.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 100 of 139 
  
There are separate  e-diary requirements for this study depending on the treatment group  
assignment : 
 Participants in all three groups will be required to fill out an e -diary to capture 
reactogenicity events after each vaccinati on. All participants will receive an injection site 
reaction measuring tool and an oral thermometer to support in completing the 
reactogenicity e-diary.  
 Participants in Group 1 and Group 2 will be required to also fill out a separate e-dairy to 
capture antibiotic compliance.  
The e-diary  to capture reactogenicity events postvaccination  will collect the following  
information : 
 each participant ’s daily oral temperature at the same time each day   
 local injection site and systemic reactogenicity events   
 whether they have used any pain medications ( eg, acetaminophen,  aspirin,  ibuprofen)   
Reactogenicity (solicited systemic and local injection site reactions) will be  monitored by the site 
for at least 30 minutes after vaccination with special attention being paid to signs and symptom 
of immediate hypersensitivity responses (eg, anaphylaxis , bronchospasm. urticaria, angioedema ). 
Thereaf ter, local injection site and systemic reactogenicity responses will be assessed daily  by 
participants in their e -diaries for at least seven  days following each vaccination. Information will 
be solicited on the following local injection site reactogenicity  reactions: warmth, tenderness, 
itching, pain, arm motion limitation, redness, lump, swelling, and bruising.  In addition, 
information will be solicited on the following systemic reactogenicity reactions:  
tiredness/fatigue, muscle ache, headache, and feve r (oral temperature).  Except for oral 
temperature, swelling, and redness, the participant  will be prompted to grade each reaction 
according to the grading scale provided below.  
 Grade 0 (Absent):  Symptom not present  
 Grade 1 (Mild):  Symptom present but d oes not interfere with activities of daily living  
 Grade 2 (Moderate):  Symptom causes some interference with activities of daily living  
 Grade 3 (Severe):  Symptom prevents activities of daily living or requires  medical 
intervention  
Participants will also b e asked to respond (yes/no) if they have taken pain/fever medications such 
as acetaminophen, aspirin, and nonsteroidal anti -inflammatory drugs (NSAIDs; eg, ibuprofen) or 
other medication in the past 24  hours. Participants will be directed to not take these  types of 
medications 24 hours before or after vaccinations  (refer to Table 3). Investigational site staff will 
review participant e -diary entries on a routine basis to assess compliance, need for re -instruction 
and evaluation against individual participant and study h alting rules.  These reviews will also 
occur on Day 23  (1 ±d)  and Day 37 (1 ±d) .  
For the assessment of severity of swelling and redness, participants will use the injection site 
reaction measurement tool t o measure redness and swelling at the injection site and then grade 
these accordingly. The redness grade will be  based on greater of the two perpendicular Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 101 of 139 
  
measurements in centimeters, while swelling grade will be based on greater of the two 
perpendicular m easurements in centimeters and the functional scale (if applicable); see  Table  12.  
Investigator  sites will be notified  of any Grade 3 or higher severi ty scores  for follow -up and/or  
further  assessment  of symptoms.  The site will record verified Grade 3 or higer e-diary reactions 
as an AE into the AE eCRF.  If these reactions start out as mild in severity on a given day, the 
start date should be recorded a s the first date that the reaction is noted as mild in severity.  If 
these reactions end as mild in severity on a given day, the end date should be recorded as the last 
date that the reaction is noted to be mild in severity.  The AE severity will be record ed as the 
highest severity score within the start and stop dates.  If severe reactions reappear in the e -diary 
after they were absent for one or more days, a second AE will be recorded on the AE 
eCRF.  During follow -up visit(s), the investigator will query t he participant about all ongoing e -
diary AEs and document the start and stop date of any Grade 3 or higher AE s on the AE page in 
the eCRF.  
If local injection site or systemic reactions continue beyond seven days, participants will be 
prompted to continue e-diary entries until they are symptom -free for two consecutive days. For 
any type of reactogenicity persisting two weeks or more, the PI or designee will evaluate the 
reaction at the next scheduled visit and/or determine based on the nature and severity i f a more 
immediate unscheduled follow -up visit is required to fully assess the reaction. Investigational 
sites will be alerted of any Grade 3 or higher (eg, ER visit or hospitalization) solicited systemic 
reactions, which will require discontinuation of va ccinations upon verification by the PI or 
designee of the Grade 3 or higher status. The PI or designee may require participants reporting 
Grade 3 or higher reactions to return to the clinic for an unscheduled visit to aid in this 
evaluation.  
In addition to  any reaction considered an AE by the PI, solicited reactions reported in the e -diary 
will be recorded by the PI or designee on the AE eCRF if they are serious (ie, a solicited reaction 
will be considered ‘serious’ if confirmed by the investigator to be a Grade 4, or a Grade 3 that 
upon the investigator’s assessment meets any of the SAE criteria outlined in Section  9.1.2 ); 
result in discontinuation of study product or withdrawal from the study; or remain unresolved for 
14 days or more. Solicited systemic reactions may require discontinuation of vaccinations based 
on individual participant halting rules (see Section  7.3). 
The rating scale to be used for reactogenicity events is the same toxicity grading scale provided 
in Appendix  A, the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials  {CBER , 2007 }, where 
symptoms are assessed as Grade 1=mild through Grade 4=potentially life -threatening. 
Additionally, a Grade of 0 will be available in the e -diary in order to allow the participant to 
record “symptom not present.” For most of the reactogenicity events, there is a direct 
corresponding symptom entry in the toxicity grading scale (eg, for systemic reactions: fever, 
headache, fatigue, myalgia; for local reactions: pain, tenderness, erythema/ redness, 
induration/swelling) – refer to Table  12.  
For reactogenicity events with no direct corresponding symptom entry in Table  12 (eg, warmth, 
itching, arm motion limitation, bruising), the grading for “illness or clinical AE” will be used to 
rate the symptom severity. The symptom -severity descript ions in Table  12 will be translated to 
lay language in the e -diary instrument to promote participant understanding.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 102 of 139 
  
Participant s in Groups 1 and 2 will  be required to complete e -diary entries to capture their 
compliance to their antibiotic doses of ciprofloxacin or doxycycline respectively. Participants in 
these groups will  begin e -diary entries as soon as they receive their first dose of antibiotic. The  e-
diary will remind  them  to self -administer their antibiotic ( cipro floxacin  or doxycycline) at 
appropriate times and record those times in the e-diary . For those participants  receiving an 
antibiotic , the investigational site staff will review e -diary entr ies with the participant at every 
visit overlapping with the antibiotic courses . 
8.4. Pharmacokinetics  Sessions  and Trough Concentrations of Antibiotics  
For the participant s randomized to Group s 1A or 2A, antibiotic serum concentrations  will be 
measured,  and PK parameters will be assessed .  
8.4.1.  Ciprofloxacin  
On days  with PK sessions  (Days 4, 8, 31 and 35), blood samples for measurement of 
cipro floxacin  concentrations will be collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 
12 hours post dose ( ± 5 min through hr 4 , then ± 15 min  thereafter ).   
Blood samples for determination of cipro floxacin  pre-dose or trough concentrations will be 
collected on Days 4, 5, 6, 7 and 8 and on  31, 32, 33, 34  and 35 prior to administration of the 
morning cipro floxacin  dose.   
8.4.2.  Doxycycline  
On days with PK sessions  (Days 2, 8, 32 and 38), blood samples for measurement of 
doxycycline  concentrations will be coll ected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 
12 hours post dose ( ± 5 min through hr 4 , then ± 15 min  thereafter ).   
Blood samples for determination of doxycycline pre-dose or trough concentrations will be 
collected on Days 2, 3, 4 , 5, 6, 7 and 8 and on  32, 33, 34 , 35, 36, 37 and 38 prior to 
administration of the morning doxycycline  dose.   
8.4.3.  Specimen Collection, Preparation, Handling, and Shipping  
Instructions for the collection, preparation, handling, storage, and shipment of the study samples  
will be provided in study -specific laboratory manuals . 
8.5. Data Safety Monitoring Board  
Independent safety oversight will be provided by a DSMB which will be notified of significant 
AEs (eg, SAEs, severe AEs recorded on the eCRF, potential AESIs of aut oimmune etiology, or 
any other events the medical monitor  deems medically relevant) as determined by the medical 
monitor  on an ongoing basis, including any that result in study halt based on prespecified 
stopping rules (refer to Section  7.1). The DSMB will c onsist of  at least three voting members, 
one of whom will be an expert in rheumatology /immunology  to specifically support the 
evaluation of potent ial AEs for autoimmune etiology.  The DSMB will make recommendations 
regarding the safety of continuing enrollment and dosing.  Study enrollment and dosing may be Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 103 of 139 
  
interrupted at the request of the DSMB Chair if it is believed that an AE represents a significant 
safety concern pending full DSMB evaluation.  
The DSMB Chair will receive and evaluate each SAE, each severe AE (reported  on the AE 
eCRF), and potential AE s of autoimmune etiology. The DSMB Chair will determine if an ad hoc  
review  by the entire DSMB is necessary. An  ad hoc  review by the entire DSMB, when it occurs, 
may be focused on a single participant or on data for all pa rticipants. The operations of the 
DSMB will be detailed in a DSMB Charter  to be finalized prior to screening of the first 
participant.  
At least one DSMB member will be an expert in autoimmune disorders (eg, rheumatologist, 
immunologist). This member will r eview all potential AESIs to assess  cases for autoimmune 
etiology, if preexisting or new onset, and relationship to the IP. Details on the recording of 
assessment  outcomes will be detailed in the DSMB  Charter . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 104 of 139 
  
9. REPORTING ADVERSE EV ENTS  
9.1. Definitions  
9.1.1.  Adverse E vent 
An AE is any untoward medical occurrence in a participant administered a n investigational 
product regardless of its causal relationship to the study treatment. An AE can therefore be any 
unfavorable and unintended sign (including an abnormal laborator y finding, for example), 
symptom, or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.  
9.1.2.  Serious Adverse Event  
A serious AE  (SAE ) is any untoward medical occurrence at any dose th at fulfils one or more of 
the following:  
 Results in death  
 Is life -threatening, ie, the participant  was, in the opinion of the investigator, at 
immediate  risk of death from the event as it occurred (does not include an event that, 
had it occurred in a more severe form, might have caused death)  
 Requires inpatient hospitalization or prolongation of existing hospitalization. (Note: a 
prescheduled hospitalization is not considered an SAE.)  
 Results in persistent or significant disability or incapacity  
 Is a congenital anomaly or birth defect  
 Is another medically significant event that, based upon appropriate medical judgment, 
may jeopardize the participant and may require medical or surgical intervention to 
prevent one of the outcomes listed above (eg, allerg ic bronchospasm requiring 
intensive treatment in an emergency room or home, blood dyscrasias or convulsions 
that do not result in hospitalization, the development of drug dependency or drug 
abuse)  
9.1.3.  Adverse Events of Special Interest  
For this trial, AESI s are defined as any AE having an autoimmune etiology. Appendix  B 
provides a list of AESI terms defined by FDA’s CBER as potentially associated with 
autoimmune disease that might represent a safety signal for vaccine -associated autoimmunity. 
Monitoring for late -onset AESIs , ie, those reported after the final visit on Day 51 , will extend 
through 12 months following the last vaccination. Potential AESIs wi ll be evaluat ed by a 
member of the DSMB having expertise in this area (refer to Section  8.5). Once assess ed as 
autoimmune in nature, the event will b e considered as a confirmed AESI.   
9.2. Eliciting and Reporting Adverse Events  
AEs (including SAEs and potential AESIs) reported spontaneously by the participant and/or in 
response to an open question from the PI or designee or revealed by observation (eg, duri ng PE Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 105 of 139 
  
or from a clinical test result) will be recorded on the AE eCRF if they occurred from the time of 
the first administration of any IP (Day 2 for Group  2, Day 4 for Groups 1 or Day 8 for Group 3) 
through Day 51  or EWV, regardless of causal association with the IP.  AE reporting is required 
for any new observation presenting after the first receipt of any IP  or for a deterioration of 
baseline condition ( eg, increased severity/frequency).  From the signing of the I CF until 
immediately before the administration of their first IP,  only AEs resulting from a study -related 
procedure will be recorded on the AE eCRF; all other events reported in th ese time period s will 
be recorded as signs and symptoms on the Medical Histo ry eCRF. If there is any doubt as to 
whether a clinical or laboratory observation is an AE, the event will be considered an AE and 
recorded on the AE eCRF. After Day 51  and through the 12 -month safety follow -up, AEs, SAEs  
(meeting definition per Section  9.1.2 ) and AEs assess ed by the DSMB to be of autoimmune 
etiology (refer to Section  8.5), ie, AESIs, will be recorded on  the AE eCRF.  
Refer to the specific sections on clinical laboratory tests ( Section  8.3.2 ), PEs ( Section  8.3.3), 
vital signs ( Section  8.3.4 ), and e -diary reactogenicity ( Section  8.3.5.1 ) for details on AE 
reporting  based on participant observation and clinical test results.  
9.2.1.  Rating the Severity of Adverse Events  
All AEs will be assessed for severity by the PI or designee using the FDA Guidance for Industry: 
Toxicity Grading Scale for Healthy Adult and Adolescent Volun teers Enrolled in Preventive 
Vaccine Clinical Trials  {CBER , 2007 (refer to Appendix  A)}.  
The toxicity grading scale has specific grading options for some clinical symptoms, such as 
nausea/vomiting, diarrhea, headache, fatigue, and myalgia.  Any AEs not specifically identified in 
the Toxicity Grading Scale will use the scale identified for systemic (general) illness or clinical 
AE. For AEs being reporting from clinical assessments, the PI or designee will refer to the 
specific sections on clinical laboratory tests(Section  8.3.2 ), PEs (Section  8.3.3 ), vital signs 
(Sectio n 8.3.4 ), and e -diary reactogenicity (Section  8.3.5.1 ) on how and when to report AEs and 
AE severity in applying the toxicity grading scale.  
9.2.2.  Rating the Causality of Adverse Events  
The PI’s (or designee’s) assessment of an AE's causal relationshi p to the IP will be documented 
on the AE eCRF. This causality assessment will be performed only by those study personnel 
listed on the Delegation of Authority Log as having both the authority and medical training to 
make such a determination. The following  guidelines are provided for this assessment.  
1. Unrelated:  there is no relationship between either the vaccine or the antibiotic  and the 
reported event.  
2. Possibly related to antibiotic  (Groups  1 and 2 ): the event follows a reasonable temporal 
sequence from th e time of antibiotic  administration and/or follows a known response 
pattern to the antibiotic , but could also have been produced by other factors . 
3. Possibly related to AV7909  (Groups  1 through  3): the event follows a reasonable 
temporal sequence from the ti me of vaccine administration and/or follows a known 
response pattern to the vaccine, but could also have been produced by other factors . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 106 of 139 
  
4. Probably related to antibiotic  (Groups  1 and 2 ): a reasonable temporal sequence of the 
event with antibiotic  administration exists and, based upon the known pharmacological 
action(s) of the antibiotic , known or previously reported adverse reactions to the 
antibiotic  or class to which the antibiotic belongs (for ciprofloxacin this would be 
fluoroquinolones and fo r doxycycline this would be tetracyclines) , or the Investigator’s 
clinical judgment, the association of the event with the antibiotic  seems likely . 
5. Probably related to AV7909  (Groups  1 through  3): a reasonable temporal sequence of the 
event with vaccine ad ministration exists and, based upon the known action of the 
vaccine, known or previously reported adverse reactions to the vaccine, or the 
Investigator’s clinical judgment, the association of the event with the vaccine seems 
likely . 
6. Definitely related to antibiotic  (Groups  1 and 2 ): a definite causal relationship exists 
between antibiotic  administration and the AE, and other conditions ( eg, concurrent 
illness, progression/expression of disease state or concurrent medication reaction) do not 
appear to explai n the event . 
7. Definitely related to AV7909 (Groups 1  through  3): a definite causal relationship exists 
between vaccine administration and the AE, and other conditions ( eg, concurrent illness, 
progression/expression of disease state or concurrent medication reaction) do not appear 
to explain the event . 
If the relationship between the AE and the IP is determined to be “possible” or “probable” or 
“definitely related,” the event will be considered to be related to the IP.  
9.2.3.  Eliciting Adverse Events from Other Saf ety Assessments  
Clinical observations during safety evaluations (ie, PEs, vital signs, clinical laboratory tests) 
determined by the PI or designee to be abnormal and to represent a clinically significant change 
from baseline must be reported on the AE eCRF  regardless of causal association with the IP. 
This includes any new observation presenting after the dose of IP (either antibiotic  or AV7909)  
or deterioration of baseline condition (ie, increased severity/frequency) after the first vaccination 
through Day 51 or EWV. If there is any doubt as to whether a clinical observation is an AE, the 
event will be considered an AE and recorded on the AE eCRF. Additionally, certain types of 
observations must be reported by the PI or designee as AEs, as follows (refer to  the listed 
sections below for details on retesting and repeat testing requirements associated with this 
reporting where applicable):  
 Following the dose of  any IP, all Grade 3 or higher clinical laboratory abnormalities 
(sample retested and, if needed, tes t repeated), unless covered under a disease or 
syndrome that is already reported as an AE; refer to Section  8.3.2  for details.  
 Following the first dose of any IP, all vital sign abnormalities found to be Grade 3 or 
higher in two out of three assessments (original plus two repeats); refer to Section  8.3.4  
for details.  
Additionally, while reactogenicity from the e -diary will not be duplicated in AE reporting, the PI 
or designee will record as AEs any e -diary reactogenicity that is serious , results in Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 107 of 139 
  
discontinuation of IP or withdrawal from the study, or remains unresolved as of Day 51 /EWV  
(refer to Section  8.3.5.1 ).  
9.3. Immediately Reportable  Events  
9.3.1.  Principal Investigator’s Responsibilities  
The following events must be reported  via email  immediately (ie, within 24 hours of awareness), 
by the site PI or designee to :  
 Any SAE regardless  of causal association with any IP  
 Any potential AESI, ie, AE of autoimmune etiology (refer to the list of AESI terms in 
Appendix  B) regardless of causal association with any IP (ie,  ciprofloxacin , 
doxycycline  or AV7909 ) 
 Any pregnancy where conception occurred after first exposure to any IP (ie, 
ciprofloxa cin, doxycycline  or AV7909 ) and prior to 12 months  after last receipt of 
either IP 
The appropriate form (listed below) will be completed and sent by email  to the following 
address:  
 
 
 
   
For S AEs and AESIs , the Serious Adverse Event and/or Adverse Event of Special Interest 
Report Form will be completed (abbreviated hereafter SAE Report Form , AESI Report Form). 
Note that the SAE and AESI Report Form are not the same as the AE eCRF. Accompanying 
these form s will be source documentation or medical records (eg, discharge summary for 
hospitalizations, lab reports) which support a diagnosis. Participant  identifiers (eg, individual’s  
name, address, telephone number, social security number, medical record number, or 
hospital/laboratory number) must be redacted from the source documentation.  
All SAEs that are unexpected (eg, adverse drug reactions) must be reported to the IRB/IEC as 
required by ICH GCP E6.  
Confirmed pregnancies where conception occurred after first exposure to any IP, and prior to 12 
months after last receipt of  any IP will be reported to Global PV using the Pregnancy 
Notification Form. Alth ough normal pregnancy is not an AE, it will mandate discontinuation of 
IP (refer to Section  9.4).  
9.3.2.  Sponsor’s Reporting Requirements  
A SUSAR is a suspected adverse reaction that is both serious and unexpected.  As specified in 
21 CFR 312.32, SUSARs will be reported by the Sponsor of the Investigational New Drug 
Application (IND) to the FDA and to all participating PIs in an IND safety report as soon  as 
possible, no later than 15 calendar days after the Sponsor becomes aware of the suspected 
adverse reaction (21 CFR 312.32(c)(1)).  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 108 of 139 
  
In addition, any unexpected fatal or life -threatening suspected adverse reaction will be reported 
to FDA no later than sev en calendar days after Emergent’s initial receipt of the information 
(21 CFR 312.32(c)(2)).  
The Sponsor will report AESIs to FDA within 15  calendar  days after becoming aware of the 
AESI.  
9.4. Pregnancy  
Prior to trial enrollment, female participants must be advi sed of the importance of avoiding 
pregnancy during trial participation and the risks of an unintentional pregnancy. The participant 
must sign an ICF stating that the risk factors and consequences were communicated.  
To be eligible to enroll in the study , any female participant must certify either that she is 
surgically sterile (ie, had a  hysterectomy , bilateral oophorectomy  or bilateral  salpingectomy ), 
postmenopausal (defined as >12 consecutive months without menses and  Screening FSH >30 
mIU/mL) or has bee n using an effective method of birth control for at least one month prior to 
Day 1. Methods of acceptable birth control are listed in Section  5.1. Additionally, WOCBP 
randomized to Groups 1 and 2 must be willing to add a double barrier method of birth control if 
they are not surgically sterile or postmenopausal, and their primary metho d of birth control is 
hormonal  or an IUD.  
All women will have a serum pregnancy test performed at screening and at the EWV, if 
applicable, unless they are postmenopausal (confirmed with FSH >30 mIU/mL at screening) or 
indicate that they are surgically ste rile. All WOCBP  will also receive a UPT  within 24 hours 
prior to each AV7909  vaccination.  Vaccinations will not be administered to participant s who test 
positive for pregnancy.    
In addition, a UPT will be performed on the Day 51  for WOCBP participants in  all groups .  
Positive UPTs will be confirmed with a serum pregnancy test.  Pregnancy is not considered an 
AE in this study.  If a participant’s  pregnan cy is detec ted between Randomization  and Day 2, no 
IP is to be administered and the participant  is to be withdrawn from the study.  
If a participant  becomes pregnant at any time after Day  2, (ie, after receipt of at least one dose of 
either IP), and where conception occurs prior to 12 months  after last receipt of either IP, the 
pregnancy is to be rep orted within 24 hours of awareness by completing the Pregnancy 
Notification F orm and forwarding  it to the Global Pharmacovigilance Department (see  
Section  9.3.1 ). No further IP will be administered to the participant .  Participant s will also be 
encouraged to continue planned safety follow -up in the study.  
All pregnancies occurring after Day 2 (ie, after receipt of at least one dose of either IP), and 
where conception occurs prior to 12 months after last receipt of either IP  are to be followed to 
outcome (eg, delivery, spontaneous abortion, or therapeutic abortion), including after the study is 
completed.  When the PI becomes aware of the outcome of the  pregnancy, a Pregnancy Outcome 
Form will be completed and forwarded to the Global Pharmacovigilance Department by email 
(see Section  9.3.1 ) within 24 hours of awareness.  A pregnancy outcome of spontaneous 
miscarriage , congenital anomaly or birth defect is considered an SAE and must be reported 
according to the procedures described in Section  9.3.1  above. As applicable, contact will be 
made when the infant is ~28 days old for a final follow -up. Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 109 of 139 
  
9.5. Reporting of Other Information – Unanticipated Problems  
As outlined by the Office for Human R esearch Protection (OHRP), unanticipated problems must 
be reported to the IRB according to the requirements of 45 CFR Part 46. Unanticipated problems 
are considered to include any incident, experience, or outcome that meets ALL of the following 
criteria:  
 Unexpected (in terms of nature, severity, or frequency) given:  
o Procedures that are described in the study -related documents, such as the IRB 
approved research protocol and informed consent document.  
o The characteristics of the participant  population being en tered into the study.  
 Related or possibly related to participation in the study which means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused 
by the sample collection.  
 Suggests that the study places participan ts or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously 
known or recognized.  
An incidence, experience, or outcome that meets the three criteria above generally will warrant 
consideration of s ubstantive changes in the study or informed consent process/document or other 
corrective actions in order to protect the safety, welfare, or rights of participant s or others. Only a 
small subset of AEs occurring in human subjects participating in a clinica l study will meet these 
three criteria for an unanticipated problem. There are other types of incidents, experiences, and 
outcomes that occur during the conduct of clinical study that represent unanticipated problems 
but are not considered AEs. For example , some unanticipated problems involve social or 
economic harm instead of the physical or psychological harm associated with AEs. In other 
cases, unanticipated problems place participant s or others at increased risk of harm, but no harm 
occurs.  
The investig ator should promptly notify the IRB when an unanticipated problem involving risks 
to participant s or others is identified. Also, the investigator should notify Emergent and CRO  of 
unanticipated problem(s).  
9.6. Procedure for Breaking the Blind for Individual Pa rticipants  
Not applicable to this study . 
9.7. Follow -up of Adverse Events  
9.7.1.  Follow -up of Nonserious Adverse Events  
Nonserious AEs that are identified on  or before  the last scheduled visit ( Day 51  or EWV) must 
be followed through and recorded on the AE eCRF. All n onserious events that are ongoing at 
Day 51 or EWV  will be recorded with the current status noted as “Not Recovered/Not Resolved” 
on the AE eCRF. The status of ongoing, previously reported AEs will be reviewed at the Day 
51/EWV to determine if resolved. For participants that continue in the study beyond Day 51 , the Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 110 of 139 
  
status of ongoing AEs will be queried at the quarterly phone contacts to determine  status  and 
update the resolution status in the AE eCRF.  
9.7.2.  Follow -up of Serious Ad verse Events or Adverse Events of Special Interest  
Participant s experiencing SAEs or AESIs will be followed clinically until their health has 
returned to  normal and all parameters have returned to baseline  or has otherwise been explained  
or they have been referred to outside care . It is expected that the PI  or designee  will provide or 
arrange appropriate supportive care for the participant . Withdrawals of participant s from 
treatment  and/or the trial are at the discretion of the PI or designee, according to  the guidance 
provided in  Section  7.3. 
All SAEs/AESIs will be followed by the PI or designee until one or the other condition is met:  
 The SAE/AESI is  resolved or stable if expected to remain chronic.  
 The participant  is referred to a specialist or other physician for treatment and follow -
up. The PI or designee will follow events even if the participant is seen by another 
physician. The PI or designee wi ll follow -up with the participant and the participant ’s 
physician to obtain information about the event outcome and any treatments and 
medications administered for the event.  
The following will be considered acceptable reasons for discontinuation of follow -up of ongoing 
SAEs /AESIs : 
 Participant withdraws consent .  
 Participant is referred to appropriate long -term medical care . 
 Participant is considered lost to follow -up (refer to Section  7.4 for description of 
contact attempts before a participant may be deemed lost to follow -up). 
It is expected that the clinical site will obtain supporting medical records from appropriate 
physic ians and record this information on the SAE /AESI Report Form (refer to Section  9.3) and 
AE eCRF.  Additional information received related to any SAE/ AESI must be forwarded within 
24 hours of awareness to the Emergent Global PV Department.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 111 of 139 
  
10. STATISTICAL ANALYSIS  
10.1. Study Endpoints and Statistical Hypotheses  
10.1.1.  Primary Endpoints  
To assess whether co -administration of AV7909 with antibiotics affects antibiotic PK  profiles, 
equivalence tests on the PK parameters (AUC 0-12h and C max) at steady state pre - and post -
vaccination will be carried out separately for ciprofloxacin and doxycycline  using PK data 
collected from subjects from independent study groups (Group  1 for ciprofloxacin, Group 2 for 
doxycycline) . 
For each of the primary endpoints  (for each of the two antibiotics ), the equivalence tests on PK 
parameters (AUC 0-12h and C max) at steady state pre - and post -vaccination will be performed.  
Therefore, demonstrati on of non -interference of steady state PK is defined separately for each 
antibiotic  and there is only one way to meet the primary endpoint for each antibiotic . 
Specifically, for each antibiotic, the null hypotheses are:  
 AUC 0-12h: The geometric mean of the within -participant ratios of post -vaccination 
(Day 35 for ciprofloxacin and Day 38 for doxycycline) over the pre -vaccination 
(Day  8) AUC 0-12h will be greater than 1.25 or less than 0.80 .  
 Cmax: The geometric mean of the within -participant ratios of the pos t-vaccination 
(Day 35 for ciprofloxacin and Day 38  doxycycline) over the pre -vaccination (Day 8) 
Cmax will be greater than 1.25 or less than 0.80 .  
The null hypothesis will be rejected when the 90% confidence intervals (CIs) of the geometric 
mean of the wi thin-participant ratios is contained entirely within the equivalence bounds of [0.8, 
1.25]. For each antibiotic, to conclude that administration of two -dose regimen of AV7909 does 
not affect the steady state of PK profile, the null hypotheses should be rej ected for both 
endpoints AUC 0-12h and C max.  
10.1.2.  Secondary Endpoints  
10.1.2.1.  Secondary Safety Endpoints  
 Incidences of AEs from the first dose of any IP through the Final Study Visit ( Day 
51 ± 1 d) 
 Incidences of serious AEs (SAEs) from the first dose of any IP until the 12 -month 
follow up (Day 388 ± 14  d) 
 Incidences of solicited systemic and injection site reactions reported in participant e -
diaries following each vaccination  
 Incidences of AESIs from the first dose of any IP until the 12 -month follow up (Day 
388 ± 14  d) 
 Incidences of clinical laboratory abnormalities  
No hypothesis testing is planned for any of the safety endpoints.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 112 of 139 
  
10.1.2.2.  Secondary Pharmacokinetic Endpoints  
To determine if the single -dose PK values of either ciprofloxacin or doxycycline are affected by 
AV7909  vaccination , separate  equivalence tests will be carried out in parallel for each antibiotic 
in the similar manner as the primary PK analyses:  
 AUC 0-12h: Geometric mean of within -participant ratios of post -vaccination (Day 31 
for ciprofloxacin and Day 32 fo r doxycycline) over the pre -vaccination (Day 4 for 
ciprofloxacin and Day 2 for doxycycline) AUC 0-12h is greater than 1.25 or less than 
0.8. 
 Cmax: Geometric mean of within -participant ratios of post -vaccination (Day 31 for 
ciprofloxacin and Day 32 for doxyc ycline) over the pre -vaccination (Day 4 for 
ciprofloxacin and Day 2 for doxycycline) Cmax is greater than 1.25 or less than 0.8 . 
No hypothesis testing is planned for the secondary PK endpoints, which will be evaluated and 
reported for information only.    
10.1.2.3.  Secondary Immunogenicity Endpoints  
To evaluate whether the co-administ ration of  antibiotics affect s the immune response after two 
IM doses of AV7909, a non -inferiority test will be conducted  independently for ciprofloxacin 
and doxycycline. Specifically, the  null hypotheses are :  
 For ciprofloxacin: the geometric mean ratio of TNA NF 50 values at Day 37 for Group 
1 over Group 3 will be less than or equal to 0.5  
 For doxycycline: the geometric mean ratio of TNA NF 50 values at Day 37 for Group 2 
over Group 3 will be less than or equal to 0.5  
The null hypothesis will be rejected when the lower bound of the two -sided 95% CI of the 
geometric mean ratio of TNA NF 50 values is greater than 0.5.  
For each antibiotic, the formal hypothesis testing for the secondary immunoge nicity endpoints 
will only be carried out after the primary PK endpoint has been met for the corresponding 
antibiotic. If the primary PK endpoint for an antibiotic is not met, the corresponding secondary 
immunogenicity endpoints will be provided for inform ation only.   
10.2. Sample Size and Power  
The sample size for this study was selected based on both the primary and secondary endpoints.  
The a ssessment as to whether vaccination with AV7909 affects the PK of either c iprofloxacin or 
doxycycline will be made based on the geometric mean of the within -participant ratios (post -
vaccination over pre -vaccination) of AUC 0-12h and Cmax. The equivalence margin for the 
geometric mean ratio is [0.80, 1.25], which will be compared with the 90% CI for the geometric 
mean of with in-participant ratios of AUC 0-12h and Cmax. Assuming the coefficient of variation 
(CV) is  30% for geometric mean ratio  and the true geometric mean ratio is 0.95 , 27 participants 
allow for  90% power  to reject the null hypothesis at a significance level of 5%. A group size of 
40 participant s for Group 1A  (AV7909 + ciprofloxacin with PK) or Group 2A (AV7909 + Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 113 of 139 
  
doxycycline with PK) is planned  to allow for up to 30% of participants being excluded from the  
PK population.  
A sample size of 53 in each of the IP groups (Group 1 = AV7909 + ciprofloxacin, Group 2 = 
AV7909 + doxycycline, Group 3 = AV7909 only) provides 90% power at the 2.5% one-sided 
significance level for the non -inferiority test, defined as the lower bound of the two -sided 95% 
CI of the geometric mean ratio of the AV7909 + antibiotic over the AV7909 only (Group 1 vs. 
Group 3, Group 2 vs. Group 3) greater than 0.5. This assumes that the true geometric mean ratio 
between the two groups is 0.85 and the CV of TNA NF 50 values in each group is 100%. A total 
of 70 per IP group is planned to allow for up to 25% of drop -out rate . 
The sample size calculation was performed using SAS 9.4 statistical software.  
10.3. Analysis Populations  
There will be four analysis p opulations for this study : 
The Intent -to-treat (ITT) Population  will include  all participant s who are randomized.  Participant 
disposition and baseline demographics will be summarized by IP group (Groups 1, 2 and 3) for 
the ITT population according to the group into which the participant is randomized.  
The Safety Population  will include all  randomized participant s who receive at least one dose of 
either antibiotic  or AV7909 . All the  safety analyses will be conducted with the Safety Population  
according to the treatment they received . 
The PK Population  will include all participant s in Group  1A and Group 2 A who: 
 Received two doses of AV7909 according to the protocol (eg, correct dose no 
temperature excursion, and within the study -specified window s) 
 If in Group 1A, r eceived at least 5 of the 7 in-clinic ciprofloxacin doses between Day 
4 through the morning of Day 8 and between Day 31 through the morning of Day 35; 
or if in Group 2A, r eceived at least 7 of the 9 in-clinic  doxycycline doses between 
Day 2 through the morning of Day 8 and between Day 32 through the morning of 
Day 38  
 Have adequate data for PK analysis for the calculation of AUC 0-12h and C max at the 
Day 8 (both Group 1A and 2A) and Day 35 (Group 1A) or Day 38 (Group 2A)  visits,   
 Have no protocol deviations  that would affect ciprofloxacin  or doxycycline PK 
Exclusion of participants from population will be done on a case -by-case basis  at the time of the 
PK parameter analysis . 
The PK Population will be used for all PK analyses.  Participants will be included in the 
treatment  group (ciprofloxacin or doxycycline) according to the antibiotic  they receive d.  
The Immunogenicity  Population  will include  all randomized participant s who meet the 
following criteria:  
 Received two AV7909  vaccinations according to the protocol (eg, correct dose, no 
temperature excursion, and within the study -specified windows ) Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 114 of 139 
  
 Had a valid immunogenicity (TNA) result at Day 1 (pre -vaccination) showing no 
evidence of previous exposure to anthrax or an anthra x vaccine (ie, TNA below the 
limit of detection)   
 Had a valid immunogenicity (TNA) result at Day 37 , within the study  specified 
window  
 Participants in Group 1 or 2 should have taken at least 50% of the protocol -specified 
antibiotic  doses  
The I mmunogenicity  Population will be used for the immunogenicity analyses. Participants will 
be included in the IP group (Group 1, 2 and 3) according to the treatment they actually receive d. 
10.4. Handling of Outliers and Missing Data  
Individual serum concentrations or entire s erum concentration -time profiles for a partici pant may 
be excluded from the analysis at the discretion of the pharmacokineticist following a review of 
available documentation ( eg, bioanalytical report, validation report , protocol deviation log ) and 
communi cation with the sponsor. Any such exclusion will be clearly listed in the clinical study 
report along with justification for exclusion. Any excluded outlier data should be flagged in the 
individual data listings.  
Missing PK sampl es or antibiotic concentrat ion values or missing immunogenicity response 
TNA NF 50 values will be handled as de scribed  in the Statistical Analysis Plan ( SAP). Antibiotic  
concentrations reported as below the lower limit of quanti fication  (< LLOQ ) will be handled as 
specified in the SA P. Non-missing TNA NF 50 values reported as <  LLOQ will be  handled as  
specified in the SAP.  
10.5. Statistical Methods  
10.5.1.  PK Analyses  
10.5.1.1.  Summary of Concentrations and PK Parameters  
Summary statistics for serum concentrations of ciprofloxacin and doxycycline will be tabulated 
by time point and study day. Summary statistics will be provided for trough concentrations of 
ciprofloxacin and doxycycline by study day. The PK parameters  shown  in Table 11 will be 
derived  from the concentration -time data  by noncompartmental analysis methods  and 
summarized by study day .  
Table 11 Antibiotic  Pharmacokinetic Parameters  
Variable  Definition  
Cmax Maximum observed serum concentration  
tmax Time of maximum observed serum concentration  
t1/2 Elimination h alf-life (calculated as ln 2/ K el) 
Kel Elimination rate  constant  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 115 of 139 
  
Variable  Definition  
AUC 0-12h Area under the serum concentration -time curve (12 hours)  
AUMC  Area under the first moment curve  
AUC 0-inf Area under the serum concentration -time curve extrapolated to infinity  
MRT  Mean residence time  
10.5.1.2.  Equivalence Testing for  Primary  PK Endpoints  
The goal of the study with the primary PK endpoints is to demonstrate that vaccination with 
AV7909 does not affect the steady -state PK profiles of either ciprofloxacin or doxycycline. The 
equivalence testing will be constructed using paired t wo one -sided t -tests (TOST) to provide the 
point estimate and 90% CIs for geometric mean of the within -participant ratios of the steady -
state values of AUC 0-12h and C max post two doses of AV7909 (Day 35 for ciprofloxacin and Day 
38 for doxycycline) vs. pre -vaccination of AV7909 (Day 8 for ciprofloxacin and doxycycline). 
To conclude that AV7909 vaccine has no effect on the steady state PK for ciprofloxacin or 
doxycycline, the 90% CIs should fall entirely within the equivalence range of [0.80, 1.25] for 
both endpoints AUC 0-12h and C max.  
To demonstrate that antibiotic  concentrations have achieved steady state , the trough value  
analysis  will be perform ed using the s tepwise testing for linear trend, the application of the 
NOSTASOT (No Statistical Significance Of  Trend) methodology proposed by  {Maganti  et al,  
2008 }. The details of the calculation will be provided in the SAP.  
10.5.1.3.  Equivalence Testing for Se condary PK Endpoints  
The secondary PK analyses will be performed to evaluate the  effect of vaccination with AV7909  
on the single -dose PK profile for either ciprofloxacin or doxycycline. The equivalence tests will  
be conducted in a similar statistical manne r as the primary analyses . If the 90% CIs for geometric 
mean of the within -participant ratios of the single -dose values of AUC 0-12h and C max post two 
doses of AV7909 (Day 31 for ciprofloxacin and Day  32 for doxycycline ) vs. pre-vaccination of  
AV7909  (Day 4  for ciprofloxacin and Day 2 for doxycycline ) fall entirely within the equivalence 
range of [0.80, 1.25]  for both endpoints , AUC 0-12h and Cmax, it will be  concluded that the 
AV7909 vaccine has no effect on the single dose PK for ciprofloxacin or doxycyclin e.  
10.5.2.  Non-Inferiority Testing for Secondary Immunogenicity  Endpoints  
Two-sided 95% CIs will be calculated for the geometric mean ratio of TNA NF 50 values  at Day 
37 between the AV7909 + antibiotic  group and the AV7909 only group (Group 1 vs. Group 3, 
Group 2 vs. Group 3) . To conclude that ciprofloxacin or doxycycline does not reduce the 
immune response to AV7909, the lower bound of the 95% CI should be greater than the non -
inferiority margin of 0.5.  
10.5.3.  Exploratory Analysis for Immunogenicity   
To evaluate the poss ible impact  on the immunogenicity endpoints  of a population not balanced 
by age and gender , exploratory  analyses will be conducted  using linear regression  to compare the Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 116 of 139 
  
immunogenicity response at Day 37 between each AV7909 + antibiotic group and the AV790 9 
only group , ie, between Group 1 (AV7909 + ciprofloxacin) and Group 3 ( AV7909) and between 
Group 2 (AV7909 + doxycycline) and Group 3 (AV7909) . In the linear regression models, the  
stratification factor , study  site, will be included in the model as a random effect ; participant sex 
and age will be included as fixed factors with age being dichotomized into ≤30 and >30 . The 
adjusted GMT ratio s for the TNA NF 50 values will be provided with 95% CI. 
10.6. Safety Analysis  
All safety data will be presented in the form of tabulations  and listings, based on the Safety 
Population. Data summaries will be tabulated by treatment group (Ciprofloxacin only, AV7909 
+ ciprofloxacin, Doxycycline only, AV7909 + doxycycline, AV7909 only, and Total , ie, all 
participants receiving any IP ) as specified in Section  10.3. Continuous variables will be 
summarized using number of participants (n), mean, standa rd deviation (SD), median, minimum, 
and maximum. Categorical variables will be summarized by the number (frequency) and 
percentage in each category.  No formal hypotheses testing will be conducted  for safety data .  
10.6.1.  Adverse Events  
All AEs will be coded to SOC and PT according to MedDRA. Treatment -emergent adverse  
events (TEAEs) are defined as AEs that present after the initiation of treatment or any AEs  
already present that worsen in either intensity or frequency following treatment. The incidences  
of TEAEs  will be presented in tabular form by MedDRA coded terms of SOC  and PT, and by 
severity (toxicity grade), seriousness,  relationship to IP, and outcome (death, discontinuation of 
IP, study withdrawal) for each treatment  group. A tabulation will be  provided of TEAE 
incidences by MedDRA PT in decreasing frequency of the “AV7909 Total” column . Separate 
tabulations by MedDRA SOC and PT will be provided for SAEs and AESIs determined to be of 
autoimmune etiology based on decision of the DSMB. Participants having t he same TEAE more 
than once will be counted in tabulations once for each PT and once within each SOC at the 
maximum severity and relatedness. The incidences of AEs from the first dose of any IP through 
the Final Study Visit ( Day 51  ± 1d), as well as incide nces of AEs from the first dose of any IP up 
to 12 -month follow -up will be tabulated separately as appropriate.  
10.6.2.  Clinical Laboratory Data  
Safety clinical laboratory results will be tabulated by visit and group and listed by individual  
participant. Observed values and changes from baseline of continuous laboratory variables  
(hematology, serum chemistry, and selected urinalysis parameters [ eg, specific gravity]) will be  
summarized using descriptive statistics (n, mean, median, SD, minimum, and maximum).  
Observ ed values of categorical laboratory variables ( eg, urinary protein), incidences of  
abnormalities by analyte according to laboratory normal ranges and highest toxicity grade (refer  
to Table  13 in Appendix  A), and shifts from baseline will be summarized descriptively (number  
and percentage) by visit and treatment group. Shift tables will be produced to reflect shifts from 
baseline  values  against the lab normal ranges (low, normal, high) as well as  against toxicity 
grading criteria (Grade 0,  Grade 1, Grade 2, Grade 3, Grade 4). Note: Grade 0 = laboratory value 
within normal range or  laboratory value does not meet criteria for toxicity of at least G rade 1 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 117 of 139 
  
(refer to Table  13 in Appendix  A). Screening (serology, urine drug screen, FSH) and pregnancy 
test results will be  listed by individual participant.  
In tabulations, the last measurement before the first IP administration will be used as the  baseline 
value. In listings, laboratory values out side of the reference range will be flagged:  L=low 
compared to the lower limit of the normal range, H=high compared to the upper limit of  the 
normal range. Additionally, laboratory abnormalities associated with a severity grade based  on 
the toxicity gradin g criteria (refer to Table  13 in Appendix  A) will be flagged: Grade 1 = Mild, 
Grade 2 = moderate, Grade 3 = severe, and Grade 4 = potentially life -threatening. Grade 3 or  
higher laboratory abnormalities will be summarized in a separate listing . 
10.6.3.  Physical Examination  
Complete PE and symptom -directed PE data will be tabulated (number of participants with  
normal/abnormal findings by body system and group) and listed by individual participant.  
10.6.4.  Vital Signs  
Vital signs data will be tabulated by visit and treatment group and listed by individual 
participant . Observed values and changes from baseline in vital signs will be summarized 
descriptively  (n, mean, median, standard deviation, minimum, and maximum; incidence of 
abnormality  according to highest toxicity grade). Baseline is defined as the last measureme nt 
before  the first IP administration . In listings, vital sign abnormalities associated with a severity 
grade based on the toxicity grading  criteria (refer to Table  12 in Appendix  A) will be flagged: 
Grade 1 = mild, Grade 2 = moderate,  Grade 3 = severe, and Grade 4 = potentially life -
threatening.  
10.6.5.  Prior and Concomitant Medications  
Medications will be coded according to the World Health Organization’s (WHO) WHO Drug  
Global Dictionary and daily dosages normalized. Data will be tabulated and listed by individual  
participant according to study period (p rior medications taken before the first IP administration,  
concomitant medications taken after the first IP administration) and treatment group.  
10.6.6.  Other Safety Variables  
10.6.6.1.  Reactogenicity  
In-clinic and e -diary reactogenicity data will be tabulated using descrip tive statistics (number and 
percentage  of participants reporting a reaction) for any symptom and each individual symptom 
by vaccination , treatment group , and  severity grade. During the assessment period post each 
vaccination, when the severity differs acro ss the daily assessments for a symptom, the maximum 
severity will be shown in summary tables.   
10.6.6.2.  Autoantibody  Testing and TSH Assessment  
Samples taken for TSH assessment and for RF, ANA and anti -ds DNA antibodies will be  banked  
and will only be tested if me dically indicated ( ie, as per PI’s discretion based on a report of Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 118 of 139 
  
potential AESI ). Results will be tabulated with negative/positive results  by study visit and listed 
by individual participant.  
10.7. Interim Analysis  
No interim analyses are planned in this study.  
10.8. Multiplicity  
In this phase 2 study, multiplicity adjustment is not planned. All the PK and immunogenicity 
endpoints are evaluated in parallel for the two antibiotics, ciprofloxacin and doxycycline.  
The primary PK endpoints for each antibiotic will be met when the 90% CIs of the geometric 
mean of ratios for both AUC 0-12h and C max are contained entirely within the equivalence bounds 
of [0.8, 1.25] . Since both parameters must satisfy the equivalence condition and each 
equivalence test is conducted at 5 % level, the overall type I error rate is controlled at less than 
5%. 
For immunogenicity, non -inferiority is evaluated as a one -sided test at 2.5% level. As a 
secondary endpoint, the test will only be  formally  evaluated when the corresponding primary PK 
endpoints have been met. Otherwise the results will be provided for information . No adjustment 
for multiplicity is required based on the closed test procedure.  
No other formal hypothesis testing will be carried out. The secondary PK endpoints  (single dose)  
will be evaluated and reported for information only . 
 
10.9. Final Analysis Plan  
A Statistical Analysis Plan (SAP) will be finalized prior to clinical database lock  [to include data 
up to and including last subject’s last in -clinic visit (Day 51 ; ie, four weeks after second 
vaccination )]. Clinical Study Report (CSR) will be generated  with data up to and including last 
subject’s last in -clinic visit (Day 51) . All data after Day 51 (ie, data up to and including last 
subject’s 12 -month safety follow up telephone call) will be included as an addendum  to the CSR. 
Details of the statistical methods and analyses will be provided in t he final SAP. Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 119 of 139 
  
11. DATA HANDLING AND RE CORD  KEE PING  
11.1. Source Documents and Access  
Source documents are defined as the re cords of original observations and activities of a clinical 
investigation. Source documents will include but are not limited to screening logs, progress 
notes, clinical and office chart s, hospital records, pharmacy dispensing records, laboratory notes, 
e-diary data, safety laboratory data  including both local and central laboratory data , memoranda, 
and recorded data from automated instruments. All source documents pertaining to this tria l will 
be maintained by the PI(s) and made available for direct inspection and copying by authorized 
persons. Investigator(s)/institution(s) will permit trial -related monitoring, audits, IRB/IEC 
review, and regulatory inspection(s) by providing direct acce ss to source data/documents by 
authorized persons as specifi ed in the ICF.  
11.2. Data Management  
A validated, electronic data capture (EDC) system will be used during the trial. The data 
management functions for the study will be outsourced to a CRO. Data manag ement activities to 
be performed for the study will be described in detail in the Data Management Plan  documents . 
The standard operating procedures (SOPs) governing data management activities will be 
mutually agreed upon by the CRO and Emergent and documen ted in the se DMP  documents . 
Emergent is responsible for the oversight and management of the CRO.  
11.3. Data Collection and Discrepancy Management  
Data collected during the study will be recorded in the eCRFs designed for this study. 
Investigational sites will have the responsibility for capturing and maintaining accurate eCRF 
data, records, and relevant source documentation, as well as conforming to  procedures 
established by the CRO/Emergent around system a ccess/security and ensuring a data audit/edit 
trail for data corrections. All source documents will be verified by the CRO study monitor for 
accuracy. Information from external sources such as labo ratory data, images , etc. as defined in 
this protocol will be collected and maintained outside the EDC and reconciled  with the eCRF 
data periodically . As data are entered into the eCRF, automated edit checks will validate data. 
Additionally, manual reviews  will be performed for data discrepancy by the CRO and queries 
will be generated into the EDC system. After clinical sites respond to queries and data 
corrections are made and reviewed by the CRO, the PI will review and electronically sign the 
eCRF for eac h participant . The CRO and Emergent will review data for accuracy, completeness, 
and consistency during the conduct of the study and prior to database lock.  
11.4. File Management  at the Investigational Site  
The PI will ensure that the trial center file is mainta ined in accordance with the ICH Guideline 
and as required by applicable local regulations. The PI/institution will take measures to prevent 
accidental or premature destruction of these documents.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 120 of 139 
  
11.5. Record Retention  at the Investigational Site  
Per ICH guideli nes, study documents will be retained for one of the following periods:  
 A period of at least two years after the date of the last approval of a marketing 
application in an ICH region until there are no pending or contemplated marketing 
applications;  
 A peri od of at least two years after Emergent has notified the regulatory authority(ies) 
that clinical investigation with this product is discontinued.  
The PI must not dispose of any records relevant to this trial without either (1) written permission 
from Emerg ent or (2) provision of an opportunity for Emergent to collect such records. The PI 
will be responsible for maintaining adequate and accurate electronic or hard copy source 
documents of all observations and data generated during this trial, including any d ata queries 
received from the Sponsor or designee. Such documentation is subject to inspection by Emergent 
and relevant regulatory agencies. If the PI withdraws from the trial (eg, due to relocation or 
retirement), all trial -related records will be transfe rred to a mutually agreed upon designee within 
an Emergent -specified timeframe. Notice of such transfer will be given to Emergent in writing.  
11.6. Protocol Deviations  
The PI or site staff may not deviate from the protocol except, in rare circumstances, as neces sary 
to eliminate immediate hazards to the trial participants. In such event, both the Sponsor and 
IRB/IEC will be immediately notified, no more than 24 hours  after the deviation is implemented.  
It is the responsibility of the PI to comply with the protoco l. A deviation occurs when site 
personnel or a participant does not adhere to the protocol’s stipulated requirements, whether 
inadvertently or planned. The occurrence of protocol deviations will be routinely monitored by 
the CRO and Sponsor for evaluation of PI compliance with the protocol, GCP, and regulatory 
requirements. The PI or designee will inform the IRB/IEC of all protocol deviations according to 
the requirements of each IRB/IEC. Deviations may be identified during the course of the study 
by the PI  or site staff, study monitor during routine or directed monitoring visits (recorded in 
monitoring reports), and Sponsor or BARDA personnel. In compliance with GCP, all identified 
protocol deviations will be documented – entered in the CRO’s Clinical Trial  Management 
System or equivalent – and classified according to procedures outlined in the protocol deviation 
plan. Deviations will be assessed by the CRO and Sponsor to identify appropriate corrective and 
preventive actions and followed up to ensure renewe d understanding and proper execution of the 
protocol.  
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (eg, violation of informed consent process, participant dosing error, treatment 
assignment error, part icipant enrolled in violation of eligibility criteria, violation of concomitant 
medication use restriction), the PI or designee will contact the MM at the earliest possible time 
by telephone, or the reverse as applicable. The PI and MM will come as quickly  as possible to a 
joint decision regarding the participant’s continuation in the trial. This decision will be 
documented by the PI and MM and reviewed by the site monitor.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 121 of 139 
  
Continued protocol deviations despite re -education of investigational site personne l, or persistent 
protocol deviations that are reportable to regulatory agencies may result in discontinued 
shipment of IP and termination of further enrollment at the investigational site, or termination of 
the investigational site  from the study . Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 122 of 139 
  
12. QUALITY CONTROL AND QUALITY ASSURANCE  
12.1. Monitoring  
The site will be monitored at regular intervals using a risk -based monitoring approach  to ensure 
compliance with the protocol, ICH GCP, applicable regulatory requirements, and current SOPs 
of the CRO and Emergent. Sites will be monitored both remotely and in -person to ensure the 
integrity of the data collection and the safety of study participants. A medical mon itoring plan 
will be established , and data will be reviewed on a monthly basis.  A Monitoring Plan, 
contain ing the frequency on-site and remote monitoring visits conducted by the CRO study 
monitors as well as monitoring requirements and contact details of the CRO study monitors will 
be developed and followed throughout the study . 
As a representative of Emergent , the CRO study monitors will visit the site periodically. In 
addition, the CRO study monitors will be available between visits via telephone and email as 
needed. The CRO study monitors will perform the following functions:  
 Provide information and support to the PI(s) and study site  
 Confirm the facility( -ies) are satisfactory to continue study conduct  
 Confirm the site is adhering to the protocol, data are being accurately recorded in the 
eCRFs, and IP accountability checks are being performed  
 Confirm that t he study site staff are routinely reviewing the participants e -diary 
records  
 Perform source data verification including a comparison of eCRF data with the 
participant’s clinic records and other records relevant to the study. This will require 
direct access  to all original records for each participant (eg, clinic charts)  
 Record and report any protocol deviations not previously sent to Emergent  
 Confirm AEs, AESIs, and SAEs have been properly documented on eCRFs; SAE, 
AESI, and pregnancy reports where concepti on occurred after first exposure to the IP 
and (ie, after receipt of at least one dose of either IP), and prior to 12 months  after last 
receipt of either IP have been sent to Emergent; and SAEs and potential AESIs 
meeting the criteria for reporting have been sent to the IRB/IEC  
 Confirm all pregnancies where conception occurred after first exposure to the IP (ie, 
after receipt of at least one dose of either IP), and prior to 12 months  after receipt of 
either IP are followed properly and that the post -birth  follow -up occurs  
The CRO study monitors may inspect all documents and required records that are maintained by 
the PI, including medical records (office, clinic, or hospital) for the participants in this trial. The 
PIs will permit unrestricted access to al l source documents.  Source documentation must be 
available to substantiate proper informed consent procedures, adherence to protocol procedures, 
adequate reporting and follow -up of AEs, accuracy of data collected on eCRFs, and device 
procedure information . A monitoring visit sign -in log will be maintained at the site. The PI and 
investigational site staff will be available for monitoring visits. It is expected that the PI will Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 123 of 139 
  
provide the CRO study monitors with a suitable working environment for review of  study -related 
documents and internet access.  
12.2. Auditing  
Emergent’s Quality Assurance Department (or designee[s]) may conduct investigational site 
audits before trial initiation, during the trial, or after trial completion, as documented in the 
Clinical Qual ity Oversight Plan . Audits will include, but are not limited to, review of drug 
supply, presence of required documents, informed consent process, and comparison of eCRFs 
with source documents. The PI agrees to participate in site audits and assist in the p rompt 
resolution of any issues found during audits.  
Regulatory authorities or the IRB/IEC may inspect the investigational site during or after the 
trial. The PI will cooperate with such inspections and will contact Emergent immediately if such 
an inspectio n occurs.  
In the event the PI is contacted by a regulatory agency in relation to this study, the PI and 
investigational site staff must be available to respond to reasonable requests and inspection 
queries made during the inspection process. The PI must pr ovide Emergent with copies of all 
correspondence that may affect the review of the current study (eg, Form FDA 483, inspectional 
observations, warning letters). Emergent may provide any needed assistance in responding to 
regulatory inspections.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 124 of 139 
  
13. ETHICS  
This trial must be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and in compliance with the  protocol, ICH E6 GCP Guideline, FDA 
regulations, and all other applicable local laws and regulatory requirem ents. Each investigational 
site will seek approval by an IRB/IEC according to regional requirements. The IRB/IEC will 
evaluate the ethical, scientific and medical appropriateness of the trial. Further, in collecting and 
handling participant  data and comple ting eCRFs, the PI and investigational site staff will take 
measures to ensure adequate care in protecting participant  privacy. To this end, a subject ID 
number  will be used to identify each participant . 
13.1. Informed Consent  
The Principal Investigator (PI) or designee at each site will ensure the participant is given full 
and adequate oral and written information about the nature, purpose, and possible risks and 
benefits of the trial. Written informed consent will be obtained from all participants and 
documente d on a written ICF. The ICF will be approved by the same institutional review board/ 
independent ethics committee (IRB/IEC) that approves this protocol. Each ICF will comply with 
the FDA regulations in 21 CFR Part 50, ICH guidelines and local regulatory re quirements.  
Investigators may discuss trial availability and the possibility for entry with a potential 
participant without first obtaining consent. However, informed consent must be obtained and 
documented prior to initiation of any procedures that are p erformed solely for the purpose of 
determining eligibility for this trial.  
Once appropriate essential information has been provided and fully explained in layman’s 
language to the participant by the PI or a qualified designee (and source documented at the site), 
the IRB/IEC approved written ICF will be signed and dated by both the participant and the 
person obtaining consent (PI or designee), as well as by any other parties required by the 
IRB/IEC. The participant will receive a copy of the signed/dated ICF ; the original shall be kept 
on file by the PI.  
13.2. Institutional Review  Board  
The final study protocol, associated ICF, and any recruitment materials must be reviewed and 
approved by the IRB/IEC at each investigational site. The potential benefits and risks f or 
participants will be considered as will the benefits to the knowledge gained through the conduct 
of the proposed study. The PI or designee must submit written approval from the IRB/IEC to 
Emergent before any participants can be screened for the study.  
The PI or designee is responsible for informing the IRB/IEC of any amendment to the protocol 
or ICF in accordance with local requirements. The protocol must be re -approved by the IRB/IEC 
upon receipt of amendments and annually, as required by local regulati ons. 
The PI or designee is also responsible for providing the IRB/IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the IP, if required by the 
IRB/IEC. Emergent will provide this information to the PI.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 125 of 139 
  
Progress reports and notifications of serious adverse drug reactions will be provided to the 
IRB/IEC according to local regulations and guidelines, if required.  
Additionally, the PI or designee will provide an IRB/IEC membership list or assurance number 
to Emergent annually. Initial IRB/IEC approval, and all materials approved by the IRB/IEC for 
the study including the ICF and recruitment materials, must be maintained by the PI and made 
available for inspection.  
13.3. Future Use of Stored Specimens  
Any remnant (l eftover)  blood samples collected for the TNA analysis will be stored frozen at a 
long-term storage facility for possible later retesting for anthrax research. Specimens will be 
identified by subject ID numbers, thereby maintaining confidentiality while in storage. 
Participants will be asked to consent to the future use of these samples as part of the informed 
consent process.  
Samples may be retained until at least 2 years after the last approval of a marketing application 
in an ICH region and until there a re no pending or contemplated marketing applications in an 
ICH region or at least 2 years have elapsed since the formal discontinuation of clinical 
development of the vaccine. They may be retained for a longer period, however, if required by 
the applicable  regulatory requirements.  
13.4. Confidentiality  
Participant confidentiality must be strictly held in trust by the participating PIs, their staff, and 
Emergent and its agents. This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relating to participants. Participants will be identified only by 
their subject  ID or other de -identifying information, on the eCRF or any other study documents 
provided to Emergent or designate(s).  
The study protocol, documentati on, data, and all other information generated will be held in 
strict confidence. No information concerning the study , or the data will be released to any 
unauthorized third party without prior written approval of Emergent.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 126 of 139 
  
14. AMENDMENT POLICY  
The PI will not make any changes to this protocol . Any permanent change to the protocol, 
whether it be an overall change or a change for specific investigational site (s), must be handled 
as a protocol amendment.  Any amendment will be initiated/ written by Emergen t. Each 
amendment will be submitted to the IRB/IEC.  Except for non -substantial , in other words , 
administrative , amendments, PIs will wait for IRB/IEC approval of the amended protocol before 
implementing the change(s).  Administrative amendments are defined as having no effect on the 
safety or physical or mental integrity of participant s, the conduct or management of the trial, the 
scientific value of the trial or the quality or safety of IP(s) used in the trial.  However, a protocol 
change intended to elimina te an apparent immediate hazard to participant s should be 
implemented immediately, followed by IRB/IEC notification within 5 working days.  Emergent  
will submit protocol amendments to the FDA or other regulatory agencies.  
When the IRB/IEC, PIs, and/or Emerg ent conclude that the protocol amendment substantially 
alters the trial design and/or increases the potential risk to the participant , the currently approved 
written ICF will require similar modification.  In such cases, after approval of the new ICF by the  
IRB/IEC, repeat informed consent will be obtained from participants  in a timely manner before 
expecting continued participation in the trial.  
 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 127 of 139 
  
15. PUBLICATION POLICY  
Following the completion of the study, the data may be considered for reporting at a scientif ic 
meeting or for publication in a scientific journal. In these cases, Emergent will be responsible for 
these activities and may work with the PI(s) to determine how the manuscript is written and 
edited, the number and order of authors, the publication to which it will be submitted and other 
related issues. Emergent has final approval authority over all such issues.  
Any proposed publication will be subject to review conditions and timelines agreed between 
Emergent and the site PI and detailed in the agreem ents with these parties prior to the start of the 
study. Emergent will also post the results of the clinical trial on ClinicalTrial.gov in a period no 
greater than 12 months from the completion of the study, defined as the time the final participant 
was ex amined or received an intervention for purposes of final collection of data for one of the  
primary endpoints . 
Data are the property of Emergent and cannot be published without prior authorization from 
Emergent, but data and publication thereof will not be unduly withheld.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 128 of 139 
  
16. LIST OF REFERENCES  
Athenahealth, Inc [US]  2019a [Internet]  Epocrates Monograph Ciprofloxacin available at:  
https://online.epocrates.com/drugs/ 50110/ciprofloxacin/Monograph   Accessed 21 Mar  2019  
Athenahealth, Inc [US]  2019b [Internet]  Epocrates Monograph Doxycycline  available at:  
https://online.epocrates.com/drugs/20310/doxycycline/Monograph   Accessed  21 March 2019  
BioThrax.com [Internet].  c2016 [updated 2016; cited 
5April 2017]. What is BioThrax. Who Should be Immunized; [about 1 screen]. Available from: 
http://biothrax.com/whoshouldbeimmunized.aspx . 
Brachman PS, Friedlander AM, Grabenstein JD. 2008. Anthrax. In: Plotkin SA, Orenstein WA, 
Offit PA, eds. Vaccines, 5th ed. Philadel phia, Pa.: W. B. Saunders Co. Pp. 111 –1267.  
CBER, Center for Biologics Evaluation and Research [Internet]. Guidance for Industry: Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials. September 2 007. Accessed 19 Jun 2018: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/ucm091977 . 
CDC, Centers for Disease Control and Prevention.  Use of Anthrax Vaccine in the United  States 
Recommendations of the Advisory Committee on Immunization Practices.  MMWR 2000; 
49(RR -15):1 -20. 
CDC, Centers for Disease Control and Prevention. Update: Investigation of bioterrorism -related 
anthrax and adverse events from antimicrobial prophylaxi s. MMWR Morb Mortal Wkly Rep. 
2001; Nov 9;50 (44):973 -6.  
CDC, Centers for Disease Control and Prevention.  Use of Anthrax Vaccine in Response to 
Terrorism: Supplemental Recommendations of the Advisory Committee on Immunization 
Practices.  MMWR 2002; 51:10 24-1026 . 
CDC Centers for Disease Control and Prevention, Department of Health and Human Services.  
Anthrax Bioterrorism Threat . Atlanta, GA  2014 updated 01Aug  2014; cited 04Jun2017  
https://www.cdc.gov/anthrax/bioterrorism/threat.html  
Coley Pharmaceutical Group, Inc., V011 study report ‘Phase 1/2, proof of concept, double -blind, 
randomized, controlled trial assessing the immunogenicity and safety of AVA (BioThrax®) 
combined with CP G 7909 (VaxImmune™) in normal volunteers.  Final Clinical Study Report. 
Issued 31 July 2006.  
Cooper  CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote 
J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to 
Engerix -B® HBV vaccine in healthy adults: a double -blind phase I/II study. J Clin Immunol 
2004;24:693 -701. 
 A Study of the Effects of Co -
Administering Ciprofloxacin and Biothrax o n the Pharmacokinetics of Ciprofloxacin in Healthy 
Adults  (EBS.AVA.009) Final Clinical Study Report. Issued 14 March 2 014 BLA 103821; 
Sequence 0110.  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 129 of 139 
  
Emergent BioSolutions [Internet]. BioThrax® (Anthrax Vaccine Adsorbed), E mergent 
BioSolutions , Prescribing  information, [Updated November 2015 ]. Available from: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProduc
ts/LicensedProductsBLAs/UCM074923.pdf. Accessed 03 May 2017  
Hopk ins RJ, Daczkowski NF, Kaptur PE, Muse D, Sheldon E, LaForce C , et al. Randomized, 
double -blind, placebo -controlled, safety and immunogenicity study of 4 formulations of anthrax 
vaccine adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine 2 013; 31(30): 
3051 -8. 
Hopkins RJ, Kalsi G, Montalvo -Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA , et al. 
Randomized, double -blind, active -controlled study evaluating the safety and immunogenicity of 
three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post -exposure 
prophylaxis in healthy adults. Vaccine. 2016 34(18):2096 -105. 
Jerniga n DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC , et al. Investigation 
of bioterrorism -related anthrax, United States, 2001: epidemiologic findings. Emerging 
infectious diseases. 2002;8(10):1019 -28. 
Kaminski MM, Sauer SW, Klemke CD, Suss D , Okun JG, Krammer PH, Gulow K , 
Mitochondrial reactive oxygen species control T cell activation by regulating IL -2 and IL -4 
expression: mechanism of ciprofloxacin -mediated immunosuppression. Journal of Immunology 
2010;184(9):4827 -41. 
Kim SK, Ragupathi G, M usselli C, Choi SJ, Park YS, Livingston PO. Comparison of the effect 
of different immunological adjuvants on the antibody and T -cell response to immunization with 
MUC1 -KLH and GD3 -KLH conjugate cancer vaccines. Vaccine. 1999; 18:597 -603. 
Krieg A. Lymphocyt e activation by CpG dinucleotide motifs in prokaryotic DNA. Trends 
Microbiol. 1996; 4:73 -84. 
Longstreth J , Blumenau J, Ervin J , Essink B , Hunter -Stitt E, Fleming A, Montalvo -Lugo VM, 
Pentikis H, Sweeney D, Hopkins RJ. Co-administration of BioThrax Vaccine and Ciprofloxacin 
as Would be Required for Post -exposure Prophylaxis of Anthrax Shows No Interactive Effects 
presented at ECMIDD , Madrid Spain 21 - 24 April 2018 . 
Li H, Soroka SD, Taylor TH Jr, Stamey KL, Stinson KW, Freeman AE, et al. Standardized 
mathema tical model -based and validated in vitro analysis of anthrax lethal toxin neutralization. J 
Immunol Methods. 2008 Apr 11; 333(1 -2): 89 -106. 
MacDougall C. Sulfonamides, Trimethoprim -Sulfamethoxazole, Quinolones, and Agents for 
Urinary Tract Infections. In: Brunton LL, Hilal -Dandan R, Knollmann BC, editors. Goodman & 
Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York. McGraw -Hill 
Medical Division; c2018. p. 1011 -1021.  
Maganti L, Panebianco D, Maes A, Evaluation of methods for estimating tim e to steady state 
with examples from Phase 1 studies. The AAPS Journal.  2008 10(1):141 –147. 
Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, Fay MP, Saul A, Zhu D, Rausch K, 
Moretz S, Zhou H, Long CA, Miller LH, Treanor J. Phase 1 trial of AMA1 -C1/A lhydrogel plus Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 130 of 139 
  
CPG 7909: an asexual blood -stage vaccine for Plasmodium falciparum malaria. PLoS One. 2008 
Aug 13;3(8):e2940.  
Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity. 1996; 5: 303 -
309. 
Pomorska -Mól M, Kwit K, Markowska -Daniel I, Pejsak Z. The effect of doxycycline treatment 
on the postvaccinal immune response in pigs. Toxicology and applied pharmacology. 2014 Jul 
1;278(1):31 -8. 
Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, et al . Marked enhancement 
of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 
7909 in healthy volunteers.  Vaccine.  2011; 29(37):6313 -6320.  
Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, Sissoko MS, Fay MP, Guindo 
MA, Kante O, Saye R , Miura K, Long C, Mullen GE, Pierce M, Martin LB, Rausch K, Dolo A, 
Diallo DA, Miller LH, Doumbo OK. A randomized and controlled Phase 1 study of the safety 
and immunogenicity of the AMA1 -C1/Alhydrogel + CPG 7909 vaccine for Plasmodium 
falciparum malaria in semi -immune Malian adults. Vaccine. 2009 Dec 9;27(52):7292 -8. 
Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation 
of autoreactive encephalitogenic T cells in vivo. J Immunol.  2000; 164(11): 5683 -5688.  
Shepard CW , Soriano -Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, et al CDC 
Adverse Events Working Group. Antimicrobial post -exposure prophylaxis for anthrax: adverse 
events and adherence. Emerg Infect Dis. 2002; 2002 8(10):1124 -32. 
Stewart VA, McGrath S, K rieg AM, Larson NS, Angov E, Smith CL, et al.  Activation of innate 
immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 
7909: safety data and interferon -inducible protein -10 kinetics for humans and macaques.  Clin 
Vaccine I mmunol.  2008; 15(2):221 -226. 
Stinson KW, Freeman A, Li H. CDC SSP AVRP -0002, An In Vitro MTT Cytotoxicity Assay for 
Quantification of Neutralizing Antibodies to Bacillus anthracis Lethal Toxin, 2005.  
Takahashi HK, Iwagaki H, Xue D, Katsuno G, Sugita S, Mi zuno K, Mori S, Saito S, Yoshino T, 
Tanaka N, Nishibori M. Effect of ciprofloxacin -induced prostaglandin E2 on interleukin -18-
treated monocytes. Antimicrobial agents and chemotherapy. 2005;49(8):3228 -33.  
Tierney BC, Martin SW, Franzke LH, Marano N, Reissm an DB, Louchart RD, et al Serious 
adverse events among participants in the Centers for Disease Control and Prevention's Anthrax 
Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism -related 
inhalational anthrax. Clin Infec Dis . 2003;37(7):905 -11. 
WHO. Anthrax in Humans and Animals 2008. Available from: 
http://apps.who.int/iris/bitstream/10665/97503/1/9789241547536_eng.pdf . 
Woo PC, Tsoi HW, Wong LP, Leung HC, Yuen KY. Antibiotics modulate vaccine -induced 
humoral immune response. Clinical and diagnostic laboratory immunology. 1999 Nov 
1;6(6):832 -7. Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 131 of 139 
  
Wright JG, Quinn CP, Shadomy S, Messonnier N. Use of anthrax vaccine in the United States: 
recom mendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 
2010;59(RR -6):1-30. Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 132 of 139 
  
17. APPENDICES  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 133 of 139 
  
APPENDIX  A. TOXICITY GRADING SCA LE FOR HEALTHY ADULT  
AND ADOLESCENT VOLUNTEERS  ENROLLED IN 
PREVENTIVE VACCINE C LINICAL TRIALS  
The toxicity grading scale s that will be used to rate the severity of local reaction to injectable 
product, vital signs, and general systemic condition related to clinical abnormality and laboratory 
abnormality are presented in Table  12 and Table  13, respectively.  
Table  12: Toxicity Grading Scale for Clinical Abnormalities in Healthy Adult and 
Adolescent Volunteers  
Toxicity  Grade 1  
(Mild)  Grade 2  
(Moderate)  Grade 3  
(Severe)  Grade 4  
(Potential Life -
Threatening)  
Local Reaction to Injectable Product  
Pain Does not interfere 
with activity  Repeated use of  
non-narcotic pain 
reliever >24 hours or 
interferes with activity  Any use of narcotic 
pain reliever or 
prevents daily activity  ER visit or 
hospitalization  
Tenderness  Mild discomfort to 
touch  Discomfort with 
movement  Significant discomfort 
at rest  ER visit or 
hospitalization  
Erythema/rednessa 2.5–5 cm 5.1–10 cm  >10 cm  Necrosis or 
exfoliative 
dermatitis  
Induration/swellingb 2.5–5 cm and does 
not interfere with 
activity  5.1–10 cm or interferes 
with activity  >10 cm or prevents 
daily activity  Necrosis  
Vital Signsc 
Fever (°C) (°F)d 38.0–38.4 
100.4 –101.1  38.5–38.9 
101.2 –102.0  39.0–40 
102.1 –104 >40 
>104  
Tachycardia  
(beats/minute)  101–115 116–130 >130  ER visit or 
hospitalization for 
arrhythmia  
Bradycardiae 
(beats/min)  50–54 45–49 <45 ER visit or 
hospitalization for 
arrhythmia  
Hypertension  –
systolic (mmHg)  141–150 151–155 >155  ER visit or 
hospitalization for 
malignant 
hypertension  
Hypertension  –
diastolic (mmHg)  91–95 96–100 >100  ER visit or 
hospitalization for 
malignant 
hypertension  
Hypotension  – 
systolic (mmHg)  85–89 80–84 <80 ER visit or 
hospitalization for 
hypotensive shock  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 134 of 139 
  
Toxicity  Grade 1  
(Mild)  Grade 2  
(Moderate)  Grade 3  
(Severe)  Grade 4  
(Potential Life -
Threatening)  
Respiratory rate  
(breaths/minute)  17–20 21–25 >25 Intubation  
Systemic (General)  
Nausea/vomiting  No interference with 
activity or 1 -2 
episodes /24 hours  Some interference with 
activity or >2 
episodes /24 hours  Prevents daily activity, 
requires outpatient IV 
hydration  ER visit or 
hospitalization for 
hypotensive shock  
Diarrhea  2–3 loose stools or 
<400 g /24 hours  4–5 stools or 400 –800 
g/24 hours  ≥ 6 watery stools or 
>800  g/24 hours or 
requires outpatient IV 
hydration  ER visit or 
hospitalization  
Headache  No interference with 
activity  Repeated use of non -
narcotic pain reliever 
>24 hours or some 
interference with 
activity  Significant; any use of 
narcotic pain reliever 
or prevents daily 
activity  ER visit or 
hospitalization  
Fatigue  No interference with 
activity  Some interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Myalgia  No interference with 
activity  Some interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Illness or clinical 
AEf No interference with 
activity  Some interference with 
activity not requiring 
medical intervention  Prevents daily activity 
and requires medical 
intervention  ER visit or 
hospitalization  
AE = adverse event; ER = emergency room;  gm = grams;  IV = intravenous  
a In addition to grading the measured loca l reaction at the greatest si ngle diameter, the measurement is recorded as a continuous 
variable.  
b Induration/swelling is evaluated and graded using the functional scale as well as the actual measurement.  
c Participant  will be at rest for all vital sign measurements.  
d Oral temperature; no recent hot or cold beverages or smoking.  
e When resting heart r ate is between 60 -100 beats per minute clinical judgment will be used when characterizing bradycardia 
among some healthy participant  populations, for example, conditioned athletes.  
f Adverse event defined according to applicable regulations.  
 
 
 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 135 of 139 
  
Table  13: Toxicity Grading of Laboratory Abnormalities  
Panel and Analytea Mild (Grade 1)  Moderate (Grade 
2) Severe (Grade 3)  Potentially Life 
Threatening  
(Grade 4)b 
Serum Chemistry  
Glucose – 
hypoglycemia 
mg/dL  65–69 55–64 45–54 < 45 
Glucose – 
hyperglycemia  
Fasting (mg/dL)  
Random (mg/dL)   
 
100–110 
110–125  
 
111–125 
126–200  
 
>125  
>200   
 
Insulin requirements or 
hyperosmolar coma  
Blood Urea 
Nitrogen (mg/dL) – 
mg/dL  23–26 27–31 > 31 Requires dialysis  
Creatinine (mg/dL)  1.5–1.7 1.8–2.0 2.1–2.5 > 2.5 or requires dialysis  
Alkaline phosphate 
increase by factor  1.1–2.0 x ULN  2.1–3.0 x ULN  3.1–10 x ULN  > 10 x ULN  
Liver Function 
Tests: ALT, AST 
increase by factor  1.1–2.5 x ULN  2.6–5.0 x ULN  5.1–10 x ULN  > 10 x ULN  
Bilirubin (when 
accompanied by any 
increase in Liver 
Function Test) 
increase by factor  1.1–1.25 x ULN  1.26–1.5 x ULN  1.51–1.75 x ULN  > 1.75 x ULN  
Bilirubin (when 
Liver Function Test 
is normal)  
increase by factor  1.1–1.5 x ULN  1.6–2.0 x ULN  2.0–3.0 x ULN  > 3.0 x ULN  
Hematology  
Hemoglobin, female 
(g/dL)  11.0–12.0 9.5–10.9 8.0–9.4 <8.0 
Hemoglobin 
decrease from 
baseline value, 
female (g/dL)  Any decrease –
1.5 1.6–2.0 2.1–5.0 >5.0 
Hemoglobin, male 
(g/dL)  12.5–13.5 10.5–12.4 8.5–10.4 <8.5 
Hemoglobin 
decrease from 
baseline value, male 
(g/dL)  Any decrease –
1.5 1.6–2.0 2.1–5.0 >5.0 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 136 of 139 
  
Panel and Analytea Mild (Grade 1)  Moderate (Grade 
2) Severe (Grade 3)  Potentially Life 
Threatening  
(Grade 4)b 
WBC increase 
(cell/mm3) 10,800 –15,000  15,001 –20,000  20,001 –25,000  >25,000  
WBC decrease 
(cell/mm3) 2,500 –3,500  1,500 –2,499  1,000 –1,499  <1,000  
Lymphocyte 
decrease (cell/mm3) 750–1,000  500–749 250–499 <250  
Neutrophil decrease 
(cell/mm3) 1,500 –2,000  1,000 –1,499  500–999 <500  
Eosinophils 
(cell/mm3) 650–1,500  1,501 –5,000  >5,000  Hypereosinophilic  
Platelets decrease 
(cell/mm3) 125,000 –
140,000  100,000 –124,000  25,000 –99,000  <25,000  
Urine  
Protein  Trace  1+ 2+ Hospitalization or 
dialysis  
Glucose  Trace  1+ 2+ Hospitalization for 
hyperglycemia  
Blood (microscopic) 
(RBC/hpf)  1–10 11–50 >50 and/or gross 
blood  Hospitalization or 
PRBC transfusion  
ALT = alanine aminotransferase; AST =  aspartate aminotransferase; HPF = high power field); PR BC = packed red blood cells; 
RBC = red blood cells; ULN = upper limit of normal range; WBC = white blood cell.  
a Laboratory normal reference ranges have  not been taken into considera tion for the toxic ity grading scale.  
b The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the laboratory 
abnormalities as Potentially Life Threatening (Grade 4). For example, a low sodium value that falls within a Gra de 3 parameter 
(125-129 mE/L) will be recorded as a Grade 4 hyponatremia event if the participant  had a new seizure associated with the low 
sodium value.   Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 137 of 139 
  
APPENDIX  B.        ADVERSE EVENTS OF SP ECIAL INTEREST  
Note: These listed AEs (Version 3, provided to Emergent by CBER on 24 October 2017 ), may 
indicate diseases with autoimmune eti ology and will be immediately reported to Emergent.  
 
Table 14: List of Adverse Events of Special Interest * 
Gastrointestinal Disorders  
 Celiac disease  
 Crohn’s disease  
 Ulcerative colitis  
 Ulcerative proctitis  
Liver Disorders  
 Autoimmune cholangitis  
 Autoimmune hepatitis  
 Primary biliary cirrhosis  
 Primary sclerosing cholangitis  
Metabolic Diseases  
 Addison’s disease  
 Autoimmune thyroiditis (including Hashimoto thyroiditis)  
 Diabetes mellitus type I  
 Graves’ or Basedow’s disease  
Musculoskeletal Disorders  
 Antisynthetase syndrome  
 Dermatomyositis  
 Juvenile chronic arthritis (including Still’s disease)  
 Mixed connective tissue disorder  
 Polymyalgia rheumatic  
 Polymyositis  
 Psoriatic arthropathy  
 Relapsing polychondritis  
 Rheumatoid arthritis  
 Scleroderma, including diffuse systemic form and CREST syndrome  
 Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter's Syndrome) and 
undifferentiated spondyloarthritis  
 Systemic lupus erythematosus  
 Systemic sclerosis  
Neuroinflammatory Disorders  
 Acute disseminated encephalomyelitis, including site specific variants ( eg, non-infectious encephalitis, 
encephalomyelitis, myelitis, radiculomyelitis)  
 Cranial nerve disorders, incl uding paralyses/paresis ( eg, Bell’s palsy)  
 Guillain -Barré syndrome, including Miller Fisher syndrome and other variants  
 Immune -mediated peripheral neuropathies and plexopathies, including chronic inflammatory 
demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with 
monoclonal gammopathy  
 Multiple sclerosis  
 Narcolepsy  
 Optic neuritis  
 Transverse Myelitis  
 Myasthenia gravis, including Eaton -Lambert syndrome  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 138 of 139 
  
Skin Disorders  
 Alopecia areata  
 Autoimmune bullous skin diseases, including pemphigus, pemphigoid and dermatitis herpetiformis  
 Cutaneous lupus erythematosus  
 Erythema nodosum  
 Erythema multiforme  
 Morphoea  
 Lichen planus  
 Psoriasis  
 Rosacea  
 Sweet’s syndrome  
 Vitiligo  
Vasculitides  
 Large  vessels vasculitis including: giant cell arteritis such as Takayasu's arteritis and temporal arteritis  
 Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, Kawasaki's disease, 
microscopic polyangiitis, Wegener's granulomatosis, Ch urg–Strauss syndrome (allergic granulomatous 
angiitis), Buerger’s disease thromboangiitis obliterans, necrotizing vasculitis and anti -neutrophil 
cytoplasmic antibody (ANCA) positive vasculitis (type unspecified), Henoch - Schonlein purpura, 
Behcet's syndrom e, leukocytoclastic vasculitis  
Others  
 Antiphospholipid syndrome  
 Autoimmune hemolytic anemia  
 Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly progressive, 
membranous glomerulonephritis, membranoproliferative glomerulonephritis, and mesangioproliferative 
glomerulonephritis)  
 Autoimmune myocarditis/cardiomyopathy  
 Autoimmune thrombocytopenia  
 Goodpasture syndrome  
 Idiopathic pulmonary fibrosis  
 Pernicious anemia  
 Raynaud’s phenomenon  
 Sarcoidosis  
 Sjögren’s syndrome  
 Stevens-Johnson syndrome  
 Uveitis  
*Emergent added erythema multiforme.  
 
 Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

AV7909  Anthrax Vaccine  
IND 014451  
Protocol EBS.AVA.210 , Version 3.0 ( 28 October 2019)    
 
Confidential & Proprietary  Page 139 of 139 
  
APPENDIX  C. SPONSOR’S GUIDANCE  ON CHRONIC CONDITIONS 
FOR INVESTIGATORS   
The Sponsor’s guidance  on the interpretation of stability or seriousness of chronic conditions for 
study eligibility purposes is outlined below . 
A chronic illness is NOT exclusionary IF the following three conditions are met:  
 The condition is not serious (no history of ER visit, hospitalization, or other urgent 
medical intervention for the conditio n)  
 The condition is stable (no clinical or medication changes in the last six months)  
 The condition  does not require treatment with any prohibited medication (protocol 
Section  6.5, Table 3) or medication that would appear on the urine drug screen.  
This guidance  would apply to  conditions such as : 
 Insomnia  
 Migraine  
 Seasonal  allergy  
 Asthma  
 Gastroesophageal reflux disease  (GERD ) 
 Anxiety  
 Attention -deficit/hyperactivity disorder (ADHD ) 
 Depression  
 Scoliosis  
 Fibromyalgia  
 Osteoarthritis (NOT rheumatoid arthritis or reactive arthritis, which are AESIs as per 
Appendix  B of the  protocol)  
Specifically , for Type 2 diabetes mellitus (DM) and hypercholesterolemia:  
 The condition  is not serious  (no history  of ER visit,  hospitalization,  or other  urgent  
medical intervention for the  condition)  
 The condition is stable (no clinical or medication changes in the last six months) AND is 
within relevan t treatment  guidelines  
o For Type 2 DM: Standards of Medical Care in Diabetes – 2019  
o For hypercholesterolemia: American College of Cardiology/American Heart 
Association (AHA/ACC ) Guideline on the Management of  Blood Cholesterol 
– 2018  
 The condition, if tre ated, requires only a single agent that is not a prohibited medication 
(Section  6.5, Table 3) or medication that would appear on the urine drug screen.  
Please note  that Exclusion criterion #22 states that a serious chronic illness  is exclusionary (not 
just cancer/malignancies).  Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

Document Approvals
Approved Date: 10/28/2019
Approval Task
Verdict:  Approve
28-Oct-2019 13:52:34 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 14:11:57 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 14:42:07 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 15:23:09 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 16:48:16 GMT+0000Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019
